US20160271249A1 - Combination of aurora kinase inhibitors and anti-cd20 antibodies - Google Patents
Combination of aurora kinase inhibitors and anti-cd20 antibodies Download PDFInfo
- Publication number
- US20160271249A1 US20160271249A1 US15/052,966 US201615052966A US2016271249A1 US 20160271249 A1 US20160271249 A1 US 20160271249A1 US 201615052966 A US201615052966 A US 201615052966A US 2016271249 A1 US2016271249 A1 US 2016271249A1
- Authority
- US
- United States
- Prior art keywords
- pyrimido
- chloro
- phenyl
- benzazepin
- azepin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003719 aurora kinase inhibitor Substances 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 48
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims abstract description 22
- 229960004641 rituximab Drugs 0.000 claims description 199
- ZLHFILGSQDJULK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical group C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 ZLHFILGSQDJULK-UHFFFAOYSA-N 0.000 claims description 154
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 16
- 206010066476 Haematological malignancy Diseases 0.000 claims description 12
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 3
- AIUYVPGHBMKGAC-UHFFFAOYSA-M sodium;4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoate Chemical group [Na+].C1=C(C([O-])=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 AIUYVPGHBMKGAC-UHFFFAOYSA-M 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 161
- 150000001875 compounds Chemical class 0.000 description 236
- 239000003981 vehicle Substances 0.000 description 83
- 206010028980 Neoplasm Diseases 0.000 description 82
- -1 without limitation Proteins 0.000 description 74
- 125000001931 aliphatic group Chemical group 0.000 description 62
- 239000000654 additive Substances 0.000 description 59
- 125000001072 heteroaryl group Chemical group 0.000 description 53
- 125000003118 aryl group Chemical group 0.000 description 51
- 230000004614 tumor growth Effects 0.000 description 49
- 125000000623 heterocyclic group Chemical group 0.000 description 47
- 241000699670 Mus sp. Species 0.000 description 43
- 230000004083 survival effect Effects 0.000 description 38
- 239000003795 chemical substances by application Substances 0.000 description 35
- 125000001424 substituent group Chemical group 0.000 description 34
- 230000000996 additive effect Effects 0.000 description 33
- 230000000694 effects Effects 0.000 description 33
- 229910052757 nitrogen Inorganic materials 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 30
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 30
- 108090000433 Aurora kinases Proteins 0.000 description 29
- 102000003989 Aurora kinases Human genes 0.000 description 29
- 230000005764 inhibitory process Effects 0.000 description 28
- 230000002195 synergetic effect Effects 0.000 description 28
- 230000008859 change Effects 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 23
- 238000011284 combination treatment Methods 0.000 description 23
- 235000002639 sodium chloride Nutrition 0.000 description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 21
- 230000037396 body weight Effects 0.000 description 20
- 150000001721 carbon Chemical group 0.000 description 19
- 125000001841 imino group Chemical group [H]N=* 0.000 description 19
- 125000004433 nitrogen atom Chemical group N* 0.000 description 19
- 206010025323 Lymphomas Diseases 0.000 description 18
- 229910052799 carbon Inorganic materials 0.000 description 18
- 229910052739 hydrogen Inorganic materials 0.000 description 17
- 239000001257 hydrogen Substances 0.000 description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 17
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 230000004907 flux Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 14
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 14
- 230000007423 decrease Effects 0.000 description 14
- 125000001475 halogen functional group Chemical group 0.000 description 14
- 125000005842 heteroatom Chemical group 0.000 description 14
- 229910052717 sulfur Inorganic materials 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 12
- 125000006413 ring segment Chemical group 0.000 description 12
- 238000004364 calculation method Methods 0.000 description 11
- 238000007920 subcutaneous administration Methods 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000013103 analytical ultracentrifugation Methods 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 125000002950 monocyclic group Chemical group 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 125000003107 substituted aryl group Chemical group 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 8
- 238000011579 SCID mouse model Methods 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000012417 linear regression Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000021375 Xenogenes Species 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 208000003950 B-cell lymphoma Diseases 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 206010033799 Paralysis Diseases 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 125000006574 non-aromatic ring group Chemical group 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 102000004000 Aurora Kinase A Human genes 0.000 description 5
- 108090000461 Aurora Kinase A Proteins 0.000 description 5
- 208000031648 Body Weight Changes Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 230000004579 body weight change Effects 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000002541 furyl group Chemical group 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 238000012066 statistical methodology Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 239000005441 aurora Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000029918 bioluminescence Effects 0.000 description 4
- 238000005415 bioluminescence Methods 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 208000009527 Refractory anemia Diseases 0.000 description 3
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 description 3
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 3
- 125000005956 isoquinolyl group Chemical group 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008600 mitotic progression Effects 0.000 description 3
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 description 3
- 239000000346 nonvolatile oil Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 125000005493 quinolyl group Chemical group 0.000 description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VRCFENKUBGJJHK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methylphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound CC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 VRCFENKUBGJJHK-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010038270 Refractory anaemia with an excess of blasts Diseases 0.000 description 2
- 208000032411 Refractory with Excess of Blasts Anemia Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- LWLRBBDMNHLNMT-UHFFFAOYSA-N n-[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]-2-(methylaminomethyl)-1,3-benzothiazol-6-amine Chemical compound C1=C2SC(CNC)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=C(F)C=CC=C1F LWLRBBDMNHLNMT-UHFFFAOYSA-N 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000013179 statistical model Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000009044 synergistic interaction Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- JIAGXOBZNQXQLP-UHFFFAOYSA-N (3,5-dimethylpiperazin-1-yl)-[7-(2-fluorophenyl)-2-(3-methoxyanilino)-5h-pyrimido[5,4-d][2]benzazepin-9-yl]methanone Chemical compound COC1=CC=CC(NC=2N=C3C4=CC=C(C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)C(=O)N2CC(C)NC(C)C2)=C1 JIAGXOBZNQXQLP-UHFFFAOYSA-N 0.000 description 1
- YFOPJKDUOQWITF-UHFFFAOYSA-N (3-amino-3-methylpyrrolidin-1-yl)-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(C)(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 YFOPJKDUOQWITF-UHFFFAOYSA-N 0.000 description 1
- PSKCHRFIACXCCL-UHFFFAOYSA-N (3-aminoazetidin-1-yl)-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 PSKCHRFIACXCCL-UHFFFAOYSA-N 0.000 description 1
- HDMPGHZWDQUVFB-UHFFFAOYSA-N (3-aminoazetidin-1-yl)-[4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(N)C2)C=C1 HDMPGHZWDQUVFB-UHFFFAOYSA-N 0.000 description 1
- SDVVHBZKMLWYNA-UHFFFAOYSA-N (3-aminoazetidin-1-yl)-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 SDVVHBZKMLWYNA-UHFFFAOYSA-N 0.000 description 1
- RNJBXXMWQRHYPF-UHFFFAOYSA-N (3-aminoazetidin-1-yl)-[4-[[9-chloro-7-[2-(trifluoromethyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)C(F)(F)F)C=2C3=CC=C(Cl)C=2)C3=N1 RNJBXXMWQRHYPF-UHFFFAOYSA-N 0.000 description 1
- QSSNZICYKMCABB-UHFFFAOYSA-N (3-aminopiperidin-1-yl)-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 QSSNZICYKMCABB-UHFFFAOYSA-N 0.000 description 1
- BABUYKSWUCYTGK-UHFFFAOYSA-N (3-aminopiperidin-1-yl)-[4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(N)CCC2)C=C1 BABUYKSWUCYTGK-UHFFFAOYSA-N 0.000 description 1
- DEARBBFOQKBFIU-UHFFFAOYSA-N (3-aminopyrrolidin-1-yl)-[2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 DEARBBFOQKBFIU-UHFFFAOYSA-N 0.000 description 1
- HPYDSNMHEKEDBX-UHFFFAOYSA-N (3-aminopyrrolidin-1-yl)-[4-[(9-chloro-7-pyridin-2-yl-5h-pyrimido[5,4-d][2]benzazepin-2-yl)amino]phenyl]methanone Chemical compound C1C(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2N=CC=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 HPYDSNMHEKEDBX-UHFFFAOYSA-N 0.000 description 1
- MRBHGHQGGUMGKT-UHFFFAOYSA-N (3-aminopyrrolidin-1-yl)-[4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(N)CC2)C=C1 MRBHGHQGGUMGKT-UHFFFAOYSA-N 0.000 description 1
- ARKMPIXDDGNXPT-UHFFFAOYSA-N (3-aminopyrrolidin-1-yl)-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 ARKMPIXDDGNXPT-UHFFFAOYSA-N 0.000 description 1
- ZRVLNNOPDZFOTR-UHFFFAOYSA-N (3-aminopyrrolidin-1-yl)-[4-[[9-chloro-7-(3-fluoropyridin-2-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CN=2)F)C3=N1 ZRVLNNOPDZFOTR-UHFFFAOYSA-N 0.000 description 1
- QATKEPSLJSBKHQ-UHFFFAOYSA-N (3-aminopyrrolidin-1-yl)-[4-[[9-chloro-7-[2-(trifluoromethyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2)C(F)(F)F)C3=N1 QATKEPSLJSBKHQ-UHFFFAOYSA-N 0.000 description 1
- QLSJWRRLRFNQPS-UHFFFAOYSA-N (4-amino-4-methylpiperidin-1-yl)-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1CC(C)(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 QLSJWRRLRFNQPS-UHFFFAOYSA-N 0.000 description 1
- WOAKHDUKZKTQBK-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-[2-chloro-5-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1CC(N)CCN1C(=O)C1=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=CC=C1Cl WOAKHDUKZKTQBK-UHFFFAOYSA-N 0.000 description 1
- WDPNHDXDQKINDC-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-[4-[(9-chloro-7-pyridin-2-yl-5h-pyrimido[5,4-d][2]benzazepin-2-yl)amino]phenyl]methanone Chemical compound C1CC(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2N=CC=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 WDPNHDXDQKINDC-UHFFFAOYSA-N 0.000 description 1
- UAHSNMUZFDALCC-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1CC(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 UAHSNMUZFDALCC-UHFFFAOYSA-N 0.000 description 1
- GQKCTBSEWQDSQQ-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-[4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCC(N)CC2)C=C1 GQKCTBSEWQDSQQ-UHFFFAOYSA-N 0.000 description 1
- YRGWWSZGYSMKIX-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1CC(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 YRGWWSZGYSMKIX-UHFFFAOYSA-N 0.000 description 1
- MRNMZZJAEAWNAC-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-[4-[[9-chloro-7-[2-(trifluoromethyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1CC(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2)C(F)(F)F)C3=N1 MRNMZZJAEAWNAC-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VHOHLAXBGVPUHE-UHFFFAOYSA-N *.B.C.CC1=NC(NC2=CC=CC=C2)=NC2=C1CN=C(C1=CC=CC=C1)C1=CC=CC=C12 Chemical compound *.B.C.CC1=NC(NC2=CC=CC=C2)=NC2=C1CN=C(C1=CC=CC=C1)C1=CC=CC=C12 VHOHLAXBGVPUHE-UHFFFAOYSA-N 0.000 description 1
- YJIDUMDUDLMVDX-UHFFFAOYSA-N *.B.C.CNC1=NC2=C(C(C)=N1)C(C)(C)N=C(C)CC2 Chemical compound *.B.C.CNC1=NC2=C(C(C)=N1)C(C)(C)N=C(C)CC2 YJIDUMDUDLMVDX-UHFFFAOYSA-N 0.000 description 1
- ZSAYBIPZZOIMRO-UHFFFAOYSA-N *.B.C.COC1=C(C(=O)O)C=CC(NC2=NC3=C(C=N2)CN=C(C2=C(F)C=CC=C2C)C2=C3C=CC(C)=C2)=C1 Chemical compound *.B.C.COC1=C(C(=O)O)C=CC(NC2=NC3=C(C=N2)CN=C(C2=C(F)C=CC=C2C)C2=C3C=CC(C)=C2)=C1 ZSAYBIPZZOIMRO-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FOXSPXGQMYTYAT-UHFFFAOYSA-N 1-[2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]-n-methyl-3-(methylamino)piperidine-3-carboxamide Chemical compound C1C(C(=O)NC)(NC)CCCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 FOXSPXGQMYTYAT-UHFFFAOYSA-N 0.000 description 1
- BMOGXCUMOSRQRR-UHFFFAOYSA-N 1-[3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-3,5,5-trimethylpiperazin-2-one Chemical compound O=C1C(C)NC(C)(C)CN1C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 BMOGXCUMOSRQRR-UHFFFAOYSA-N 0.000 description 1
- CXEPBVHUNMONEQ-UHFFFAOYSA-N 1-[3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-3-(dimethylamino)propan-1-one Chemical compound CN(C)CCC(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 CXEPBVHUNMONEQ-UHFFFAOYSA-N 0.000 description 1
- YDORAPUNMRRTAQ-UHFFFAOYSA-N 1-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]-3-(methylamino)pyrrolidine-3-carboxamide Chemical compound C1C(NC)(C(N)=O)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 YDORAPUNMRRTAQ-UHFFFAOYSA-N 0.000 description 1
- RXTIZMUNHWWQFH-UHFFFAOYSA-N 1-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]-4-(methylamino)piperidine-4-carboxamide Chemical compound C1CC(NC)(C(N)=O)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 RXTIZMUNHWWQFH-UHFFFAOYSA-N 0.000 description 1
- HWLZTATUGZXFGL-UHFFFAOYSA-N 1-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]-n-methyl-3-(methylamino)pyrrolidine-3-carboxamide Chemical compound C1C(C(=O)NC)(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HWLZTATUGZXFGL-UHFFFAOYSA-N 0.000 description 1
- CLFJFHDOTKKSDD-UHFFFAOYSA-N 1-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]-n-methyl-4-(methylamino)piperidine-4-carboxamide Chemical compound C1CC(C(=O)NC)(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 CLFJFHDOTKKSDD-UHFFFAOYSA-N 0.000 description 1
- NTEWOXIWFXTYRC-UHFFFAOYSA-N 1-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]piperazine-2-carboxylic acid Chemical compound OC(=O)C1CNCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 NTEWOXIWFXTYRC-UHFFFAOYSA-N 0.000 description 1
- OITHRBNKPHWCOB-UHFFFAOYSA-N 1-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 OITHRBNKPHWCOB-UHFFFAOYSA-N 0.000 description 1
- UCBKCEBAAONDMP-UHFFFAOYSA-N 1-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 UCBKCEBAAONDMP-UHFFFAOYSA-N 0.000 description 1
- TVSIEZUOIWNLLG-UHFFFAOYSA-N 1-[n'-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]carbamimidoyl]piperidine-3-carboxamide Chemical compound C1C(C(=O)N)CCCN1C(=N)NC(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 TVSIEZUOIWNLLG-UHFFFAOYSA-N 0.000 description 1
- MQVOZBMMQCYNBK-UHFFFAOYSA-N 1-[n'-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]carbamimidoyl]pyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1C(=N)NC(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 MQVOZBMMQCYNBK-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- RGBJBZCEUBXFMV-UHFFFAOYSA-N 10-bromo-n-(3,4-dimethoxyphenyl)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC(Br)=CC=2)C3=N1 RGBJBZCEUBXFMV-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- BMQBPMMJQSNENI-UHFFFAOYSA-N 2-(3,4-dimethoxyanilino)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepine-10-carboxylic acid Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC(=CC=2)C(O)=O)C3=N1 BMQBPMMJQSNENI-UHFFFAOYSA-N 0.000 description 1
- DXUMDXDNZIAPHG-UHFFFAOYSA-N 2-(4-carbamoylanilino)-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepine-9-carboxylic acid Chemical compound C1=CC(C(=O)N)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(C=2)C(O)=O)C=2C(=CC=CC=2F)F)C3=N1 DXUMDXDNZIAPHG-UHFFFAOYSA-N 0.000 description 1
- FCZCZXISRXYSAW-UHFFFAOYSA-N 2-(4-carboxyanilino)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepine-9-carboxylic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(C=2)C(O)=O)C3=N1 FCZCZXISRXYSAW-UHFFFAOYSA-N 0.000 description 1
- LJYTXCGWRBZLJH-UHFFFAOYSA-N 2-(aminomethyl)-n-[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]-1,3-benzoxazol-5-amine Chemical compound C=1C=C2OC(CN)=NC2=CC=1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=C(F)C=CC=C1F LJYTXCGWRBZLJH-UHFFFAOYSA-N 0.000 description 1
- HDWYKJPTZKCUEW-UHFFFAOYSA-N 2-[3-[[9-chloro-7-(2-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]acetamide Chemical compound NC(=O)CC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)Cl)=NCC3=CN=2)=C1 HDWYKJPTZKCUEW-UHFFFAOYSA-N 0.000 description 1
- UXMDAZZNAZVUHG-UHFFFAOYSA-N 2-[3-[[9-chloro-7-(2-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)Cl)=NCC3=CN=2)=C1 UXMDAZZNAZVUHG-UHFFFAOYSA-N 0.000 description 1
- BAOOTCDCPBKPGA-UHFFFAOYSA-N 2-[3-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-1-(4-methylpiperazin-1-yl)ethanone Chemical compound C1CN(C)CCN1C(=O)CC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)=C1 BAOOTCDCPBKPGA-UHFFFAOYSA-N 0.000 description 1
- JGEWBEAFEKNGIN-UHFFFAOYSA-N 2-[3-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-n-[3-(4-methylpiperazin-1-yl)propyl]acetamide Chemical compound C1CN(C)CCN1CCCNC(=O)CC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)=C1 JGEWBEAFEKNGIN-UHFFFAOYSA-N 0.000 description 1
- JTAXVNQSWTUGCT-UHFFFAOYSA-N 2-[3-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)=C1 JTAXVNQSWTUGCT-UHFFFAOYSA-N 0.000 description 1
- CBLVDMAMRWPFLY-UHFFFAOYSA-N 2-[4-(3,5-dimethylpiperazine-1-carbonyl)anilino]-9-methoxy-5,6-dihydropyrimido[5,4-d][2]benzazepin-7-one Chemical compound C=1C(OC)=CC=C(C2=N3)C=1C(=O)NCC2=CN=C3NC(C=C1)=CC=C1C(=O)N1CC(C)NC(C)C1 CBLVDMAMRWPFLY-UHFFFAOYSA-N 0.000 description 1
- VCGZPJSQGKBQNN-UHFFFAOYSA-N 2-[4-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]piperazin-1-yl]-n-propan-2-ylacetamide Chemical compound C1CN(CC(=O)NC(C)C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 VCGZPJSQGKBQNN-UHFFFAOYSA-N 0.000 description 1
- FDZKAXQFIJKGEC-UHFFFAOYSA-N 2-[4-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]piperazin-1-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1N1CCN(C(=O)C=2C=CC(NC=3N=C4C5=CC=C(Cl)C=C5C(C=5C(=CC=CC=5)F)=NCC4=CN=3)=CC=2)CC1 FDZKAXQFIJKGEC-UHFFFAOYSA-N 0.000 description 1
- YFXWSZOXHWBHRT-UHFFFAOYSA-N 2-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-1,4,5,6-tetrahydropyrimidin-5-ol Chemical compound C1C(O)CNC(C=2C=CC(NC=3N=C4C5=CC=C(Cl)C=C5C(=NCC4=CN=3)C=3C(=CC=CC=3F)F)=CC=2)=N1 YFXWSZOXHWBHRT-UHFFFAOYSA-N 0.000 description 1
- NDOVQJVMKQBURZ-UHFFFAOYSA-N 2-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-4,5-dihydro-1h-imidazole-5-carboxylic acid Chemical compound N1C(C(=O)O)CN=C1C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 NDOVQJVMKQBURZ-UHFFFAOYSA-N 0.000 description 1
- LECCAVXHLUVTGQ-UHFFFAOYSA-N 2-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]guanidine Chemical compound C1=CC(NC(=N)N)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 LECCAVXHLUVTGQ-UHFFFAOYSA-N 0.000 description 1
- BSHOQLHPKVTOOU-UHFFFAOYSA-N 2-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-1-(4-methylpiperazin-1-yl)ethanone Chemical compound C1CN(C)CCN1C(=O)CC(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 BSHOQLHPKVTOOU-UHFFFAOYSA-N 0.000 description 1
- RHHGRLUONLSEPM-UHFFFAOYSA-N 2-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-n-(2-morpholin-4-ylethyl)acetamide Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC(C=C1)=CC=C1CC(=O)NCCN1CCOCC1 RHHGRLUONLSEPM-UHFFFAOYSA-N 0.000 description 1
- QPUOXZLCRHZPSB-UHFFFAOYSA-N 2-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 QPUOXZLCRHZPSB-UHFFFAOYSA-N 0.000 description 1
- DCTDXUDKMAZKMR-UHFFFAOYSA-N 2-[[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]amino]benzamide Chemical compound NC(=O)C1=CC=CC=C1NC(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 DCTDXUDKMAZKMR-UHFFFAOYSA-N 0.000 description 1
- RHEKNYLNBLOXOL-UHFFFAOYSA-N 2-[[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]amino]butanedioic acid Chemical compound C1=CC(C(=O)NC(CC(=O)O)C(O)=O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 RHEKNYLNBLOXOL-UHFFFAOYSA-N 0.000 description 1
- XOPVLAHBJDDFEL-UHFFFAOYSA-N 2-[[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]amino]propanoic acid Chemical compound C1=CC(C(=O)NC(C)C(O)=O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 XOPVLAHBJDDFEL-UHFFFAOYSA-N 0.000 description 1
- USUBUUGNJRLGCS-UHFFFAOYSA-N 2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-1,3-oxazole-4-carboxylic acid Chemical compound OC(=O)C1=COC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=N1 USUBUUGNJRLGCS-UHFFFAOYSA-N 0.000 description 1
- MJBQIUVILPQAOO-UHFFFAOYSA-N 2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-1,3-oxazole-5-carboxylic acid Chemical compound O1C(C(=O)O)=CN=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 MJBQIUVILPQAOO-UHFFFAOYSA-N 0.000 description 1
- DIPFRAMINFECJW-UHFFFAOYSA-N 2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=N1 DIPFRAMINFECJW-UHFFFAOYSA-N 0.000 description 1
- IPRIHHMBMGPDQU-UHFFFAOYSA-N 2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methyl-1,3-thiazole-4-carboxamide Chemical compound CNC(=O)C1=CSC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=N1 IPRIHHMBMGPDQU-UHFFFAOYSA-N 0.000 description 1
- CEVBLQCGXDBVDR-UHFFFAOYSA-N 2-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-1h-imidazole-5-carboxylic acid Chemical compound OC(=O)C1=CNC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)=N1 CEVBLQCGXDBVDR-UHFFFAOYSA-N 0.000 description 1
- MWLFQGAIUUZLMF-UHFFFAOYSA-N 2-amino-n-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-2-methylpropanamide Chemical compound C1=CC(NC(=O)C(C)(N)C)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 MWLFQGAIUUZLMF-UHFFFAOYSA-N 0.000 description 1
- QFWBWWNWSWAQGO-UHFFFAOYSA-N 2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=C(Cl)C(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 QFWBWWNWSWAQGO-UHFFFAOYSA-N 0.000 description 1
- VPYXEEVPFJNYOD-UHFFFAOYSA-N 2-chloro-4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=C(Cl)C(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 VPYXEEVPFJNYOD-UHFFFAOYSA-N 0.000 description 1
- IMWRKJJNESWEFA-UHFFFAOYSA-N 2-chloro-5-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methyl-n-[2-(methylamino)ethyl]benzamide Chemical compound C1=C(Cl)C(C(=O)N(C)CCNC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 IMWRKJJNESWEFA-UHFFFAOYSA-N 0.000 description 1
- KVPUKGOREHZUJO-UHFFFAOYSA-N 2-chloro-5-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=C(Cl)C(C(=O)O)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 KVPUKGOREHZUJO-UHFFFAOYSA-N 0.000 description 1
- TZEUEFFTRUIVDM-UHFFFAOYSA-N 2-chloro-5-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=C(Cl)C(C(=O)O)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)=C1 TZEUEFFTRUIVDM-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 1
- SGVJGELYUGOGCR-UHFFFAOYSA-N 3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 SGVJGELYUGOGCR-UHFFFAOYSA-N 0.000 description 1
- ROUSCZLMVWRAKD-UHFFFAOYSA-N 3-[[9-chloro-7-(2-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound NC(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)Cl)=NCC3=CN=2)=C1 ROUSCZLMVWRAKD-UHFFFAOYSA-N 0.000 description 1
- NZHHZQXOBAOWFS-UHFFFAOYSA-N 3-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[3-(dimethylamino)propyl]-n-methylbenzamide Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC(C(=O)N(C)CCCN(C)C)=C1 NZHHZQXOBAOWFS-UHFFFAOYSA-N 0.000 description 1
- PQXJMERAOLLBRU-UHFFFAOYSA-N 3-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)=C1 PQXJMERAOLLBRU-UHFFFAOYSA-N 0.000 description 1
- DQSCLJKLQPOFMM-UHFFFAOYSA-N 3-amino-1-[2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]pyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)(N)CCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 DQSCLJKLQPOFMM-UHFFFAOYSA-N 0.000 description 1
- ZRMBBWINSMYQFN-UHFFFAOYSA-N 3-amino-1-[3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]propan-1-one Chemical compound NCCC(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 ZRMBBWINSMYQFN-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- XJKXGZNVBSSQPZ-UHFFFAOYSA-N 4-[(9-chloro-5h-pyrimido[5,4-d][2]benzazepin-2-yl)-cyclopenta[b]pyran-2-ylamino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C=1OC2=CC=CC2=CC=1)C1=NC=C(CN=CC=2C3=CC=C(Cl)C=2)C3=N1 XJKXGZNVBSSQPZ-UHFFFAOYSA-N 0.000 description 1
- GQOKXTUWJTWWDL-UHFFFAOYSA-N 4-[(9-chloro-7-phenyl-5h-pyrimido[5,4-d][2]benzazepin-2-yl)amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C=CC=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 GQOKXTUWJTWWDL-UHFFFAOYSA-N 0.000 description 1
- NLNNHKRHERFZND-UHFFFAOYSA-N 4-[(9-chloro-7-pyridin-2-yl-5h-pyrimido[5,4-d][2]benzazepin-2-yl)amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2N=CC=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 NLNNHKRHERFZND-UHFFFAOYSA-N 0.000 description 1
- PGUNZZOONXNIHT-UHFFFAOYSA-N 4-[(9-chloro-7-thiophen-2-yl-5h-pyrimido[5,4-d][2]benzazepin-2-yl)amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2SC=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 PGUNZZOONXNIHT-UHFFFAOYSA-N 0.000 description 1
- JOQLNQIDODVLEF-UHFFFAOYSA-N 4-[(9-methoxy-7-oxo-5,6-dihydropyrimido[5,4-d][2]benzazepin-2-yl)amino]benzoic acid Chemical compound C=1C(OC)=CC=C(C2=N3)C=1C(=O)NCC2=CN=C3NC1=CC=C(C(O)=O)C=C1 JOQLNQIDODVLEF-UHFFFAOYSA-N 0.000 description 1
- JXDVLJCKEXTWFW-UHFFFAOYSA-N 4-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]-n-methylpiperazine-2-carboxamide Chemical compound C1CNC(C(=O)NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 JXDVLJCKEXTWFW-UHFFFAOYSA-N 0.000 description 1
- DLKAWFWEKFAATR-UHFFFAOYSA-N 4-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]piperazine-2-carboxamide Chemical compound C1CNC(C(=O)N)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 DLKAWFWEKFAATR-UHFFFAOYSA-N 0.000 description 1
- HAMUPHZXFBAMAY-UHFFFAOYSA-N 4-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]piperazine-2-carboxylic acid Chemical compound C1CNC(C(=O)O)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HAMUPHZXFBAMAY-UHFFFAOYSA-N 0.000 description 1
- PAKDRZWRYWHQQH-UHFFFAOYSA-N 4-[[10-bromo-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC(Br)=CC=2)C3=N1 PAKDRZWRYWHQQH-UHFFFAOYSA-N 0.000 description 1
- XGZUTOAIHCBLDT-UHFFFAOYSA-N 4-[[10-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC(Cl)=CC=2)C3=N1 XGZUTOAIHCBLDT-UHFFFAOYSA-N 0.000 description 1
- NCTQZSBTLBAPIG-UHFFFAOYSA-N 4-[[10-fluoro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC(F)=CC=2)C3=N1 NCTQZSBTLBAPIG-UHFFFAOYSA-N 0.000 description 1
- BPZTZLCQRBDFOR-UHFFFAOYSA-N 4-[[11-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=C(Cl)C=CC=2)C3=N1 BPZTZLCQRBDFOR-UHFFFAOYSA-N 0.000 description 1
- AFLJRURKKDIOSL-UHFFFAOYSA-N 4-[[11-fluoro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=C(F)C=CC=2)C3=N1 AFLJRURKKDIOSL-UHFFFAOYSA-N 0.000 description 1
- RRFKVENYDIGPGB-UHFFFAOYSA-N 4-[[4-(aminomethyl)-9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound N=1C(C2=CC=C(Cl)C=C2C(C=2C(=CC=CC=2)F)=NC2)=C2C(CN)=NC=1NC1=CC=C(C(O)=O)C=C1 RRFKVENYDIGPGB-UHFFFAOYSA-N 0.000 description 1
- DLPLLXJMIXMJNT-UHFFFAOYSA-N 4-[[4-amino-9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound N=1C(C2=CC=C(Cl)C=C2C(=NC2)C=3C(=CC=CC=3F)F)=C2C(N)=NC=1NC1=CC=C(C(O)=O)C=C1 DLPLLXJMIXMJNT-UHFFFAOYSA-N 0.000 description 1
- KOBUFCASZMLIHQ-UHFFFAOYSA-N 4-[[7-(2-bromo-6-chlorophenyl)-9-chloro-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2Cl)Br)C3=N1 KOBUFCASZMLIHQ-UHFFFAOYSA-N 0.000 description 1
- SRFVRJILPIASPG-UHFFFAOYSA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-(1-methylpyrrol-2-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C=2N(C=CC=2)C)=C1 SRFVRJILPIASPG-UHFFFAOYSA-N 0.000 description 1
- PSTMNQSMUJBCFU-UHFFFAOYSA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-(2-methylphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C=2C(=CC=CC=2)C)=C1 PSTMNQSMUJBCFU-UHFFFAOYSA-N 0.000 description 1
- VEDQAVJPCQBGOZ-UHFFFAOYSA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-(3-methoxyprop-1-ynyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C=1C(C#CCOC)=CC=C(C2=N3)C=1C(C=1C(=CC=CC=1F)OC)=NCC2=CN=C3NC1=CC=C(C(O)=O)C(OC)=C1 VEDQAVJPCQBGOZ-UHFFFAOYSA-N 0.000 description 1
- ZZBMEBMXRCHMKT-UHFFFAOYSA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-(3-methylfuran-2-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C2=C(C=CO2)C)=C1 ZZBMEBMXRCHMKT-UHFFFAOYSA-N 0.000 description 1
- BTMPSJZQWXFMIF-UHFFFAOYSA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-(4-methylthiophen-3-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C=2C(=CSC=2)C)=C1 BTMPSJZQWXFMIF-UHFFFAOYSA-N 0.000 description 1
- OWEDUAXNWDZLQZ-UHFFFAOYSA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-(furan-2-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C=2OC=CC=2)=C1 OWEDUAXNWDZLQZ-UHFFFAOYSA-N 0.000 description 1
- OBRWBFWNJNYDOY-GQCTYLIASA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-[(e)-prop-1-enyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(\C=C\C)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 OBRWBFWNJNYDOY-GQCTYLIASA-N 0.000 description 1
- LWISYUZIQQDMPJ-UHFFFAOYSA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-phenyl-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C=2C=CC=CC=2)=C1 LWISYUZIQQDMPJ-UHFFFAOYSA-N 0.000 description 1
- KKKMPZKQQMONNW-UHFFFAOYSA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-prop-1-ynyl-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C#CC)=C1 KKKMPZKQQMONNW-UHFFFAOYSA-N 0.000 description 1
- IRIPXVDZWWQLLK-UHFFFAOYSA-N 4-[[7-(2-fluorophenyl)-10-methoxy-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C=1C(OC)=CC=C(C(=NCC2=CN=3)C=4C(=CC=CC=4)F)C=1C2=NC=3NC1=CC=C(C(O)=O)C=C1 IRIPXVDZWWQLLK-UHFFFAOYSA-N 0.000 description 1
- CTSLXIDZUBXSDE-UHFFFAOYSA-N 4-[[7-(2-fluorophenyl)-10-methyl-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C=1C(C)=CC=C(C(=NCC2=CN=3)C=4C(=CC=CC=4)F)C=1C2=NC=3NC1=CC=C(C(O)=O)C=C1 CTSLXIDZUBXSDE-UHFFFAOYSA-N 0.000 description 1
- ZDBBBFLEZGIMSP-UHFFFAOYSA-N 4-[[7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=CC=2)C3=N1 ZDBBBFLEZGIMSP-UHFFFAOYSA-N 0.000 description 1
- YCJFWCVJBYYELC-UHFFFAOYSA-N 4-[[7-(2-fluorophenyl)-9-methoxy-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n,n-bis(2-hydroxyethyl)benzamide Chemical compound C=1C(OC)=CC=C(C2=N3)C=1C(C=1C(=CC=CC=1)F)=NCC2=CN=C3NC1=CC=C(C(=O)N(CCO)CCO)C=C1 YCJFWCVJBYYELC-UHFFFAOYSA-N 0.000 description 1
- QWZVSCMYUUBQRR-UHFFFAOYSA-N 4-[[7-(2-fluorophenyl)-9-methoxy-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C=1C(OC)=CC=C(C2=N3)C=1C(C=1C(=CC=CC=1)F)=NCC2=CN=C3NC1=CC=C(C(O)=O)C=C1 QWZVSCMYUUBQRR-UHFFFAOYSA-N 0.000 description 1
- XLEYQRNUHAUSFT-UHFFFAOYSA-N 4-[[7-(2-fluorophenyl)-9-methyl-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C(C)=CC=C(C2=N3)C=1C(C=1C(=CC=CC=1)F)=NCC2=CN=C3NC(C=C1)=CC=C1C(=O)NCCN1CCOCC1 XLEYQRNUHAUSFT-UHFFFAOYSA-N 0.000 description 1
- CEQMFZDFBRTFRE-UHFFFAOYSA-N 4-[[7-(2-fluorophenyl)-9-methyl-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[3-(4-methylpiperazin-1-yl)propyl]benzamide Chemical compound C1CN(C)CCN1CCCNC(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(C)C=2)C3=N1 CEQMFZDFBRTFRE-UHFFFAOYSA-N 0.000 description 1
- JHYWJMAQULKIJO-UHFFFAOYSA-N 4-[[7-(2-fluorophenyl)-9-methyl-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C=1C(C)=CC=C(C2=N3)C=1C(C=1C(=CC=CC=1)F)=NCC2=CN=C3NC1=CC=C(C(O)=O)C=C1 JHYWJMAQULKIJO-UHFFFAOYSA-N 0.000 description 1
- DKAHVJYKEGHJHO-UHFFFAOYSA-N 4-[[7-[2-(2-aminoethylamino)-6-fluorophenyl]-9-chloro-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)NCCN)C3=N1 DKAHVJYKEGHJHO-UHFFFAOYSA-N 0.000 description 1
- UQIPYZHWHXYKHL-UHFFFAOYSA-N 4-[[7-[2-(4-aminopiperidin-1-yl)-6-fluorophenyl]-9-chloro-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)N2CCC(N)CC2)C3=N1 UQIPYZHWHXYKHL-UHFFFAOYSA-N 0.000 description 1
- YRMWUFXTEUCQFV-UHFFFAOYSA-N 4-[[7-[2-(aminomethyl)phenyl]-9-chloro-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound NCC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 YRMWUFXTEUCQFV-UHFFFAOYSA-N 0.000 description 1
- NECRLMIKRBVQAF-UHFFFAOYSA-N 4-[[8-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=CC=2Cl)C3=N1 NECRLMIKRBVQAF-UHFFFAOYSA-N 0.000 description 1
- UMMQZQVVUPECPB-UHFFFAOYSA-N 4-[[8-fluoro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=CC=2F)C3=N1 UMMQZQVVUPECPB-UHFFFAOYSA-N 0.000 description 1
- ATSOFYUMBYNLAW-UHFFFAOYSA-N 4-[[9,10-dichloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC(Cl)=C(Cl)C=2)C3=N1 ATSOFYUMBYNLAW-UHFFFAOYSA-N 0.000 description 1
- IVSSKWXSHUTVNU-UHFFFAOYSA-N 4-[[9-(3-aminoprop-1-ynyl)-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C=1C(C#CCN)=CC=C(C2=N3)C=1C(C=1C(=CC=CC=1F)F)=NCC2=CN=C3NC1=CC=C(C(O)=O)C=C1 IVSSKWXSHUTVNU-UHFFFAOYSA-N 0.000 description 1
- SRDXCUJEGMZNGM-UHFFFAOYSA-N 4-[[9-(aminomethyl)-7-phenyl-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C=1C(CN)=CC=C(C2=N3)C=1C(C=1C=CC=CC=1)=NCC2=CN=C3NC1=CC=C(C(O)=O)C=C1 SRDXCUJEGMZNGM-UHFFFAOYSA-N 0.000 description 1
- OSWRURQLZRZMQM-UHFFFAOYSA-N 4-[[9-bromo-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Br)C=2)C=2C(=CC=CC=2F)F)C3=N1 OSWRURQLZRZMQM-UHFFFAOYSA-N 0.000 description 1
- TVWZFPJKUNNMFQ-UHFFFAOYSA-N 4-[[9-chloro-7-(1-methylimidazol-2-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound CN1C=CN=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 TVWZFPJKUNNMFQ-UHFFFAOYSA-N 0.000 description 1
- QKBIVRCKFWWZRW-UHFFFAOYSA-N 4-[[9-chloro-7-(1-methylpyrrol-2-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound CN1C=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 QKBIVRCKFWWZRW-UHFFFAOYSA-N 0.000 description 1
- LEIMNPZWHBTGSA-UHFFFAOYSA-N 4-[[9-chloro-7-(1h-pyrazol-5-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2NN=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 LEIMNPZWHBTGSA-UHFFFAOYSA-N 0.000 description 1
- QDOJEUVQQCURKH-UHFFFAOYSA-N 4-[[9-chloro-7-(2,3-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=C(F)C=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 QDOJEUVQQCURKH-UHFFFAOYSA-N 0.000 description 1
- QVBSQDLYYDHSNV-UHFFFAOYSA-N 4-[[9-chloro-7-(2,3-difluorophenyl)-7h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(C=NC(C=2C(=C(F)C=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 QVBSQDLYYDHSNV-UHFFFAOYSA-N 0.000 description 1
- GCWGVDYATPTTEA-UHFFFAOYSA-N 4-[[9-chloro-7-(2,3-dimethoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound COC1=CC=CC(C=2C3=CC(Cl)=CC=C3C3=NC(NC=4C=CC(=CC=4)C(O)=O)=NC=C3CN=2)=C1OC GCWGVDYATPTTEA-UHFFFAOYSA-N 0.000 description 1
- VKPWWVKFRILNMD-UHFFFAOYSA-N 4-[[9-chloro-7-(2,4-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC(F)=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 VKPWWVKFRILNMD-UHFFFAOYSA-N 0.000 description 1
- GKCWESFHJXQXBK-UHFFFAOYSA-N 4-[[9-chloro-7-(2,4-difluorophenyl)-7h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(C=NC(C=2C(=CC(F)=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 GKCWESFHJXQXBK-UHFFFAOYSA-N 0.000 description 1
- QLGXDUIDHBJHMU-UHFFFAOYSA-N 4-[[9-chloro-7-(2,4-dimethoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound COC1=CC(OC)=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 QLGXDUIDHBJHMU-UHFFFAOYSA-N 0.000 description 1
- BZVMGBNSNLBDNB-UHFFFAOYSA-N 4-[[9-chloro-7-(2,5-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=C(F)C=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 BZVMGBNSNLBDNB-UHFFFAOYSA-N 0.000 description 1
- JEWTYPJJSDUXFI-UHFFFAOYSA-N 4-[[9-chloro-7-(2,5-dimethoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound COC1=CC=C(OC)C(C=2C3=CC(Cl)=CC=C3C3=NC(NC=4C=CC(=CC=4)C(O)=O)=NC=C3CN=2)=C1 JEWTYPJJSDUXFI-UHFFFAOYSA-N 0.000 description 1
- NQDIAQSYIRAUHH-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5-methyl-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound N=1C=C2C(C)N=C(C=3C(=CC=CC=3F)F)C3=CC(Cl)=CC=C3C2=NC=1NC1=CC=C(C(O)=O)C=C1 NQDIAQSYIRAUHH-UHFFFAOYSA-N 0.000 description 1
- CCRLUFMMOYBDEU-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-N-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 CCRLUFMMOYBDEU-UHFFFAOYSA-N 0.000 description 1
- HHFBDROWDBDFBR-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HHFBDROWDBDFBR-UHFFFAOYSA-N 0.000 description 1
- MDCKGBAKEDQUNI-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 MDCKGBAKEDQUNI-UHFFFAOYSA-N 0.000 description 1
- JACKKXMTVKLIMK-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)benzamide Chemical compound CN1C(C2)CCC1CC2NC(=O)C(C=C1)=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=C(F)C=CC=C1F JACKKXMTVKLIMK-UHFFFAOYSA-N 0.000 description 1
- ZJVKOGUJHFOIIB-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-(diaminomethylidene)benzamide Chemical compound C1=CC(C(=O)NC(=N)N)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 ZJVKOGUJHFOIIB-UHFFFAOYSA-N 0.000 description 1
- BITVTLFNIDCPTC-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[2-(dimethylamino)ethyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)N(C)CCN(C)C)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 BITVTLFNIDCPTC-UHFFFAOYSA-N 0.000 description 1
- ZBROEVYPJZMXNC-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[3-(dimethylamino)propyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)N(C)CCCN(C)C)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 ZBROEVYPJZMXNC-UHFFFAOYSA-N 0.000 description 1
- MYQQYMKPATUPSR-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methyl-n-[2-(methylamino)ethyl]benzamide Chemical compound C1=CC(C(=O)N(C)CCNC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 MYQQYMKPATUPSR-UHFFFAOYSA-N 0.000 description 1
- CXHSUMSITMDOLT-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methyl-n-[3-(methylamino)propyl]benzamide Chemical compound C1=CC(C(=O)N(C)CCCNC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 CXHSUMSITMDOLT-UHFFFAOYSA-N 0.000 description 1
- PWXOHKPSRDYOKQ-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 PWXOHKPSRDYOKQ-UHFFFAOYSA-N 0.000 description 1
- FWLJKAPQUYTYTQ-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzonitrile Chemical compound FC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C#N)C=C1 FWLJKAPQUYTYTQ-UHFFFAOYSA-N 0.000 description 1
- NKJSANVAPCGHJB-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-7h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(C=NC(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 NKJSANVAPCGHJB-UHFFFAOYSA-N 0.000 description 1
- RXIIMYGEAPMYMK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-chloro-6-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)Cl)C3=N1 RXIIMYGEAPMYMK-UHFFFAOYSA-N 0.000 description 1
- PIASAAQUZGWWHN-UHFFFAOYSA-N 4-[[9-chloro-7-(2-chlorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenol Chemical compound C1=CC(O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)Cl)C=2C3=CC=C(Cl)C=2)C3=N1 PIASAAQUZGWWHN-UHFFFAOYSA-N 0.000 description 1
- ZMACWTZGUYDXMD-UHFFFAOYSA-N 4-[[9-chloro-7-(2-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-hydroxy-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C=C(C(=O)NCCN2CCOCC2)C(O)=CC=1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=CC=CC=C1Cl ZMACWTZGUYDXMD-UHFFFAOYSA-N 0.000 description 1
- FTIJSVYQPLBYQQ-UHFFFAOYSA-N 4-[[9-chloro-7-(2-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)Cl)C=2C3=CC=C(Cl)C=2)C3=N1 FTIJSVYQPLBYQQ-UHFFFAOYSA-N 0.000 description 1
- FRASZTXXDOONAB-UHFFFAOYSA-N 4-[[9-chloro-7-(2-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C(Cl)=CC=C(C2=N3)C=1C(C=1C(=CC=CC=1)Cl)=NCC2=CN=C3NC(C=C1)=CC=C1C(=O)NCCN1CCOCC1 FRASZTXXDOONAB-UHFFFAOYSA-N 0.000 description 1
- GJNIQLKGIGAVRY-UHFFFAOYSA-N 4-[[9-chloro-7-(2-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(NC=3N=C4C5=CC=C(Cl)C=C5C(C=5C(=CC=CC=5)Cl)=NCC4=CN=3)=CC=2)=N1 GJNIQLKGIGAVRY-UHFFFAOYSA-N 0.000 description 1
- FLCQGVRZZWFILU-UHFFFAOYSA-N 4-[[9-chloro-7-(2-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[3-(4-methylpiperazin-1-yl)propyl]benzamide Chemical compound C1CN(C)CCN1CCCNC(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)Cl)C=2C3=CC=C(Cl)C=2)C3=N1 FLCQGVRZZWFILU-UHFFFAOYSA-N 0.000 description 1
- ORONNKFITWUNQM-UHFFFAOYSA-N 4-[[9-chloro-7-(2-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)Cl)C=2C3=CC=C(Cl)C=2)C3=N1 ORONNKFITWUNQM-UHFFFAOYSA-N 0.000 description 1
- FKJUMSOAYCCTID-UHFFFAOYSA-N 4-[[9-chloro-7-(2-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)Cl)C=2C3=CC=C(Cl)C=2)C3=N1 FKJUMSOAYCCTID-UHFFFAOYSA-N 0.000 description 1
- HHJPSBROCVPKLT-UHFFFAOYSA-N 4-[[9-chloro-7-(2-ethoxy-6-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound CCOC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 HHJPSBROCVPKLT-UHFFFAOYSA-N 0.000 description 1
- WBCFWQRQASBGSM-UHFFFAOYSA-N 4-[[9-chloro-7-(2-ethoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound CCOC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 WBCFWQRQASBGSM-UHFFFAOYSA-N 0.000 description 1
- JOYIUQHYPVFGEJ-UHFFFAOYSA-N 4-[[9-chloro-7-(2-ethynylphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)C#C)C=2C3=CC=C(Cl)C=2)C3=N1 JOYIUQHYPVFGEJ-UHFFFAOYSA-N 0.000 description 1
- UDSRUEBASZTLQC-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-hydroxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(O)cccc2F)ccc1C(O)=O UDSRUEBASZTLQC-UHFFFAOYSA-N 0.000 description 1
- BMOKTUMVDQVMHA-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-hydroxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2O)F)C3=N1 BMOKTUMVDQVMHA-UHFFFAOYSA-N 0.000 description 1
- FEMRNCIHZYHSSB-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[2-(dimethylamino)ethyl]-n-methylbenzamide Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N(C)CCN(C)C)C=C1 FEMRNCIHZYHSSB-UHFFFAOYSA-N 0.000 description 1
- RDVBUVWXVRXLLC-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[3-(dimethylamino)propyl]-n-methylbenzamide Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N(C)CCCN(C)C)C=C1 RDVBUVWXVRXLLC-UHFFFAOYSA-N 0.000 description 1
- HNOYXNAMQHTCOB-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methyl-n-[2-(methylamino)ethyl]benzamide Chemical compound C1=CC(C(=O)N(C)CCNC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)OC)C3=N1 HNOYXNAMQHTCOB-UHFFFAOYSA-N 0.000 description 1
- PYVWPGHQRPOZKP-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methyl-n-[3-(methylamino)propyl]benzamide Chemical compound C1=CC(C(=O)N(C)CCCNC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)OC)C3=N1 PYVWPGHQRPOZKP-UHFFFAOYSA-N 0.000 description 1
- UQXPONWWSBAXMI-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 UQXPONWWSBAXMI-UHFFFAOYSA-N 0.000 description 1
- ZNHZAPIMANDPNM-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-propan-2-yloxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound CC(C)OC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 ZNHZAPIMANDPNM-UHFFFAOYSA-N 0.000 description 1
- MLNWQPNCJHTDNB-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-4-methyl-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound N=1C(C2=CC=C(Cl)C=C2C(C=2C(=CC=CC=2)F)=NC2)=C2C(C)=NC=1NC1=CC=C(C(O)=O)C=C1 MLNWQPNCJHTDNB-UHFFFAOYSA-N 0.000 description 1
- FNFWCIIKWUJRGO-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-(trifluoromethyl)benzoic acid Chemical compound C1=C(C(F)(F)F)C(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 FNFWCIIKWUJRGO-UHFFFAOYSA-N 0.000 description 1
- RQGDZCBUSDNJIX-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-fluorobenzoic acid Chemical compound C1=C(F)C(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 RQGDZCBUSDNJIX-UHFFFAOYSA-N 0.000 description 1
- HDWFLJRSJUZKMD-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 HDWFLJRSJUZKMD-UHFFFAOYSA-N 0.000 description 1
- HOIKREHNTRIKOE-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)=C1 HOIKREHNTRIKOE-UHFFFAOYSA-N 0.000 description 1
- ISMMDEVCMHTOBG-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methylbenzoic acid Chemical compound C1=C(C(O)=O)C(C)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)=C1 ISMMDEVCMHTOBG-UHFFFAOYSA-N 0.000 description 1
- FXYUKKQSXWUGSG-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n,n-bis(2-hydroxyethyl)benzamide Chemical compound C1=CC(C(=O)N(CCO)CCO)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 FXYUKKQSXWUGSG-UHFFFAOYSA-N 0.000 description 1
- HKJWWSHUNMBPEO-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NCCN2CCOCC2)C=C1 HKJWWSHUNMBPEO-UHFFFAOYSA-N 0.000 description 1
- GVODKPTYHXTNRQ-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzenesulfonamide Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(S(=O)(=O)NCCN2CCOCC2)C=C1 GVODKPTYHXTNRQ-UHFFFAOYSA-N 0.000 description 1
- GLEXTCPLZZQLSD-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-(2-pyridin-2-ylethyl)benzamide Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NCCC=2N=CC=CC=2)C=C1 GLEXTCPLZZQLSD-UHFFFAOYSA-N 0.000 description 1
- OTTMZEVUTDWPRP-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-(2-pyridin-3-ylethyl)benzamide Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NCCC=2C=NC=CC=2)C=C1 OTTMZEVUTDWPRP-UHFFFAOYSA-N 0.000 description 1
- LGNPVKSDFDLADU-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-(2-pyridin-4-ylethyl)benzamide Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NCCC=2C=CN=CC=2)C=C1 LGNPVKSDFDLADU-UHFFFAOYSA-N 0.000 description 1
- HZBWTOABWGBVHE-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[2-(1h-imidazol-5-yl)ethyl]benzamide Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NCCC=2N=CNC=2)C=C1 HZBWTOABWGBVHE-UHFFFAOYSA-N 0.000 description 1
- YHGCPBKMTMTNEZ-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[2-(dimethylamino)ethyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)N(C)CCN(C)C)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 YHGCPBKMTMTNEZ-UHFFFAOYSA-N 0.000 description 1
- NOTUXRSQUHYCEP-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[2-(dimethylamino)ethyl]benzamide Chemical compound C1=CC(C(=O)NCCN(C)C)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 NOTUXRSQUHYCEP-UHFFFAOYSA-N 0.000 description 1
- AAZZIPJJNHUYOK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[2-(methylamino)ethyl]benzamide Chemical compound C1=CC(C(=O)NCCNC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 AAZZIPJJNHUYOK-UHFFFAOYSA-N 0.000 description 1
- MUDQEKDBTHVADN-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[3-(4-methylpiperazin-1-yl)propyl]benzamide Chemical compound C1CN(C)CCN1CCCNC(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 MUDQEKDBTHVADN-UHFFFAOYSA-N 0.000 description 1
- RFUOOBNVPMIZBD-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[3-(dimethylamino)propyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)N(C)CCCN(C)C)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 RFUOOBNVPMIZBD-UHFFFAOYSA-N 0.000 description 1
- FYMYLUASZZIJSM-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[3-(dimethylamino)propyl]benzamide Chemical compound C1=CC(C(=O)NCCCN(C)C)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 FYMYLUASZZIJSM-UHFFFAOYSA-N 0.000 description 1
- YPOAJVSLIZOOGG-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[3-(methylamino)propyl]benzamide Chemical compound C1=CC(C(=O)NCCCNC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 YPOAJVSLIZOOGG-UHFFFAOYSA-N 0.000 description 1
- AUGLHTGPRBHFEB-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methyl-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)C=CC=1C(=O)N(C)C1CCN(C)C1 AUGLHTGPRBHFEB-UHFFFAOYSA-N 0.000 description 1
- OBUBDHYTVRPEPH-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methyl-n-(2-pyridin-2-ylethyl)benzamide Chemical compound C=1C=C(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)C=CC=1C(=O)N(C)CCC1=CC=CC=N1 OBUBDHYTVRPEPH-UHFFFAOYSA-N 0.000 description 1
- JKSPDRABZSBTQT-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methyl-n-[2-(methylamino)ethyl]benzamide Chemical compound C1=CC(C(=O)N(C)CCNC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 JKSPDRABZSBTQT-UHFFFAOYSA-N 0.000 description 1
- NJDSQWQSAYKNTC-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-piperidin-4-ylbenzamide Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NC2CCNCC2)C=C1 NJDSQWQSAYKNTC-UHFFFAOYSA-N 0.000 description 1
- LLAIVPUTXXGBIS-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 LLAIVPUTXXGBIS-UHFFFAOYSA-N 0.000 description 1
- JFJIJBMWCBALGN-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzenesulfonic acid Chemical compound C1=CC(S(=O)(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 JFJIJBMWCBALGN-UHFFFAOYSA-N 0.000 description 1
- USEFICSVVKKZGA-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 USEFICSVVKKZGA-UHFFFAOYSA-N 0.000 description 1
- UCNWTTLSCQGAOI-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzonitrile Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C#N)C=C1 UCNWTTLSCQGAOI-UHFFFAOYSA-N 0.000 description 1
- FJSSSGMNQPHBSG-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 FJSSSGMNQPHBSG-UHFFFAOYSA-N 0.000 description 1
- XRVXDGQWSXSOIE-UHFFFAOYSA-N 4-[[9-chloro-7-(2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-(3-morpholin-4-ylpropyl)benzamide Chemical compound COC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NCCCN2CCOCC2)C=C1 XRVXDGQWSXSOIE-UHFFFAOYSA-N 0.000 description 1
- PQNZWCUQBQWCRQ-UHFFFAOYSA-N 4-[[9-chloro-7-(2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[3-(4-methylpiperazin-1-yl)propyl]benzamide Chemical compound COC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NCCCN2CCN(C)CC2)C=C1 PQNZWCUQBQWCRQ-UHFFFAOYSA-N 0.000 description 1
- HZKLSYDUQPQDOL-UHFFFAOYSA-N 4-[[9-chloro-7-(2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound COC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 HZKLSYDUQPQDOL-UHFFFAOYSA-N 0.000 description 1
- ZEKLLNZHKZCMDO-UHFFFAOYSA-N 4-[[9-chloro-7-(2-methylphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound CC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NCCN2CCOCC2)C=C1 ZEKLLNZHKZCMDO-UHFFFAOYSA-N 0.000 description 1
- LRZQXDMWNOBNRS-UHFFFAOYSA-N 4-[[9-chloro-7-(2-methylphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[3-(4-methylpiperazin-1-yl)propyl]benzamide Chemical compound C1CN(C)CCN1CCCNC(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)C)C=2C3=CC=C(Cl)C=2)C3=N1 LRZQXDMWNOBNRS-UHFFFAOYSA-N 0.000 description 1
- BKLYJESIVMHNOR-UHFFFAOYSA-N 4-[[9-chloro-7-(2-methylphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound CC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 BKLYJESIVMHNOR-UHFFFAOYSA-N 0.000 description 1
- PRDYWBKCXQBMCM-UHFFFAOYSA-N 4-[[9-chloro-7-(2-propan-2-yloxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound CC(C)OC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 PRDYWBKCXQBMCM-UHFFFAOYSA-N 0.000 description 1
- GVOVAPMRCYNCIZ-UHFFFAOYSA-N 4-[[9-chloro-7-(3-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound FC1=CC=CC(C=2C3=CC(Cl)=CC=C3C3=NC(NC=4C=CC(=CC=4)C(=O)NCCN4CCOCC4)=NC=C3CN=2)=C1 GVOVAPMRCYNCIZ-UHFFFAOYSA-N 0.000 description 1
- UALQCZKUTNUJOB-UHFFFAOYSA-N 4-[[9-chloro-7-(3-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C=C(F)C=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 UALQCZKUTNUJOB-UHFFFAOYSA-N 0.000 description 1
- NOQCRZBDXRGSGX-UHFFFAOYSA-N 4-[[9-chloro-7-(3-fluoropyridin-2-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CN=2)F)C3=N1 NOQCRZBDXRGSGX-UHFFFAOYSA-N 0.000 description 1
- CKHLPHUPRRWPOT-UHFFFAOYSA-N 4-[[9-chloro-7-(3-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound COC1=CC=CC(C=2C3=CC(Cl)=CC=C3C3=NC(NC=4C=CC(=CC=4)C(O)=O)=NC=C3CN=2)=C1 CKHLPHUPRRWPOT-UHFFFAOYSA-N 0.000 description 1
- TVTOQVJTDLQUPX-UHFFFAOYSA-N 4-[[9-chloro-7-(3-methoxypyridin-2-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound COC1=CC=CN=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 TVTOQVJTDLQUPX-UHFFFAOYSA-N 0.000 description 1
- MCQHFHQVBLCPTO-UHFFFAOYSA-N 4-[[9-chloro-7-(4-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C1=CC(F)=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NCCN2CCOCC2)C=C1 MCQHFHQVBLCPTO-UHFFFAOYSA-N 0.000 description 1
- GIGXFSMNPJUQAZ-UHFFFAOYSA-N 4-[[9-chloro-7-(4-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[3-(4-methylpiperazin-1-yl)propyl]benzamide Chemical compound C1CN(C)CCN1CCCNC(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C=CC(F)=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 GIGXFSMNPJUQAZ-UHFFFAOYSA-N 0.000 description 1
- YIGCDMWYAWHDJZ-UHFFFAOYSA-N 4-[[9-chloro-7-(4-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(OC)=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 YIGCDMWYAWHDJZ-UHFFFAOYSA-N 0.000 description 1
- GRGCNYCCLBOPEP-UHFFFAOYSA-N 4-[[9-chloro-7-(5-fluoro-2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound COC1=CC=C(F)C=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 GRGCNYCCLBOPEP-UHFFFAOYSA-N 0.000 description 1
- AOZJODGUNAEING-UHFFFAOYSA-N 4-[[9-chloro-7-[2-(2-methylpropyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound CC(C)CC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 AOZJODGUNAEING-UHFFFAOYSA-N 0.000 description 1
- VGPXJVMNYCEMFN-UHFFFAOYSA-N 4-[[9-chloro-7-[2-(trifluoromethoxy)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)OC(F)(F)F)C=2C3=CC=C(Cl)C=2)C3=N1 VGPXJVMNYCEMFN-UHFFFAOYSA-N 0.000 description 1
- PZLIVYQCUBSQGN-UHFFFAOYSA-N 4-[[9-chloro-7-[2-(trifluoromethyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)C(F)(F)F)C=2C3=CC=C(Cl)C=2)C3=N1 PZLIVYQCUBSQGN-UHFFFAOYSA-N 0.000 description 1
- CXNWXQIOLUPIFA-UHFFFAOYSA-N 4-[[9-chloro-7-[2-[2-(dimethylamino)ethylamino]-6-fluorophenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)NCCN(C)C)C3=N1 CXNWXQIOLUPIFA-UHFFFAOYSA-N 0.000 description 1
- CKIBXQMNSSOMLY-UHFFFAOYSA-N 4-[[9-chloro-7-[2-[4-(dimethylamino)piperidin-1-yl]-6-fluorophenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)N2CCC(CC2)N(C)C)C3=N1 CKIBXQMNSSOMLY-UHFFFAOYSA-N 0.000 description 1
- HPOCSUYHZCLQHF-UHFFFAOYSA-N 4-[[9-chloro-7-[2-fluoro-6-(2,2,2-trifluoroethoxy)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OCC(F)(F)F)=C1 HPOCSUYHZCLQHF-UHFFFAOYSA-N 0.000 description 1
- FOVOQGNRFWKHHP-UHFFFAOYSA-N 4-[[9-chloro-7-[2-fluoro-6-(2-hydroxyethylamino)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)NCCO)C3=N1 FOVOQGNRFWKHHP-UHFFFAOYSA-N 0.000 description 1
- DVJZVJYCBPYPBM-UHFFFAOYSA-N 4-[[9-chloro-7-[2-fluoro-6-(methylamino)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)NC)C3=N1 DVJZVJYCBPYPBM-UHFFFAOYSA-N 0.000 description 1
- PTAZGIIWAMTJNC-UHFFFAOYSA-N 4-[[9-chloro-7-[2-fluoro-6-(trifluoromethoxy)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC(F)(F)F)=C1 PTAZGIIWAMTJNC-UHFFFAOYSA-N 0.000 description 1
- VOHOBTTXEWZKQH-UHFFFAOYSA-N 4-[[9-chloro-7-[2-fluoro-6-(trifluoromethoxy)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)OC(F)(F)F)C3=N1 VOHOBTTXEWZKQH-UHFFFAOYSA-N 0.000 description 1
- UCZOHMWZLSWKPI-UHFFFAOYSA-N 4-[[9-chloro-7-[2-fluoro-6-(trifluoromethyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)C(F)(F)F)C3=N1 UCZOHMWZLSWKPI-UHFFFAOYSA-N 0.000 description 1
- YQCKGCMPPQNOEY-UHFFFAOYSA-N 4-[[9-chloro-7-[2-fluoro-6-[methyl-[2-(methylamino)ethyl]amino]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound CNCCN(C)C1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NC)C=C1 YQCKGCMPPQNOEY-UHFFFAOYSA-N 0.000 description 1
- MENXJDQSXIKZRN-UHFFFAOYSA-N 4-[[9-chloro-7-[2-fluoro-6-[methyl-[2-(methylamino)ethyl]amino]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound CNCCN(C)C1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 MENXJDQSXIKZRN-UHFFFAOYSA-N 0.000 description 1
- LNOQYFKUBZRESO-UHFFFAOYSA-N 4-[[9-chloro-7-[2-fluoro-6-[methyl-[3-(methylamino)propyl]amino]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound CNCCCN(C)C1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 LNOQYFKUBZRESO-UHFFFAOYSA-N 0.000 description 1
- CDFXUAGQGZBFKW-UHFFFAOYSA-N 4-[[9-chloro-7-[3-fluoro-2-(trifluoromethoxy)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=C(F)C=CC=2)OC(F)(F)F)C=2C3=CC=C(Cl)C=2)C3=N1 CDFXUAGQGZBFKW-UHFFFAOYSA-N 0.000 description 1
- YGZJUOWPZSLWNV-UHFFFAOYSA-N 4-[[9-ethenyl-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 YGZJUOWPZSLWNV-UHFFFAOYSA-N 0.000 description 1
- NRJOLMQQQLDIPP-UHFFFAOYSA-N 4-[[9-ethynyl-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C#C)=C1 NRJOLMQQQLDIPP-UHFFFAOYSA-N 0.000 description 1
- JWNVXNYHPMJAPN-UHFFFAOYSA-N 4-[[9-ethynyl-7-[2-fluoro-6-(2,2,2-trifluoroethoxy)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OCC(F)(F)F)C#C)=C1 JWNVXNYHPMJAPN-UHFFFAOYSA-N 0.000 description 1
- YFCYIMYBUUIUEN-UHFFFAOYSA-N 4-[[9-fluoro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(F)C=2)C3=N1 YFCYIMYBUUIUEN-UHFFFAOYSA-N 0.000 description 1
- HKHVPVKKKFXKQF-UHFFFAOYSA-N 4-amino-1-[2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]-n,n-dimethylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)N(C)C)(N)CCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HKHVPVKKKFXKQF-UHFFFAOYSA-N 0.000 description 1
- AHGMVDSJIDRREM-UHFFFAOYSA-N 4-amino-1-[2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]-n-methylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)NC)(N)CCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 AHGMVDSJIDRREM-UHFFFAOYSA-N 0.000 description 1
- ZRZIZHAMCPSKNV-UHFFFAOYSA-N 4-amino-1-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]-n-methylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)NC)(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 ZRZIZHAMCPSKNV-UHFFFAOYSA-N 0.000 description 1
- CAOPIWJDDHZFGX-UHFFFAOYSA-N 4-amino-1-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)N)(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 CAOPIWJDDHZFGX-UHFFFAOYSA-N 0.000 description 1
- POHSJAQZZZPOEX-UHFFFAOYSA-N 4-amino-1-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]piperidine-4-carboxylic acid Chemical compound C1CC(N)(C(O)=O)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 POHSJAQZZZPOEX-UHFFFAOYSA-N 0.000 description 1
- CFHCQZXHPXULBF-UHFFFAOYSA-N 4-n-[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]benzene-1,4-diamine Chemical compound C1=CC(N)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 CFHCQZXHPXULBF-UHFFFAOYSA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- IBWUHCOBBBPVHQ-UHFFFAOYSA-N 5-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-fluorobenzoic acid Chemical compound C1=C(F)C(C(=O)O)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)=C1 IBWUHCOBBBPVHQ-UHFFFAOYSA-N 0.000 description 1
- PXQOEZNTCSSTCQ-UHFFFAOYSA-N 5-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 PXQOEZNTCSSTCQ-UHFFFAOYSA-N 0.000 description 1
- OIGDIAFDUXHQOM-UHFFFAOYSA-N 5-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methylbenzoic acid Chemical compound C1=C(C(O)=O)C(C)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 OIGDIAFDUXHQOM-UHFFFAOYSA-N 0.000 description 1
- DXQRLAIHSDVTIU-UHFFFAOYSA-N 5-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]pyridine-2-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 DXQRLAIHSDVTIU-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- DEWIUKZYVVHLCU-UHFFFAOYSA-N 6-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]pyridazine-3-carboxylic acid Chemical compound N1=NC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 DEWIUKZYVVHLCU-UHFFFAOYSA-N 0.000 description 1
- LEKYTBGKQOOZEK-UHFFFAOYSA-N 6-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]pyridine-3-carboxylic acid Chemical compound N1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 LEKYTBGKQOOZEK-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- JUIYNSILCQPBJT-UHFFFAOYSA-N 7-(2,6-difluorophenyl)-2-(3-methoxyanilino)-5h-pyrimido[5,4-d][2]benzazepine-9-carboxylic acid Chemical compound COC1=CC=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)C(O)=O)=C1 JUIYNSILCQPBJT-UHFFFAOYSA-N 0.000 description 1
- JFTULWXHKFILPC-UHFFFAOYSA-N 7-(2,6-difluorophenyl)-2-[(4-methyl-1,3-thiazol-2-yl)amino]-5h-pyrimido[5,4-d][2]benzazepine-9-carboxylic acid Chemical compound CC1=CSC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)C(O)=O)=N1 JFTULWXHKFILPC-UHFFFAOYSA-N 0.000 description 1
- YZUHJDPYQJAPQS-UHFFFAOYSA-N 7-(2,6-difluorophenyl)-n-(3-methoxyphenyl)-9-(3-pyrrolidin-1-ylprop-1-ynyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)C#CCN2CCCC2)=C1 YZUHJDPYQJAPQS-UHFFFAOYSA-N 0.000 description 1
- BEGNCKCSHRRKRJ-UHFFFAOYSA-N 7-(2-bromophenyl)-9-chloro-n-(3,4-dimethoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)Br)C=2C3=CC=C(Cl)C=2)C3=N1 BEGNCKCSHRRKRJ-UHFFFAOYSA-N 0.000 description 1
- YXFTUNPBIWOEAD-UHFFFAOYSA-N 7-(2-fluorophenyl)-2-(3-methoxyanilino)-5h-pyrimido[5,4-d][2]benzazepine-9-carboxylic acid Chemical compound COC1=CC=CC(NC=2N=C3C4=CC=C(C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)C(O)=O)=C1 YXFTUNPBIWOEAD-UHFFFAOYSA-N 0.000 description 1
- WIFYBVWAADZGAA-UHFFFAOYSA-N 7-(2-fluorophenyl)-2-(3-methoxyanilino)-n-(3-morpholin-4-ylpropyl)-5h-pyrimido[5,4-d][2]benzazepine-9-carboxamide Chemical compound COC1=CC=CC(NC=2N=C3C4=CC=C(C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)C(=O)NCCCN2CCOCC2)=C1 WIFYBVWAADZGAA-UHFFFAOYSA-N 0.000 description 1
- KKOSUEPSCNZVOX-UHFFFAOYSA-N 7-(2-fluorophenyl)-2-(3-methoxyanilino)-n-methyl-n-[3-(methylamino)propyl]-5h-pyrimido[5,4-d][2]benzazepine-9-carboxamide Chemical compound C=1C(C(=O)N(C)CCCNC)=CC=C(C2=N3)C=1C(C=1C(=CC=CC=1)F)=NCC2=CN=C3NC1=CC=CC(OC)=C1 KKOSUEPSCNZVOX-UHFFFAOYSA-N 0.000 description 1
- PSSONIFMGYLJDG-UHFFFAOYSA-N 7-[3-[[7-(2-fluoro-6-methoxyphenyl)-9-methoxy-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-1,7-diazaspiro[4.4]nonan-6-one Chemical compound C=1C(OC)=CC=C(C2=N3)C=1C(C=1C(=CC=CC=1F)OC)=NCC2=CN=C3NC(C=1)=CC=CC=1N(C1=O)CCC21CCCN2 PSSONIFMGYLJDG-UHFFFAOYSA-N 0.000 description 1
- NNZGRBVSQCHTNB-UHFFFAOYSA-N 9,10-dichloro-n-(3,4-dimethoxyphenyl)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC(Cl)=C(Cl)C=2)C3=N1 NNZGRBVSQCHTNB-UHFFFAOYSA-N 0.000 description 1
- CFBCJATVPAJXKX-UHFFFAOYSA-N 9-(3-aminoprop-1-ynyl)-7-(2,6-difluorophenyl)-n-(3-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)C#CCN)=C1 CFBCJATVPAJXKX-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- YZAMGXFGCNKHRD-UHFFFAOYSA-N 9-bromo-7-(2,6-difluorophenyl)-n-(3-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3C4=CC=C(Br)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 YZAMGXFGCNKHRD-UHFFFAOYSA-N 0.000 description 1
- GTFVVWYYXBXPIG-UHFFFAOYSA-N 9-chloro-2-(3,4-dimethoxyanilino)-5,6-dihydropyrimido[5,4-d][2]benzazepin-7-one Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CNC(=O)C=2C3=CC=C(Cl)C=2)C3=N1 GTFVVWYYXBXPIG-UHFFFAOYSA-N 0.000 description 1
- ZJYARRRIOWFIBQ-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-(3-iodophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound FC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC(I)=C1 ZJYARRRIOWFIBQ-UHFFFAOYSA-N 0.000 description 1
- NXFRTLPEWJLCNZ-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-(4-nitrophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 NXFRTLPEWJLCNZ-UHFFFAOYSA-N 0.000 description 1
- YIKFBKOBWIWMFZ-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-(5-methyl-1h-pyrazol-3-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound N1N=C(C)C=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 YIKFBKOBWIWMFZ-UHFFFAOYSA-N 0.000 description 1
- VOYXSUZPNLKNPN-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[2-(methylaminomethyl)-3h-benzimidazol-5-yl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C2NC(CNC)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=C(F)C=CC=C1F VOYXSUZPNLKNPN-UHFFFAOYSA-N 0.000 description 1
- HSRQBJXYTYQIQH-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[3-(2,2,6,6-tetramethylpiperidin-4-yl)oxyphenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1C(C)(C)NC(C)(C)CC1OC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 HSRQBJXYTYQIQH-UHFFFAOYSA-N 0.000 description 1
- OVMCGKSXHJMTKO-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[3-(3,5-dimethylpiperazine-1-carboximidoyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1C(C)NC(C)CN1C(=N)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 OVMCGKSXHJMTKO-UHFFFAOYSA-N 0.000 description 1
- SEUICABNDIEZGK-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound CN(C)CC#CC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 SEUICABNDIEZGK-UHFFFAOYSA-N 0.000 description 1
- CQDNUGURIHTGBD-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[3-[3-(dimethylamino)propyl]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound CN(C)CCCC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 CQDNUGURIHTGBD-UHFFFAOYSA-N 0.000 description 1
- AKDKGEOUADXKBO-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[4-(3,5-dimethylpiperazine-1-carboximidoyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1C(C)NC(C)CN1C(=N)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 AKDKGEOUADXKBO-UHFFFAOYSA-N 0.000 description 1
- XKHWJBZPHITCMS-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[4-(5,5-dimethyl-1,4-dihydroimidazol-2-yl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound N1C(C)(C)CN=C1C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 XKHWJBZPHITCMS-UHFFFAOYSA-N 0.000 description 1
- QIYQPPYNEXEYGT-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[4-[3-(dimethylamino)azetidine-1-carboximidoyl]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1C(N(C)C)CN1C(=N)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 QIYQPPYNEXEYGT-UHFFFAOYSA-N 0.000 description 1
- MVKQXBBJRQOBJV-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[4-[3-(dimethylamino)pyrrolidine-1-carboximidoyl]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1C(N(C)C)CCN1C(=N)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 MVKQXBBJRQOBJV-UHFFFAOYSA-N 0.000 description 1
- FWOGTUIEZYZYED-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[4-[3-(methylamino)pyrrolidine-1-carboximidoyl]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1C(NC)CCN1C(=N)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 FWOGTUIEZYZYED-UHFFFAOYSA-N 0.000 description 1
- AVDMAQJRJPBQAI-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[4-[4-(dimethylamino)piperidine-1-carboximidoyl]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1CC(N(C)C)CCN1C(=N)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 AVDMAQJRJPBQAI-UHFFFAOYSA-N 0.000 description 1
- GVGUVZGCXSJZMO-UHFFFAOYSA-N 9-chloro-7-(2-chlorophenyl)-n-(3,4-dimethoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)Cl)C=2C3=CC=C(Cl)C=2)C3=N1 GVGUVZGCXSJZMO-UHFFFAOYSA-N 0.000 description 1
- KTECHXDJJANQFQ-UHFFFAOYSA-N 9-chloro-7-(2-chlorophenyl)-n-(3,5-dimethoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound COC1=CC(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)Cl)=NCC3=CN=2)=C1 KTECHXDJJANQFQ-UHFFFAOYSA-N 0.000 description 1
- RGOBTVCYHYWRED-UHFFFAOYSA-N 9-chloro-7-(2-chlorophenyl)-n-(4-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=CC(Cl)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)Cl)C=2C3=CC=C(Cl)C=2)C3=N1 RGOBTVCYHYWRED-UHFFFAOYSA-N 0.000 description 1
- XZYLGEZRZDWFOB-UHFFFAOYSA-N 9-chloro-7-(2-chlorophenyl)-n-pyridin-2-yl-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C=1C(Cl)=CC=C(C2=N3)C=1C(C=1C(=CC=CC=1)Cl)=NCC2=CN=C3NC1=CC=CC=N1 XZYLGEZRZDWFOB-UHFFFAOYSA-N 0.000 description 1
- QJNNRZWUSJOLLW-UHFFFAOYSA-N 9-chloro-7-(2-fluorophenyl)-n-(2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound COC1=CC=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 QJNNRZWUSJOLLW-UHFFFAOYSA-N 0.000 description 1
- PILGINUIAZACRU-UHFFFAOYSA-N 9-chloro-7-(2-fluorophenyl)-n-(3-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)=C1 PILGINUIAZACRU-UHFFFAOYSA-N 0.000 description 1
- RUNOSUYPDVCSGZ-UHFFFAOYSA-N 9-chloro-7-(2-fluorophenyl)-n-(4-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=CC(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 RUNOSUYPDVCSGZ-UHFFFAOYSA-N 0.000 description 1
- CKAJIJKDYGYVFB-UHFFFAOYSA-N 9-chloro-7-(2-fluorophenyl)-n-(4-morpholin-4-ylphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 CKAJIJKDYGYVFB-UHFFFAOYSA-N 0.000 description 1
- FIVVJGUHEHSWFM-UHFFFAOYSA-N 9-chloro-7-(2-fluorophenyl)-n-(4-nitrophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 FIVVJGUHEHSWFM-UHFFFAOYSA-N 0.000 description 1
- QVPBYYVGOOTSBG-UHFFFAOYSA-N 9-chloro-7-(2-fluorophenyl)-n-[2-(methylaminomethyl)-3h-benzimidazol-5-yl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C2NC(CNC)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=CC=CC=C1F QVPBYYVGOOTSBG-UHFFFAOYSA-N 0.000 description 1
- NQBYWMYNOIBLMS-UHFFFAOYSA-N 9-chloro-7-(2-fluorophenyl)-n-[4-(4-methylpiperazin-1-yl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 NQBYWMYNOIBLMS-UHFFFAOYSA-N 0.000 description 1
- LQGWPHLVXANSBM-UHFFFAOYSA-N 9-chloro-7-(2-fluorophenyl)-n-[4-(pyridin-4-ylmethyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC(C=C1)=CC=C1CC1=CC=NC=C1 LQGWPHLVXANSBM-UHFFFAOYSA-N 0.000 description 1
- YMNXATYHFIWEQL-UHFFFAOYSA-N 9-chloro-7-(2-fluorophenyl)-n-[4-(trifluoromethylsulfonyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 YMNXATYHFIWEQL-UHFFFAOYSA-N 0.000 description 1
- RMNWUBYXBGAIJG-UHFFFAOYSA-N 9-chloro-7-(2-fluorophenyl)-n-phenyl-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC=C1 RMNWUBYXBGAIJG-UHFFFAOYSA-N 0.000 description 1
- XASQKCMCASHVTL-UHFFFAOYSA-N 9-chloro-n-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(OCCO2)C2=C1 XASQKCMCASHVTL-UHFFFAOYSA-N 0.000 description 1
- DRZGPJMNVJATED-UHFFFAOYSA-N 9-chloro-n-(2-chlorophenyl)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC=C1Cl DRZGPJMNVJATED-UHFFFAOYSA-N 0.000 description 1
- RIANRLGCWZVRCV-UHFFFAOYSA-N 9-chloro-n-(3,4-dichlorophenyl)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(Cl)C(Cl)=C1 RIANRLGCWZVRCV-UHFFFAOYSA-N 0.000 description 1
- FREIKFDIGVBZGB-UHFFFAOYSA-N 9-chloro-n-(3,4-dimethoxyphenyl)-7-(2-fluorophenyl)-4-methyl-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC(C)=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 FREIKFDIGVBZGB-UHFFFAOYSA-N 0.000 description 1
- YADXMNGUVRGUTB-UHFFFAOYSA-N 9-chloro-n-(3,4-dimethoxyphenyl)-7-(2-fluorophenyl)-6,7-dihydro-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CNC(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 YADXMNGUVRGUTB-UHFFFAOYSA-N 0.000 description 1
- MRDNUYACRGVHOT-UHFFFAOYSA-N 9-chloro-n-(3,4-dimethoxyphenyl)-7-(2-methylphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)C)C=2C3=CC=C(Cl)C=2)C3=N1 MRDNUYACRGVHOT-UHFFFAOYSA-N 0.000 description 1
- CTMQQWLPOQFGGR-UHFFFAOYSA-N 9-chloro-n-(3,4-dimethoxyphenyl)-7-[2-[(dimethylamino)methyl]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)CN(C)C)C=2C3=CC=C(Cl)C=2)C3=N1 CTMQQWLPOQFGGR-UHFFFAOYSA-N 0.000 description 1
- LHRCJNMFSBZJEK-UHFFFAOYSA-N 9-chloro-n-(3,4-dimethoxyphenyl)-7-phenyl-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C=CC=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 LHRCJNMFSBZJEK-UHFFFAOYSA-N 0.000 description 1
- WZBOZFSJWXOIQV-UHFFFAOYSA-N 9-chloro-n-(3,5-dichlorophenyl)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC(Cl)=CC(Cl)=C1 WZBOZFSJWXOIQV-UHFFFAOYSA-N 0.000 description 1
- SPHHJDCDSYWTJZ-UHFFFAOYSA-N 9-chloro-n-(3,5-dimethylphenyl)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound CC1=CC(C)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)=C1 SPHHJDCDSYWTJZ-UHFFFAOYSA-N 0.000 description 1
- WPWIKZIOEGNAED-UHFFFAOYSA-N 9-chloro-n-(3-chlorophenyl)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC(Cl)=C1 WPWIKZIOEGNAED-UHFFFAOYSA-N 0.000 description 1
- FYOAYOGEULNWFZ-UHFFFAOYSA-N 9-chloro-n-(4-chlorophenyl)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(Cl)C=C1 FYOAYOGEULNWFZ-UHFFFAOYSA-N 0.000 description 1
- RGYFQBKYUYICEW-UHFFFAOYSA-N 9-chloro-n-(4-ethoxyphenyl)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=CC(OCC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 RGYFQBKYUYICEW-UHFFFAOYSA-N 0.000 description 1
- PKJPBROKYIXSJW-UHFFFAOYSA-N 9-chloro-n-(4-fluoro-3-methoxyphenyl)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(F)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)=C1 PKJPBROKYIXSJW-UHFFFAOYSA-N 0.000 description 1
- LXFHDCCVRHNYCZ-UHFFFAOYSA-N 9-chloro-n-[2-[(dimethylamino)methyl]-3h-benzimidazol-5-yl]-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C2NC(CN(C)C)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=CC=CC=C1F LXFHDCCVRHNYCZ-UHFFFAOYSA-N 0.000 description 1
- IRHNNUSKDHCDIX-UHFFFAOYSA-N 9-chloro-n-[4-(2,6-dimethylpiperidin-4-yl)phenyl]-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C2CC(C)NC(C)C2)C=C1 IRHNNUSKDHCDIX-UHFFFAOYSA-N 0.000 description 1
- 101150056293 AJUBA gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- BQNHAOZWMNDAFY-UHFFFAOYSA-N C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C2=C3C4=CC=CC=C4O2)C=2C(=CC=CC=2F)F)C3=N1 Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C2=C3C4=CC=CC=C4O2)C=2C(=CC=CC=2F)F)C3=N1 BQNHAOZWMNDAFY-UHFFFAOYSA-N 0.000 description 1
- BELGOWCULXOWOB-UHFFFAOYSA-N C1C(C)(C)NC(C)(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C2=C3SC=C2)C=2C(=CC=CC=2F)F)C3=N1 Chemical compound C1C(C)(C)NC(C)(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C2=C3SC=C2)C=2C(=CC=CC=2F)F)C3=N1 BELGOWCULXOWOB-UHFFFAOYSA-N 0.000 description 1
- BBOFYWCRJFNXNC-UHFFFAOYSA-N C1C(C)NC(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CNC(=O)C=2N(C=CC=22)C)C2=N1 Chemical compound C1C(C)NC(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CNC(=O)C=2N(C=CC=22)C)C2=N1 BBOFYWCRJFNXNC-UHFFFAOYSA-N 0.000 description 1
- VVAIOPVYTNPCHW-UHFFFAOYSA-N C1C(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C2=C3C=C(C)O2)C=2C(=CC=CC=2F)F)C3=N1 Chemical compound C1C(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C2=C3C=C(C)O2)C=2C(=CC=CC=2F)F)C3=N1 VVAIOPVYTNPCHW-UHFFFAOYSA-N 0.000 description 1
- BDDAPWWRCPGMSB-UHFFFAOYSA-N C1CNC(C(=O)NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C2=C3OC=C2)C=2C(=CC=CC=2F)F)C3=N1 Chemical compound C1CNC(C(=O)NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C2=C3OC=C2)C=2C(=CC=CC=2F)F)C3=N1 BDDAPWWRCPGMSB-UHFFFAOYSA-N 0.000 description 1
- UAPYMMAOYLNGRA-UHFFFAOYSA-N C1CNC(C(=O)NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C2=C3ON=C2)C=2C(=CC=CC=2F)F)C3=N1 Chemical compound C1CNC(C(=O)NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C2=C3ON=C2)C=2C(=CC=CC=2F)F)C3=N1 UAPYMMAOYLNGRA-UHFFFAOYSA-N 0.000 description 1
- UOIDECOHFXDHKT-UHFFFAOYSA-N C=1C=C2C(C)=NNC2=CC=1NC(N=C1C2=C3C4=CC=CC=C4N2)=NC=C1CN=C3C1=CC=CC=C1F Chemical compound C=1C=C2C(C)=NNC2=CC=1NC(N=C1C2=C3C4=CC=CC=C4N2)=NC=C1CN=C3C1=CC=CC=C1F UOIDECOHFXDHKT-UHFFFAOYSA-N 0.000 description 1
- YCVKEOMQSDTQPF-UHFFFAOYSA-N CC(N)(C)C(=O)N(C)C1=CC=CC(NC=2N=C3C4=C(C)SC(C)=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 Chemical compound CC(N)(C)C(=O)N(C)C1=CC=CC(NC=2N=C3C4=C(C)SC(C)=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 YCVKEOMQSDTQPF-UHFFFAOYSA-N 0.000 description 1
- ZCRHMKSEQASPAD-UHFFFAOYSA-N CC1=NSC(C(=NCC2=CN=3)C=4C(=CC=CC=4F)F)=C1C2=NC=3NC(C=C1)=CC=C1C(=O)N(C1)CC21CCCN2 Chemical compound CC1=NSC(C(=NCC2=CN=3)C=4C(=CC=CC=4F)F)=C1C2=NC=3NC(C=C1)=CC=C1C(=O)N(C1)CC21CCCN2 ZCRHMKSEQASPAD-UHFFFAOYSA-N 0.000 description 1
- 125000006519 CCH3 Chemical group 0.000 description 1
- BYWYLFDDCCJZIC-UHFFFAOYSA-N CN1C=CC(C2=N3)=C1C(=O)NCC2=CN=C3NC1=CC=C(C(O)=O)C=C1 Chemical compound CN1C=CC(C2=N3)=C1C(=O)NCC2=CN=C3NC1=CC=C(C(O)=O)C=C1 BYWYLFDDCCJZIC-UHFFFAOYSA-N 0.000 description 1
- YHZZEXRKEPGDSZ-UHFFFAOYSA-N CN1C=NC(C(=NCC2=CN=3)C=4C(=CC=CC=4F)F)=C1C2=NC=3NC(C=C1)=CC=C1C1=NC=CN1 Chemical compound CN1C=NC(C(=NCC2=CN=3)C=4C(=CC=CC=4F)F)=C1C2=NC=3NC(C=C1)=CC=C1C1=NC=CN1 YHZZEXRKEPGDSZ-UHFFFAOYSA-N 0.000 description 1
- AUCGPCQXKQQBOP-UHFFFAOYSA-N CN1N=CC(C(=NCC2=CN=3)C=4C(=CC=CC=4F)F)=C1C2=NC=3NC1=CC=C(C(O)=O)C=C1 Chemical compound CN1N=CC(C(=NCC2=CN=3)C=4C(=CC=CC=4F)F)=C1C2=NC=3NC1=CC=C(C(O)=O)C=C1 AUCGPCQXKQQBOP-UHFFFAOYSA-N 0.000 description 1
- KWWHKAHCGYIDAB-UHFFFAOYSA-N COC1=CC=CC(NC=2N=C3C4=C(N(C=C4)C)C(=O)NCC3=CN=2)=C1 Chemical compound COC1=CC=CC(NC=2N=C3C4=C(N(C=C4)C)C(=O)NCC3=CN=2)=C1 KWWHKAHCGYIDAB-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 108010076303 Centromere Protein A Proteins 0.000 description 1
- 102000011682 Centromere Protein A Human genes 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 101001124881 Cricetulus griseus Peroxiredoxin-1 Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 102100033636 Histone H3.2 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000960484 Homo sapiens Inner centromere protein Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102100039872 Inner centromere protein Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101000864132 Mus musculus Dipeptidase 3 Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 102000005640 Myosin Type II Human genes 0.000 description 1
- 108010045128 Myosin Type II Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000005569 Protein Phosphatase 1 Human genes 0.000 description 1
- 108010059000 Protein Phosphatase 1 Proteins 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 102100037414 Rac GTPase-activating protein 1 Human genes 0.000 description 1
- 101710196218 Rac GTPase-activating protein 1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- AHIMOUYSCBWMGQ-UHFFFAOYSA-N S1C(C)=CC(C(=NCC2=CN=3)C=4C(=CC=CC=4F)F)=C1C2=NC=3NC1=CC=C(C(O)=O)C=C1 Chemical compound S1C(C)=CC(C(=NCC2=CN=3)C=4C(=CC=CC=4F)F)=C1C2=NC=3NC1=CC=C(C(O)=O)C=C1 AHIMOUYSCBWMGQ-UHFFFAOYSA-N 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 102000000763 Survivin Human genes 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 201000000170 Thyroid lymphoma Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 231100000480 WST assay Toxicity 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- OXVJTPVQRUVXBF-UHFFFAOYSA-N [2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-1,3-oxazol-4-yl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=COC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=N1 OXVJTPVQRUVXBF-UHFFFAOYSA-N 0.000 description 1
- XWSOMTBCBJCKPN-UHFFFAOYSA-N [2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-1,3-oxazol-5-yl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C(O1)=CN=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 XWSOMTBCBJCKPN-UHFFFAOYSA-N 0.000 description 1
- GUKHLEIFWXAXDX-UHFFFAOYSA-N [2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-1,3-thiazol-4-yl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=CSC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=N1 GUKHLEIFWXAXDX-UHFFFAOYSA-N 0.000 description 1
- MMWWLLXGJODWDC-CQSZACIVSA-N [2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-1,3-thiazol-4-yl]-[(3r)-3-methylpiperazin-1-yl]methanone Chemical compound C1CN[C@H](C)CN1C(=O)C1=CSC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=N1 MMWWLLXGJODWDC-CQSZACIVSA-N 0.000 description 1
- ZUFGUHAPXIWEFW-UHFFFAOYSA-N [2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3-methylpiperazin-1-yl)methanone Chemical compound C1CNC(C)CN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 ZUFGUHAPXIWEFW-UHFFFAOYSA-N 0.000 description 1
- ZDKMDXHVXGDYSL-UHFFFAOYSA-N [2-chloro-4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3-methylpiperazin-1-yl)methanone Chemical compound C1CNC(C)CN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 ZDKMDXHVXGDYSL-UHFFFAOYSA-N 0.000 description 1
- WOYLUGMXNZTSFS-UHFFFAOYSA-N [2-chloro-5-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)azetidin-1-yl]methanone Chemical compound C1C(NC)CN1C(=O)C1=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=CC=C1Cl WOYLUGMXNZTSFS-UHFFFAOYSA-N 0.000 description 1
- RDKPHXFXZHAQON-UHFFFAOYSA-N [3-(aminomethyl)azetidin-1-yl]-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(CN)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 RDKPHXFXZHAQON-UHFFFAOYSA-N 0.000 description 1
- RFHIDHFLYPPTHW-UHFFFAOYSA-N [3-(dimethylamino)azetidin-1-yl]-[7-(2-fluorophenyl)-2-(3-methoxyanilino)-5h-pyrimido[5,4-d][2]benzazepin-9-yl]methanone Chemical compound COC1=CC=CC(NC=2N=C3C4=CC=C(C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)C(=O)N2CC(C2)N(C)C)=C1 RFHIDHFLYPPTHW-UHFFFAOYSA-N 0.000 description 1
- VOCBMCLMCJWHJP-UHFFFAOYSA-N [3-(dimethylamino)pyrrolidin-1-yl]-[4-[[7-(2-fluorophenyl)-9-methoxy-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound N=1C=C2CN=C(C=3C(=CC=CC=3)F)C3=CC(OC)=CC=C3C2=NC=1NC(C=C1)=CC=C1C(=O)N1CCC(N(C)C)C1 VOCBMCLMCJWHJP-UHFFFAOYSA-N 0.000 description 1
- FPWKWLRIMBPMPP-UHFFFAOYSA-N [3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 FPWKWLRIMBPMPP-UHFFFAOYSA-N 0.000 description 1
- SRACDMHDBCBLCE-UHFFFAOYSA-N [3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 SRACDMHDBCBLCE-UHFFFAOYSA-N 0.000 description 1
- QCSIIGVRKKZRNQ-UHFFFAOYSA-N [3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)azetidin-1-yl]methanone Chemical compound C1C(N(C)C)CN1C(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 QCSIIGVRKKZRNQ-UHFFFAOYSA-N 0.000 description 1
- AZULRYAVQSYDEE-UHFFFAOYSA-N [3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(N(C)C)CCN1C(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 AZULRYAVQSYDEE-UHFFFAOYSA-N 0.000 description 1
- SVYOHTBHNSKSEB-UHFFFAOYSA-N [3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(dimethylamino)piperidin-1-yl]methanone Chemical compound C1CC(N(C)C)CCN1C(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 SVYOHTBHNSKSEB-UHFFFAOYSA-N 0.000 description 1
- CFPCXOXZWZIHLB-UHFFFAOYSA-N [3-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC(C(=O)N2CC(C)NC(C)C2)=C1 CFPCXOXZWZIHLB-UHFFFAOYSA-N 0.000 description 1
- WJHWFOPIRQIOKP-UHFFFAOYSA-N [3-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC(C(=O)N2CCN(C)CC2)=C1 WJHWFOPIRQIOKP-UHFFFAOYSA-N 0.000 description 1
- LCOQJGSBZMGDGI-UHFFFAOYSA-N [3-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)azetidin-1-yl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC(C(=O)N2CC(C2)N(C)C)=C1 LCOQJGSBZMGDGI-UHFFFAOYSA-N 0.000 description 1
- NYIODPTWPANCLJ-UHFFFAOYSA-N [3-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)pyrrolidin-1-yl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC(C(=O)N2CC(CC2)N(C)C)=C1 NYIODPTWPANCLJ-UHFFFAOYSA-N 0.000 description 1
- JPFVLUUDWMCCAG-UHFFFAOYSA-N [3-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(dimethylamino)piperidin-1-yl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC(C(=O)N2CCC(CC2)N(C)C)=C1 JPFVLUUDWMCCAG-UHFFFAOYSA-N 0.000 description 1
- QURNEUJXLFENLS-UHFFFAOYSA-N [3-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)=C1 QURNEUJXLFENLS-UHFFFAOYSA-N 0.000 description 1
- HFKBMAQAJZRFIP-UHFFFAOYSA-N [4-[(9-chloro-7-pyridin-2-yl-5h-pyrimido[5,4-d][2]benzazepin-2-yl)amino]phenyl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2N=CC=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 HFKBMAQAJZRFIP-UHFFFAOYSA-N 0.000 description 1
- UOEWNLVURFTZMF-UHFFFAOYSA-N [4-[(9-chloro-7-pyridin-2-yl-5h-pyrimido[5,4-d][2]benzazepin-2-yl)amino]phenyl]-[4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2N=CC=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 UOEWNLVURFTZMF-UHFFFAOYSA-N 0.000 description 1
- IDLWYBQNVTZOGD-UHFFFAOYSA-N [4-[[7-(2-fluorophenyl)-9-methyl-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(C)C=2)C3=N1 IDLWYBQNVTZOGD-UHFFFAOYSA-N 0.000 description 1
- UEOKIKQGOFBIMC-UHFFFAOYSA-N [4-[[9-chloro-7-(2,4-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC(F)=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 UEOKIKQGOFBIMC-UHFFFAOYSA-N 0.000 description 1
- SGPLKDXBSQWSBP-UHFFFAOYSA-N [4-[[9-chloro-7-(2,4-dimethoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound COC1=CC(OC)=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(C)NC(C)C2)C=C1 SGPLKDXBSQWSBP-UHFFFAOYSA-N 0.000 description 1
- DRCDQFVPGQYTGE-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-fluorophenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C(C(=C1)F)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 DRCDQFVPGQYTGE-UHFFFAOYSA-N 0.000 description 1
- RKGRLMWQUSSEKX-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(1,7-diazaspiro[4.4]nonan-7-yl)methanone Chemical compound FC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC3(NCCC3)CC2)C=C1 RKGRLMWQUSSEKX-UHFFFAOYSA-N 0.000 description 1
- CNTXXRJMWPIXTO-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,3,5-trimethylpiperazin-1-yl)methanone Chemical compound C1C(C)(C)NC(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 CNTXXRJMWPIXTO-UHFFFAOYSA-N 0.000 description 1
- JWWDPRNGKZVUMX-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,3-dimethylpiperazin-1-yl)methanone Chemical compound C1CNC(C)(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 JWWDPRNGKZVUMX-UHFFFAOYSA-N 0.000 description 1
- KYQZHCBVZKULNV-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 KYQZHCBVZKULNV-UHFFFAOYSA-N 0.000 description 1
- VJCKVVTYEDVBED-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,8-diazabicyclo[3.2.1]octan-3-yl)methanone Chemical compound FC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC3CCC(N3)C2)C=C1 VJCKVVTYEDVBED-UHFFFAOYSA-N 0.000 description 1
- SEYRFEUDBMZPCH-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 SEYRFEUDBMZPCH-UHFFFAOYSA-N 0.000 description 1
- IVGJRVQOUHYMLJ-QGZVFWFLSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[(2r)-2-methylpiperazin-1-yl]methanone Chemical compound C[C@@H]1CNCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 IVGJRVQOUHYMLJ-QGZVFWFLSA-N 0.000 description 1
- UENJLDMULQEBHP-QGZVFWFLSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[(3r)-3-methylpiperazin-1-yl]methanone Chemical compound C1CN[C@H](C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 UENJLDMULQEBHP-QGZVFWFLSA-N 0.000 description 1
- UENJLDMULQEBHP-KRWDZBQOSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[(3s)-3-methylpiperazin-1-yl]methanone Chemical compound C1CN[C@@H](C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 UENJLDMULQEBHP-KRWDZBQOSA-N 0.000 description 1
- WGEPKVSOIXBWQW-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)azetidin-1-yl]methanone Chemical compound C1C(N(C)C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 WGEPKVSOIXBWQW-UHFFFAOYSA-N 0.000 description 1
- MGSGOFCZEMKUCR-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)piperidin-1-yl]methanone Chemical compound C1C(N(C)C)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 MGSGOFCZEMKUCR-UHFFFAOYSA-N 0.000 description 1
- MEIGAGMDRBJICH-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 MEIGAGMDRBJICH-UHFFFAOYSA-N 0.000 description 1
- SCRPSVZKDSAKPL-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)azetidin-1-yl]methanone Chemical compound C1C(NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 SCRPSVZKDSAKPL-UHFFFAOYSA-N 0.000 description 1
- GYSKVJHJGKIETN-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)piperidin-1-yl]methanone Chemical compound C1C(NC)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 GYSKVJHJGKIETN-UHFFFAOYSA-N 0.000 description 1
- ZAKCNGDZKHVRHF-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 ZAKCNGDZKHVRHF-UHFFFAOYSA-N 0.000 description 1
- CEOUNIBGRHYQQQ-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(dimethylamino)piperidin-1-yl]methanone Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 CEOUNIBGRHYQQQ-UHFFFAOYSA-N 0.000 description 1
- GMGDXUNAZFDGOM-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 GMGDXUNAZFDGOM-UHFFFAOYSA-N 0.000 description 1
- ZSVJENQHRNFUIP-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound FC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCNCC2)C=C1 ZSVJENQHRNFUIP-UHFFFAOYSA-N 0.000 description 1
- ZCAIBCLXMDOENG-UHFFFAOYSA-N [4-[[9-chloro-7-(2-chloro-6-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)Cl)C3=N1 ZCAIBCLXMDOENG-UHFFFAOYSA-N 0.000 description 1
- PGCYCKUBIDACLU-UHFFFAOYSA-N [4-[[9-chloro-7-(2-chloro-6-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3-methylpiperazin-1-yl)methanone Chemical compound C1CNC(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)Cl)C3=N1 PGCYCKUBIDACLU-UHFFFAOYSA-N 0.000 description 1
- FNZFUKLUWKTHFW-UHFFFAOYSA-N [4-[[9-chloro-7-(2-chloro-6-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)azetidin-1-yl]methanone Chemical compound C1C(NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)Cl)C3=N1 FNZFUKLUWKTHFW-UHFFFAOYSA-N 0.000 description 1
- MLTMXRTWNAKQMG-UHFFFAOYSA-N [4-[[9-chloro-7-(2-chloro-6-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)piperidin-1-yl]methanone Chemical compound C1C(NC)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)Cl)C3=N1 MLTMXRTWNAKQMG-UHFFFAOYSA-N 0.000 description 1
- FLXROWSQTLOAJX-UHFFFAOYSA-N [4-[[9-chloro-7-(2-chloro-6-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)Cl)C3=N1 FLXROWSQTLOAJX-UHFFFAOYSA-N 0.000 description 1
- AQAXYAXPHYNCFW-UHFFFAOYSA-N [4-[[9-chloro-7-(2-chloro-6-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)Cl)C3=N1 AQAXYAXPHYNCFW-UHFFFAOYSA-N 0.000 description 1
- DVHYWGUDQNNVIN-UHFFFAOYSA-N [4-[[9-chloro-7-(2-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)Cl)C=2C3=CC=C(Cl)C=2)C3=N1 DVHYWGUDQNNVIN-UHFFFAOYSA-N 0.000 description 1
- GQZMHHNJASLKHG-UHFFFAOYSA-N [4-[[9-chloro-7-(2-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-morpholin-4-ylmethanone Chemical compound C=1C(Cl)=CC=C(C2=N3)C=1C(C=1C(=CC=CC=1)Cl)=NCC2=CN=C3NC(C=C1)=CC=C1C(=O)N1CCOCC1 GQZMHHNJASLKHG-UHFFFAOYSA-N 0.000 description 1
- QQSWJLPPKVFTKY-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(C)NC(C)C2)C=C1 QQSWJLPPKVFTKY-UHFFFAOYSA-N 0.000 description 1
- QVMLEHCETZHYGS-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3-methylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(C)NCC2)C=C1 QVMLEHCETZHYGS-UHFFFAOYSA-N 0.000 description 1
- LRYDYNYVXSTZRZ-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCN(C)CC2)C=C1 LRYDYNYVXSTZRZ-UHFFFAOYSA-N 0.000 description 1
- AKUXUDHJYZZIQE-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)azetidin-1-yl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(C2)N(C)C)C=C1 AKUXUDHJYZZIQE-UHFFFAOYSA-N 0.000 description 1
- GNMZSSZQDIVGRS-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)pyrrolidin-1-yl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(CC2)N(C)C)C=C1 GNMZSSZQDIVGRS-UHFFFAOYSA-N 0.000 description 1
- MNCFMJGFDNSRHG-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)azetidin-1-yl]methanone Chemical compound C1C(NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)OC)C3=N1 MNCFMJGFDNSRHG-UHFFFAOYSA-N 0.000 description 1
- FESBJMYHIBQZSK-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)piperidin-1-yl]methanone Chemical compound C1C(NC)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)OC)C3=N1 FESBJMYHIBQZSK-UHFFFAOYSA-N 0.000 description 1
- JFVGHUIGWMJZSE-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)OC)C3=N1 JFVGHUIGWMJZSE-UHFFFAOYSA-N 0.000 description 1
- VMAWGROBIQSXOO-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCNCC2)C=C1 VMAWGROBIQSXOO-UHFFFAOYSA-N 0.000 description 1
- JSVWQMNITPGROU-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(2-methylpiperazin-1-yl)methanone Chemical compound CC1CNCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 JSVWQMNITPGROU-UHFFFAOYSA-N 0.000 description 1
- APEDHXVIPWEEBI-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 APEDHXVIPWEEBI-UHFFFAOYSA-N 0.000 description 1
- SYOWXVNWNAFKBA-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3-methylpiperazin-1-yl)methanone Chemical compound C1CNC(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 SYOWXVNWNAFKBA-UHFFFAOYSA-N 0.000 description 1
- KUOQAGWUGXBGEF-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 KUOQAGWUGXBGEF-UHFFFAOYSA-N 0.000 description 1
- NFUMINIKCHIFEY-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-pyridin-2-ylpiperazin-1-yl)methanone Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCN(CC2)C=2N=CC=CC=2)C=C1 NFUMINIKCHIFEY-UHFFFAOYSA-N 0.000 description 1
- PALAFUUAIJDZQG-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-pyrimidin-2-ylpiperazin-1-yl)methanone Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCN(CC2)C=2N=CC=CN=2)C=C1 PALAFUUAIJDZQG-UHFFFAOYSA-N 0.000 description 1
- CVGHOSLULCCMBP-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)azetidin-1-yl]methanone Chemical compound C1C(N(C)C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 CVGHOSLULCCMBP-UHFFFAOYSA-N 0.000 description 1
- LBXCBNYQSVOXAR-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 LBXCBNYQSVOXAR-UHFFFAOYSA-N 0.000 description 1
- ORBWUBFHYRDJIW-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-[(dimethylamino)methyl]azetidin-1-yl]methanone Chemical compound C1C(CN(C)C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 ORBWUBFHYRDJIW-UHFFFAOYSA-N 0.000 description 1
- KUZNSVLBLFXAAI-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(2-ethoxyphenyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC=CC=C1N1CCN(C(=O)C=2C=CC(NC=3N=C4C5=CC=C(Cl)C=C5C(C=5C(=CC=CC=5)F)=NCC4=CN=3)=CC=2)CC1 KUZNSVLBLFXAAI-UHFFFAOYSA-N 0.000 description 1
- ZZZJQNBDPXRRMA-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]methanone Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCN(CCN3CCCC3)CC2)C=C1 ZZZJQNBDPXRRMA-UHFFFAOYSA-N 0.000 description 1
- GBYPRJRJXDRTIE-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(dimethylamino)piperidin-1-yl]methanone Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 GBYPRJRJXDRTIE-UHFFFAOYSA-N 0.000 description 1
- KKJRAJNOPIWLOK-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCNCC2)C=C1 KKJRAJNOPIWLOK-UHFFFAOYSA-N 0.000 description 1
- JGRIIIWNTCUFMU-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]phosphonic acid Chemical compound C1=CC(P(O)(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 JGRIIIWNTCUFMU-UHFFFAOYSA-N 0.000 description 1
- CEIKCVXEVNUPHX-UHFFFAOYSA-N [4-[[9-chloro-7-(2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(C)NC(C)C2)C=C1 CEIKCVXEVNUPHX-UHFFFAOYSA-N 0.000 description 1
- YFILSMVPEUGYQH-UHFFFAOYSA-N [4-[[9-chloro-7-(2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3-methylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(C)NCC2)C=C1 YFILSMVPEUGYQH-UHFFFAOYSA-N 0.000 description 1
- BFPAPLYZOBLOCM-UHFFFAOYSA-N [4-[[9-chloro-7-(2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCN(C)CC2)C=C1 BFPAPLYZOBLOCM-UHFFFAOYSA-N 0.000 description 1
- ZNZWMZUHXSNPES-UHFFFAOYSA-N [4-[[9-chloro-7-(2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)piperidin-1-yl]methanone Chemical compound C1C(NC)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)OC)C=2C3=CC=C(Cl)C=2)C3=N1 ZNZWMZUHXSNPES-UHFFFAOYSA-N 0.000 description 1
- FMQYOABKPQSROW-UHFFFAOYSA-N [4-[[9-chloro-7-(2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)OC)C=2C3=CC=C(Cl)C=2)C3=N1 FMQYOABKPQSROW-UHFFFAOYSA-N 0.000 description 1
- SAJIRGBREXTLIH-UHFFFAOYSA-N [4-[[9-chloro-7-(2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)OC)C=2C3=CC=C(Cl)C=2)C3=N1 SAJIRGBREXTLIH-UHFFFAOYSA-N 0.000 description 1
- DQNYWRYOKXUOAO-UHFFFAOYSA-N [4-[[9-chloro-7-(2-methylphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)C)C=2C3=CC=C(Cl)C=2)C3=N1 DQNYWRYOKXUOAO-UHFFFAOYSA-N 0.000 description 1
- SWYCAQDPGZLPCK-UHFFFAOYSA-N [4-[[9-chloro-7-(3-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C=C(F)C=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 SWYCAQDPGZLPCK-UHFFFAOYSA-N 0.000 description 1
- YQQZTYSDNITSOW-UHFFFAOYSA-N [4-[[9-chloro-7-(4-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C=CC(F)=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 YQQZTYSDNITSOW-UHFFFAOYSA-N 0.000 description 1
- PUAPYPFCEDXFAQ-UHFFFAOYSA-N [4-[[9-chloro-7-[2-(trifluoromethyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2)C(F)(F)F)C3=N1 PUAPYPFCEDXFAQ-UHFFFAOYSA-N 0.000 description 1
- MXGAEISYBDKLSD-UHFFFAOYSA-N [4-[[9-chloro-7-[2-(trifluoromethyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2)C(F)(F)F)C3=N1 MXGAEISYBDKLSD-UHFFFAOYSA-N 0.000 description 1
- GDQCFWNDQNGBGL-UHFFFAOYSA-N [5-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-fluorophenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=CC=C1F GDQCFWNDQNGBGL-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- PRFSSNFDGRXIPZ-UHFFFAOYSA-N amino 4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)ON)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 PRFSSNFDGRXIPZ-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 125000004321 azepin-2-yl group Chemical group [H]N1C([H])=C([H])C([H])=C([H])C([H])=C1* 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- XTJDVICDTALLDH-UHFFFAOYSA-N benzyl 4-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]piperazine-1-carboxylate Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCN(CC2)C(=O)OCC=2C=CC=CC=2)C=C1 XTJDVICDTALLDH-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000005770 chromosome separation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- RHJVIGLEIFVHIJ-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1[CH]CCCC1 RHJVIGLEIFVHIJ-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- PUEVFZUTYWDOSX-RUZDIDTESA-N ethyl (2r)-4-amino-2-[[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]amino]butanoate Chemical compound C1=CC(C(=O)N[C@H](CCN)C(=O)OCC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 PUEVFZUTYWDOSX-RUZDIDTESA-N 0.000 description 1
- BPWHGIJLRXHJHH-UHFFFAOYSA-N ethyl 2-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-4,5-dihydro-1h-imidazole-5-carboxylate Chemical compound N1C(C(=O)OCC)CN=C1C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 BPWHGIJLRXHJHH-UHFFFAOYSA-N 0.000 description 1
- JGQSPTSVNCRKBW-UHFFFAOYSA-N ethyl 2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=N1 JGQSPTSVNCRKBW-UHFFFAOYSA-N 0.000 description 1
- SIJKQHUEZRGNKT-UHFFFAOYSA-N ethyl 2-amino-4-[[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]amino]butanoate Chemical compound C1=CC(C(=O)NCCC(N)C(=O)OCC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 SIJKQHUEZRGNKT-UHFFFAOYSA-N 0.000 description 1
- UWBMQMFABJTBTE-UHFFFAOYSA-N ethyl 4-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 UWBMQMFABJTBTE-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GKZHZCOPPNPZJO-UHFFFAOYSA-N methyl 2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoate Chemical compound C1=C(Cl)C(C(=O)OC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 GKZHZCOPPNPZJO-UHFFFAOYSA-N 0.000 description 1
- LDJKMLLDCJCAKM-UHFFFAOYSA-N methyl 4-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]piperazine-2-carboxylate Chemical compound C1CNC(C(=O)OC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 LDJKMLLDCJCAKM-UHFFFAOYSA-N 0.000 description 1
- OKDFRKWJNUNWCK-UHFFFAOYSA-N methyl 4-[[9-chloro-7-(2,3-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1NC1=NC=C(CN=C(C=2C(=C(F)C=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 OKDFRKWJNUNWCK-UHFFFAOYSA-N 0.000 description 1
- OTYDDRXMCDIOPI-UHFFFAOYSA-N methyl 4-[[9-chloro-7-(2,5-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=C(F)C=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 OTYDDRXMCDIOPI-UHFFFAOYSA-N 0.000 description 1
- MZUPEVWVNYJWNN-UHFFFAOYSA-N methyl 4-amino-1-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 MZUPEVWVNYJWNN-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000036456 mitotic arrest Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QVNJSNBFEUZNSN-UHFFFAOYSA-N n'-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-3,5-dimethylpiperazine-1-carboximidamide Chemical compound C1C(C)NC(C)CN1C(=N)NC(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 QVNJSNBFEUZNSN-UHFFFAOYSA-N 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- CGAYGJTYJUSLKS-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1N(CC2)CCC2C1N(C)C(=O)C(C=C1)=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=C(F)C=CC=C1F CGAYGJTYJUSLKS-UHFFFAOYSA-N 0.000 description 1
- UVWUWEXPLBAVJA-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound FC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NC2C3CCN(CC3)C2)C=C1 UVWUWEXPLBAVJA-UHFFFAOYSA-N 0.000 description 1
- UOKNHTIHWYPJKN-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N(C)C2C3CCN(CC3)C2)C=C1 UOKNHTIHWYPJKN-UHFFFAOYSA-N 0.000 description 1
- LEJCCDWWRZHAMO-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound FC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=NC2=CC=CC=C2N1 LEJCCDWWRZHAMO-UHFFFAOYSA-N 0.000 description 1
- CNNKLRZRCWFXMV-UHFFFAOYSA-N n-(2-amino-2-methylpropyl)-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)NCC(C)(N)C)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 CNNKLRZRCWFXMV-UHFFFAOYSA-N 0.000 description 1
- GXHXPDHTDDYSFM-UHFFFAOYSA-N n-(2-amino-2-methylpropyl)-4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)NCC(C)(N)C)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 GXHXPDHTDDYSFM-UHFFFAOYSA-N 0.000 description 1
- VWWHOZYCTHVRRF-UHFFFAOYSA-N n-(2-aminoethyl)-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)N(CCN)C)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 VWWHOZYCTHVRRF-UHFFFAOYSA-N 0.000 description 1
- GYXVPOGEOJOMKM-UHFFFAOYSA-N n-(2-aminoethyl)-4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N(C)CCN)C=C1 GYXVPOGEOJOMKM-UHFFFAOYSA-N 0.000 description 1
- GKCXXKJJRFLNKW-UHFFFAOYSA-N n-(2-aminoethyl)-4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)N(CCN)C)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 GKCXXKJJRFLNKW-UHFFFAOYSA-N 0.000 description 1
- DJGYPBYEIMXENG-UHFFFAOYSA-N n-(2-aminoethyl)-4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)NCCN)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 DJGYPBYEIMXENG-UHFFFAOYSA-N 0.000 description 1
- ITMYKUSUQUNYFV-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-10-fluoro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC(F)=CC=2)C3=N1 ITMYKUSUQUNYFV-UHFFFAOYSA-N 0.000 description 1
- DKZVUEILMGAJQT-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-7-(2-fluorophenyl)-10-(trifluoromethyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC(=CC=2)C(F)(F)F)C3=N1 DKZVUEILMGAJQT-UHFFFAOYSA-N 0.000 description 1
- PTGSRMPILZRTEN-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-7-(2-fluorophenyl)-10-methoxy-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C=1C(OC)=CC=C(C(=NCC2=CN=3)C=4C(=CC=CC=4)F)C=1C2=NC=3NC1=CC=C(OC)C(OC)=C1 PTGSRMPILZRTEN-UHFFFAOYSA-N 0.000 description 1
- SFRUQQAEBYPAAE-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-7-(2-fluorophenyl)-10-methyl-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC(C)=CC=2)C3=N1 SFRUQQAEBYPAAE-UHFFFAOYSA-N 0.000 description 1
- GNKOZFIDAXFFEA-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-7-(2-fluorophenyl)-11-methyl-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=C(C)C=CC=2)C3=N1 GNKOZFIDAXFFEA-UHFFFAOYSA-N 0.000 description 1
- MECAFPCIOLGAIN-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=CC=2)C3=N1 MECAFPCIOLGAIN-UHFFFAOYSA-N 0.000 description 1
- IPSANAZXDGLGNP-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-7-(2-fluorophenyl)-9-methoxy-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound N=1C=C2CN=C(C=3C(=CC=CC=3)F)C3=CC(OC)=CC=C3C2=NC=1NC1=CC=C(OC)C(OC)=C1 IPSANAZXDGLGNP-UHFFFAOYSA-N 0.000 description 1
- DLCMQVWQUMFGIC-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-7-(2-fluorophenyl)-9-methyl-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(C)C=2)C3=N1 DLCMQVWQUMFGIC-UHFFFAOYSA-N 0.000 description 1
- BJQRXJBKUBRUBE-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-7-(2-fluorophenyl)-9-propan-2-yl-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(C=2)C(C)C)C3=N1 BJQRXJBKUBRUBE-UHFFFAOYSA-N 0.000 description 1
- ZJBHAWQXDCSKLI-UHFFFAOYSA-N n-(3-aminopropyl)-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)N(CCCN)C)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 ZJBHAWQXDCSKLI-UHFFFAOYSA-N 0.000 description 1
- KJHREAWVRQOONJ-UHFFFAOYSA-N n-(3-aminopropyl)-4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N(C)CCCN)C=C1 KJHREAWVRQOONJ-UHFFFAOYSA-N 0.000 description 1
- BVMHOVCBSVCQEC-UHFFFAOYSA-N n-(3-aminopropyl)-4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)N(CCCN)C)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 BVMHOVCBSVCQEC-UHFFFAOYSA-N 0.000 description 1
- SVNVSSHTHIHQTG-UHFFFAOYSA-N n-(3-aminopropyl)-4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)NCCCN)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 SVNVSSHTHIHQTG-UHFFFAOYSA-N 0.000 description 1
- AQHKEFTVRWPDLM-UHFFFAOYSA-N n-(8-azabicyclo[3.2.1]octan-3-yl)-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1C(N2)CCC2CC1N(C)C(=O)C(C=C1)=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=C(F)C=CC=C1F AQHKEFTVRWPDLM-UHFFFAOYSA-N 0.000 description 1
- ZGXSVPBBJWYHTJ-UHFFFAOYSA-N n-[2-(aminomethyl)-3h-benzimidazol-5-yl]-9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C2NC(CN)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=CC=CC=C1F ZGXSVPBBJWYHTJ-UHFFFAOYSA-N 0.000 description 1
- IKKORWACCYVNQL-UHFFFAOYSA-N n-[3-(3-aminoprop-1-ynyl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound NCC#CC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 IKKORWACCYVNQL-UHFFFAOYSA-N 0.000 description 1
- BQWPHMFMLAYMSG-UHFFFAOYSA-N n-[3-(3-aminopropyl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound NCCCC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 BQWPHMFMLAYMSG-UHFFFAOYSA-N 0.000 description 1
- LJPBXJHIGJTHMR-UHFFFAOYSA-N n-[3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-n,3,5-trimethylpiperazine-1-carboximidamide Chemical compound C1C(C)NC(C)CN1C(=N)N(C)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 LJPBXJHIGJTHMR-UHFFFAOYSA-N 0.000 description 1
- HNYZCNTVOLHSBC-UHFFFAOYSA-N n-[4-(2-aminopropan-2-yl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=CC(C(C)(N)C)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HNYZCNTVOLHSBC-UHFFFAOYSA-N 0.000 description 1
- DSGORMRWLDLWJD-UHFFFAOYSA-N n-[4-(3-aminopyrrolidine-1-carboximidoyl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1C(N)CCN1C(=N)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 DSGORMRWLDLWJD-UHFFFAOYSA-N 0.000 description 1
- GOKSUBYHVSNOEO-UHFFFAOYSA-N n-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-2-(dimethylamino)acetamide Chemical compound C1=CC(NC(=O)CN(C)C)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 GOKSUBYHVSNOEO-UHFFFAOYSA-N 0.000 description 1
- RYWAVKNACUAFFX-UHFFFAOYSA-N n-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-4-methylpiperazine-1-carboxamide Chemical compound C1CN(C)CCN1C(=O)NC(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 RYWAVKNACUAFFX-UHFFFAOYSA-N 0.000 description 1
- AJNXOMNOGKUFRX-UHFFFAOYSA-N n-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-n,3,5-trimethylpiperazine-1-carboximidamide Chemical compound C1C(C)NC(C)CN1C(=N)N(C)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 AJNXOMNOGKUFRX-UHFFFAOYSA-N 0.000 description 1
- DNYSGUARLAYSPH-UHFFFAOYSA-N n-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]piperidine-4-carboxamide Chemical compound FC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC(C=C1)=CC=C1NC(=O)C1CCNCC1 DNYSGUARLAYSPH-UHFFFAOYSA-N 0.000 description 1
- ZUGMRLYZBBKMBV-UHFFFAOYSA-N n-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-n-methylacetamide Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 ZUGMRLYZBBKMBV-UHFFFAOYSA-N 0.000 description 1
- XHRROFJZSNGMIU-UHFFFAOYSA-N n-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 XHRROFJZSNGMIU-UHFFFAOYSA-N 0.000 description 1
- HZRKQUYYBNRBOG-UHFFFAOYSA-N n-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 HZRKQUYYBNRBOG-UHFFFAOYSA-N 0.000 description 1
- QXRQEGYLMFFLTJ-UHFFFAOYSA-N n-[5-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-fluorophenyl]-n,3,5-trimethylpiperazine-1-carboximidamide Chemical compound C1C(C)NC(C)CN1C(=N)N(C)C1=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=CC=C1F QXRQEGYLMFFLTJ-UHFFFAOYSA-N 0.000 description 1
- YXQFSBBYATXRJN-UHFFFAOYSA-N n-[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]-2-(methylaminomethyl)-1,3-benzoxazol-6-amine Chemical compound C1=C2OC(CNC)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=C(F)C=CC=C1F YXQFSBBYATXRJN-UHFFFAOYSA-N 0.000 description 1
- AFNYBWFXRSXFKZ-UHFFFAOYSA-N n-[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound CC1=CSC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=N1 AFNYBWFXRSXFKZ-UHFFFAOYSA-N 0.000 description 1
- CQYDWYWXUWKLQS-UHFFFAOYSA-N n-[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]-2-(methylaminomethyl)-1,3-benzothiazol-6-amine Chemical compound C1=C2SC(CNC)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=CC=CC=C1F CQYDWYWXUWKLQS-UHFFFAOYSA-N 0.000 description 1
- RDPVZBDRLHROEM-UHFFFAOYSA-N n-[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]-2-(methylaminomethyl)-1,3-benzoxazol-6-amine Chemical compound C1=C2OC(CNC)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=CC=CC=C1F RDPVZBDRLHROEM-UHFFFAOYSA-N 0.000 description 1
- NCOGYDYZWODWKA-UHFFFAOYSA-N n-[amino(dimethylamino)methylidene]-4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)NC(=N)N(C)C)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 NCOGYDYZWODWKA-UHFFFAOYSA-N 0.000 description 1
- LXNGQNNERXXOHX-UHFFFAOYSA-N n-[amino(piperazin-1-yl)methylidene]-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound FC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NC(=N)N2CCNCC2)C=C1 LXNGQNNERXXOHX-UHFFFAOYSA-N 0.000 description 1
- BYSDQZISISFLHW-UHFFFAOYSA-N n-[amino(piperazin-1-yl)methylidene]-4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NC(=N)N2CCNCC2)C=C1 BYSDQZISISFLHW-UHFFFAOYSA-N 0.000 description 1
- CTEZUXITSPOPNT-UHFFFAOYSA-N n-[amino-(3,5-dimethylpiperazin-1-yl)methylidene]-3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound C1C(C)NC(C)CN1C(=N)NC(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 CTEZUXITSPOPNT-UHFFFAOYSA-N 0.000 description 1
- XNEKXYDTWRIQFD-UHFFFAOYSA-N n-[amino-(3,5-dimethylpiperazin-1-yl)methylidene]-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound C1C(C)NC(C)CN1C(=N)NC(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 XNEKXYDTWRIQFD-UHFFFAOYSA-N 0.000 description 1
- YRIPUBNALZQTAP-UHFFFAOYSA-N n-[amino-(3,5-dimethylpiperazin-1-yl)methylidene]-4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound C1C(C)NC(C)CN1C(=N)NC(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 YRIPUBNALZQTAP-UHFFFAOYSA-N 0.000 description 1
- YDGXUSGRQMEJBY-UHFFFAOYSA-N n-[amino-(3-methylpiperazin-1-yl)methylidene]-4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound C1CNC(C)CN1C(=N)NC(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 YDGXUSGRQMEJBY-UHFFFAOYSA-N 0.000 description 1
- PGNDFTAPJKGEBC-UHFFFAOYSA-N n-[amino-(4-methylpiperazin-1-yl)methylidene]-4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound C1CN(C)CCN1C(=N)NC(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 PGNDFTAPJKGEBC-UHFFFAOYSA-N 0.000 description 1
- LKUQPQHOZCRZKS-UHFFFAOYSA-N n-[amino-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]anilino]methylidene]cyclopropanecarboxamide Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC(C=C1)=CC=C1NC(=N)NC(=O)C1CC1 LKUQPQHOZCRZKS-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- HAMAGKWXRRTWCJ-UHFFFAOYSA-N pyrido[2,3-b][1,4]oxazin-3-one Chemical compound C1=CN=C2OC(=O)C=NC2=C1 HAMAGKWXRRTWCJ-UHFFFAOYSA-N 0.000 description 1
- IQHXABCGSFAKPN-UHFFFAOYSA-N pyrrolidine-3-carboxamide Chemical compound NC(=O)C1CCNC1 IQHXABCGSFAKPN-UHFFFAOYSA-N 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000024355 spindle assembly checkpoint Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Definitions
- This invention relates to methods for the treatment of hematological malignancies.
- the invention provides methods for treatment of hematological malignancies by administering Aurora kinase inhibitors in combination with anti-CD20 antibodies.
- Mitosis is a stage in the cell cycle during which a series of complex events ensure the fidelity of chromosome separation into two daughter cells.
- Several current cancer therapies including the taxanes and vinca alkaloids, act to inhibit the mitotic machinery. Mitotic progression is largely regulated by proteolysis and by phosphorylation events that are mediated by mitotic kinases.
- Aurora kinase family members regulate mitotic progression through modulation of centrosome separation, spindle dynamics, spindle assembly checkpoint, chromosome alignment/segregation, and cytokinesis (Dutertre et al., Oncogene, 21: 6175 (2002); Berdnik et al., Curr. Biol., 12: 640 (2002)).
- Overexpression and/or amplification of Aurora kinases have been linked to oncogenesis in several tumor types including those of colon and breast (Warner et al., Mol.
- CD20 (also known as Bp35) is a B-lymphocyte-restricted differentiation antigen that is expressed during early pre-B-cell development and remains until plasma cell differentiation. CD20 is a useful target for B-cell lymphomas as this antigen is expressed at very high densities on the surface of malignant B-cells, i.e., B-cells wherein unabated proliferation can lead to B-cell lymphomas.
- the Food and Drug Administration has approved the therapeutic use of an anti-CD20 antibody, rituximab (RITUXAN®), for use in relapsed and previously treated low-grade non-Hodgkin's lymphoma (NHL).
- Rituximab acts by binding to the CD20 antigen on B cells which results in the lysis of the B cell by a mechanism thought to involve complement-dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).
- CDC complement-dependent cytotoxicity
- ADCC antibody-dependent cell mediated cytotoxicity
- anti-CD20 antibodies and, in particular, rituximab have been reported to be effective for treatment of B-cell lymphomas, such as non-Hodgkin's lymphoma
- the treated patients are often subject to disease relapse. Therefore, it would be beneficial if more effective treatment regimens could be developed.
- Combined treatment regimens could be helpful for patients suffering from B cell related tumors or other hematological malignancies, and might potentially even decrease the rate of relapse or overcome the resistance to a particular anticancer agent sometime seen in these patients.
- combinations of anticancer agents may have additive, or even synergistic, therapeutic effects.
- the present invention provides new combination therapies for the treatment of hematological malignancies.
- the present invention provides a method to treat a patient suffering from a hematological malignancy comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g., before or after) an anti-CD20 antibody.
- Aurora kinase refers to any one of a family of related serine/threonine kinases involved in mitotic progression.
- a variety of cellular proteins that play a role in cell division are substrates for phosphorylation by Aurora kinase enzymes, including, without limitation, histone H3, p53, CENP-A, myosin II regulatory light chain, protein phosphatase-1, TPX-2, INCENP, survivin, topoisomerase II alpha, vimentin, MBD-3, MgcRacGAP, desmin, Ajuba, XIEg5 (in Xenopus ), Ndc10p (in budding yeast), and D-TACC (in Drosophila ).
- Aurora kinase enzymes also are themselves substrates for autophosphorylation, e.g., at Thr288.
- the term “Aurora kinase” is meant to refer to any Aurora kinase protein from any species, including, without limitation, Aurora A, Aurora B, and Aurora C, preferably Aurora A or B.
- the Aurora kinase is a human Aurora kinase.
- Aurora kinase inhibitor or “inhibitor of Aurora kinase” is used to signify a compound which is capable of interacting with an Aurora kinase and inhibiting its enzymatic activity. Inhibiting Aurora kinase enzymatic activity means reducing the ability of an Aurora kinase to phosphorylate a substrate peptide or protein. In various embodiments, such reduction of Aurora kinase activity is at least about 50%, at least about 75%, at least about 90%, at least about 95%, or at least about 99%.
- the concentration of Aurora kinase inhibitor required to reduce an Aurora kinase enzymatic activity is less than about 1 ⁇ M, less than about 500 nM, less than about 100 nM, or less than about 50 nM.
- such inhibition is selective, i.e., the Aurora kinase inhibitor reduces the ability of an Aurora kinase to phosphorylate a substrate peptide or protein at a concentration that is lower than the concentration of the inhibitor that is required to produce another, unrelated biological effect, e.g., reduction of the enzymatic activity of a different kinase.
- the Aurora kinase inhibitor also reduces the enzymatic activity of another kinase, preferably one that is implicated in cancer.
- CD20 antigen is a 35 kDa, non-glycosylated phosphoprotein found on the surface of greater than 90% of B cells from peripheral blood or lymphoid organs. CD20 is expressed during early pre-B cell development and remains until plasma cell differentiation. CD20 is present on both normal B cells as well as malignant B cells. Other names for CD20 in the literature include “B-lymphocyte-restricted antigen” and “Bp35”.
- the CD20 antigen is described in, e.g., Clark et al. PNAS (USA) 82:1766 (1985).
- antibody herein is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, humanized antibodies, human antibodies, chimeric antibodies, multispecific antibodies (e.g., bispecific antibodies) formed from at least two intact antibodies, and antibody fragments, so long as they exhibit the desired biological activity.
- Antibodies may be produced by one of skill in the art using conventional methods.
- the term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins.
- the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
- the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567).
- the “monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson et al., Nature, 352:624-628 (1991) and Marks et al, J. MoL Biol., 222:581-597 (1991), for example.
- the monoclonal antibodies herein specifically include but are not limited to “chimeric” or “humanized” forms.
- aliphatic or “aliphatic group”, as used herein, means a substituted or unsubstituted straight-chain, branched or cyclic C 1-12 hydrocarbon, which is completely saturated or which contains one or more units of unsaturation, but which is not aromatic.
- suitable aliphatic groups include substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl, alkynyl groups and hybrids thereof, such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
- alkyl refers to a straight and branched chain aliphatic group having from 1 to 12 carbon atoms.
- alkyl will be used when the carbon atom attaching the aliphatic group to the rest of the molecule is a saturated carbon atom.
- an alkyl group may include unsaturation at other carbon atoms.
- alkyl groups include, without limitation, methyl, ethyl, propyl, allyl, propargyl, butyl, pentyl, and hexyl.
- alkenyl will be used when the carbon atom attaching the aliphatic group to the rest of the molecule forms part of a carbon-carbon double bond.
- Alkenyl groups include, without limitation, vinyl, 1-propenyl, 1-butenyl, 1-pentenyl, and 1-hexenyl.
- alkynyl will be used when the carbon atom attaching the aliphatic group to the rest of the molecule forms part of a carbon-carbon triple bond.
- Alkynyl groups include, without limitation, ethynyl, 1-propynyl, 1-butynyl, 1-pentynyl, and 1-hexynyl.
- cycloaliphatic used alone or as part of a larger moiety, refers to a saturated or partially unsaturated cyclic aliphatic ring system having from 3 to about 14 members, wherein the aliphatic ring system is optionally substituted.
- the cycloaliphatic is a monocyclic hydrocarbon having 3-8 or 3-6 ring carbon atoms.
- Nonlimiting examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, and cyclooctadienyl.
- the cycloaliphatic is a bridged or fused bicyclic hydrocarbon having 6-12, 6-10, or 6-8 ring carbon atoms, wherein any individual ring in the bicyclic ring system has 3-8 members.
- two adjacent substituents on the cycloaliphatic ring taken together with the intervening ring atoms, form an optionally substituted fused 5- to 6-membered aromatic or 3- to 8-membered non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S.
- cycloaliphatic includes aliphatic rings that are fused to one or more aryl, heteroaryl, or heterocyclyl rings.
- Nonlimiting examples include indanyl, 5,6,7,8-tetrahydroquinoxalinyl, decahydronaphthyl, or tetrahydronaphthyl, where the radical or point of attachment is on the aliphatic ring.
- cycloaliphatic may be used interchangeably with the terms “carbocycle”, “carbocyclyl”, “carbocyclo”, or “carbocyclic”.
- aryl and “ar-”, used alone or as part of a larger moiety e.g., “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refer to a C 6 to C 14 aromatic hydrocarbon, comprising one to three rings, each of which is optionally substituted.
- the aryl group is a C 6-10 aryl group.
- Aryl groups include, without limitation, phenyl, naphthyl, and anthracenyl.
- two adjacent substituents on the aryl ring taken together with the intervening ring atoms, form an optionally substituted fused 5- to 6-membered aromatic or 4- to 8-membered non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S.
- aryl includes groups in which an aromatic ring is fused to one or more heteroaryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the aromatic ring.
- Nonlimiting examples of such fused ring systems include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, fluorenyl, indanyl, phenanthridinyl, tetrahydronaphthyl, indolinyl, phenoxazinyl, benzodioxanyl, and benzodioxolyl.
- aryl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic.
- aryl may be used interchangeably with the terms “aryl group”, “aryl moiety”, and “aryl ring”.
- an “aralkyl” or “arylalkyl” group comprises an aryl group covalently attached to an alkyl group, either of which independently is optionally substituted.
- the aralkyl group is C 6-10 aryl(C 1-6 )alkyl, C 6-10 aryl(C 1-4 )alkyl, or C 6-10 aryl(C 1-3 )alkyl, including, without limitation, benzyl, phenethyl, and naphthylmethyl.
- heteroaryl and “heteroar-”, used alone or as part of a larger moiety, e.g., heteroaralkyl, or “heteroaralkoxy”, refer to groups having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 ⁇ electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to four heteroatoms.
- heteroatom refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.
- Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl.
- heteroaryl taken together with the intervening ring atoms, form an optionally substituted fused 5- to 6-membered aromatic or 4- to 8-membered non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S.
- heteroaryl and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring.
- Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one.
- a heteroaryl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic.
- heteroaryl may be used interchangeably with the terms “heteroaryl ring”, “heteroaryl group”, or “heteroaromatic”, any of which terms include rings that are optionally substituted.
- heteroarylkyl refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
- heterocycle As used herein, the terms “heterocycle”, “heterocyclyl”, “heterocyclic radical”, and “heterocyclic ring” are used interchangeably and refer to a stable 3- to 7-membered monocyclic, or to a fused 7- to 10-membered or bridged 6- to 10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above.
- nitrogen includes a substituted nitrogen.
- the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or + NR (as in N-substituted pyrrolidinyl).
- a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any of the ring atoms can be optionally substituted.
- saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl.
- two adjacent substituents on a heterocyclic ring taken together with the intervening ring atoms, for an optionally substituted fused 5- to 6-membered aromatic or 3- to 8-membered non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S.
- heterocycle used interchangeably herein, and include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the heterocyclyl ring.
- a heterocyclyl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic.
- heterocyclylalkyl refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
- partially unsaturated refers to a ring moiety that includes at least one double or triple bond between ring atoms.
- the term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
- haloaliphatic refers to an aliphatic, alkyl, alkenyl or alkoxy group, as the case may be, which is substituted with one or more halogen atoms.
- halogen or “halo” means F, Cl, Br, or I.
- fluoroaliphatic refers to a haloaliphatic wherein the halogen is fluoro.
- alkylene refers to a bivalent alkyl group.
- An “alkylene chain” is a polymethylene group, i.e., —(CH 2 ) n —, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3.
- a substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms is replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
- An alkylene chain also may be substituted at one or more positions with an aliphatic group or a substituted aliphatic group.
- substituted means that a hydrogen radical of the designated moiety is replaced with the radical of a specified substituent, provided that the substitution results in a stable or chemically feasible compound.
- substituents refers to a number of substituents that equals from one to the maximum number of substituents possible based on the number of available bonding sites, provided that the above conditions of stability and chemical feasibility are met.
- an optionally substituted group may have a substituent at each substitutable position of the group, and the substituents may be either the same or different.
- aryl including the aryl moiety in aralkyl, aralkoxy, aryloxyalkyl and the like
- heteroaryl including the heteroaryl moiety in heteroaralkyl and heteroaralkoxy and the like
- Suitable substituents on the unsaturated carbon atom of an aryl or heteroaryl group include -halo, —NO 2 , —CN, —R*, —C(R*) ⁇ C(R*) 2 , —C ⁇ C—R*, —OR*, —SR o , —S(O)R o , —SO 2 R o , —SO 3 R o , —SO 2 N(R + ) 2 , —N(R + ) 2 , —NR + C(O)R*, —NR + C(O)N(R + ) 2 , —NR + CO 2 R o , —O—CO 2 R*, —OC(O)N(R + ) 2 , —O—C(O)R*, —CO 2 R*, —C(O)—C(O)R*, —C(O)N(R + ) 2 ,
- aryl including the aryl moiety in aralkyl, aralkoxy, aryloxyalkyl and the like
- heteroaryl including the heteroaryl moiety in heteroaralkyl and heteroaralkoxy and the like
- Suitable substituents on the unsaturated carbon atom of an aryl or heteroaryl group include -halo, —NO 2 , —CN, —R*, —C(R*) ⁇ C(R*) 2 , —C ⁇ C—R*, —OR*, —SR o , —S(O)R o , —SO 2 R o , —SO 3 R o , —SO 2 N(R + ) 2 , —N(R + ) 2 , —NR + C(O)R*, —NR + C(O)N(R + ) 2 , —NR + CO 2 R o , —O—CO 2 R*, —OC(O)N(R + ) 2 , —O—C(O)R*, —CO 2 R*, —C(O)—C(O)R*, —C(O)N(R + ) 2 ,
- Each R + is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group, or two R + on the same nitrogen atom, taken together with the nitrogen atom, form a 5-8 membered aromatic or non-aromatic ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S.
- Each R* independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group.
- Each R o is an optionally substituted aliphatic or aryl group.
- An aliphatic group or a non-aromatic heterocyclic ring may be substituted with one or more substituents.
- suitable substituents on the saturated carbon of an aliphatic group or of a non-aromatic heterocyclic ring include, without limitation, those listed above for the unsaturated carbon of an aryl or heteroaryl group and the following: ⁇ O, ⁇ S, ⁇ C(R*) 2 , ⁇ N—N(R*) 2 , ⁇ N—OR*, ⁇ N—NHC(O)R*, ⁇ N—NHCO 2 R o , ⁇ N—NHSO 2 R o , or ⁇ N—R*, where each R* and R o is as defined above.
- Suitable substituents on the nitrogen atom of a non-aromatic heterocyclic ring include —R*, —N(R*) 2 , —C(O)R*, —CO 2 R*, —C(O)—C(O)R*—C(O)CH 2 C(O)R*, —SO 2 R*, —SO 2 N(R*) 2 , —C( ⁇ S)N(R*) 2 , —C( ⁇ NH)—N(R*) 2 , and —NR*SO 2 R*; wherein each R* is as defined above.
- structures depicted herein are meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
- compounds having the present structure except for the replacement of a hydrogen atom by a deuterium or tritium, or the replacement of a carbon atom by a 13 C- or 14 C-enriched carbon are within the scope of the invention.
- Aurora kinase inhibitors include the compounds described herein, as well as compounds disclosed in, for example, WO 05/111039, US2005/0256102, US2007/0185087, WO 08/021038, US2008/0045501, WO 08/063525, US2008/0167292, WO 07/113212, EP1644376, US2005/0032839, WO 05/005427, WO 06/070192, WO 06/070198, WO 06/070202, WO 06/070195, WO 06/003440, WO 05/002576, WO 05/002552, WO 04/071507, WO 04/058781, WO 06/055528, WO 06/055561, WO 05/118544, WO 05/013996, WO 06/036266, US2006/
- Aurora kinase inhibitors can be prepared in a number of ways well known to one skilled in the art of organic synthesis, including, but not limited to, the methods of synthesis described in detail in the above references.
- the Aurora kinase inhibitor is a compound represented by formula (I):
- Ring A is a substituted or unsubstituted 5- or 6-membered aryl, heteroaryl, cycloaliphatic, or heterocyclyl ring.
- Ring A include furano, dihydrofurano, thieno, dihydrothieno, cyclopenteno, cyclohexeno, 2H-pyrrolo, pyrrolo, pyrrolino, pyrrolidino, oxazolo, thiazolo, imidazolo, imidazolino, imidazolidino, pyrazolo, pyrazolino, pyrazolidino, isoxazolo, isothiazolo, oxadiazolo, triazolo, thiadiazolo, 2H-pyrano, 4H-pyrano, benzo, pyridino, piperidino, dioxano, morpholino, dithiano, thiomorpholino, pyridazino,
- Ring A examples include, without limitation, substituted or unsubstituted rings selected from the group consisting of furano, thieno, pyrrolo, oxazolo, thiazolo, imidazolo, pyrazolo, isoxazolo, isothiazolo, triazolo, benzo, pyridino, pyridazino, pyrimidino, and pyrazino.
- Ring A may be substituted or unsubstituted.
- each substitutable saturated ring carbon atom in Ring A is unsubstituted or is substituted with ⁇ O, ⁇ S, ⁇ C(R 5 ) 2 , ⁇ N—N(R 4 ) 2 , ⁇ N—OR 5 , ⁇ N—NHC(O)R 5 , ⁇ N—NHCO 2 R 6 , ⁇ N—NHSO 2 R 6 , ⁇ N—R 5 or —R b , where R b , R 4 , R 5 , and R 6 are as defined below.
- Each substitutable unsaturated ring carbon atom in Ring A is unsubstituted or substituted with —R b .
- Each substitutable ring nitrogen atom in Ring A is unsubstituted or is substituted with —R 9b , and one ring nitrogen atom in Ring A optionally is oxidized.
- Each R 9b independently is —C(O)R 5 , —C(O)N(R 4 ) 2 , —CO 2 R 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , or a C 1-4 aliphatic optionally substituted with R 3 or R 7 .
- Each R b independently is R 2b , an optionally substituted aliphatic, or an optionally substituted aryl, heterocyclyl, or heteroaryl group; or two adjacent R b , taken together with the intervening ring atoms, form an optionally substituted fused 4- to 8-membered aromatic or non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S.
- Each R 2b independently is -halo, —NO 2 , —CN, —C(R 5 ) ⁇ C(R 5 ) 2 , —C(R 5 ) ⁇ C(R 5 )(R 10 ), —C ⁇ C—R 5 , —C ⁇ C—R 10 , —OR 5 , —SR 6 , —S(O)R 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , —N(R 4 ) 2 , —NR 4 C(O)R 5 , —NR 4 C(O)N(R 4 ) 2 , —NR 4 CO 2 R 6 , —O—CO 2 R 5 , —OC(O)N(R 4 ) 2 , —O—C(O)R 5 , —CO 2 R 5 , —C(O)—C(O)R 5 , —C(O)N(R 4 ) 2
- Ring A is substituted by 0-2 substituents Rb.
- each Rb independently is C 1-3 aliphatic or R 2b
- each R 2b independently is selected from the group consisting of -halo, —NO 2 , —C(R 5 ) ⁇ C(R 5 ) 2 , —OR 5 , and —N(R 4 ) 2 .
- each Rb independently is selected from the group consisting of -halo, C 1-3 aliphatic, C 1-3 fluoroaliphatic, and —OR 5 , where R 5 is hydrogen or C 1-3 aliphatic.
- Ring A is substituted with 0, 1, or 2 substituents, preferably 0 or 1 substituents, independently selected from the group consisting of chloro, fluoro, bromo, methyl, trifluoromethyl, and methoxy.
- Ring B is a substituted or unsubstituted mono- or bicyclic aryl or heteroaryl ring selected from the group consisting of furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indolyl, isoindolyl, indazolyl, benzo[b]furanyl, benzo[b]thienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, purinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl
- Each substitutable saturated ring carbon atom in Ring B is unsubstituted or is substituted with ⁇ O, ⁇ S, ⁇ C(R 5 ) 2 , ⁇ N—N(R 4 ) 2 , ⁇ N—OR 5 , ⁇ N—NHC(O)R 5 , ⁇ N—NHCO 2 R 6 , ⁇ N—NHSO 2 R 6 , ⁇ N—R 5 or —R c .
- Each substitutable unsaturated ring carbon atom in Ring B is unsubstituted or substituted with —R c .
- Each substitutable ring nitrogen atom in Ring B is unsubstituted or is substituted with —R 9c , and one ring nitrogen atom in Ring B optionally is oxidized.
- Each R 9c independently is —C(O)R 5 , —C(O)N(R 4 ) 2 , —CO 2 R 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , or a C 1-4 aliphatic optionally substituted with R 3 or R 7 .
- Ring B may be unsubstituted or may be substituted on any one or more of its component rings, wherein the substituents may be the same or different. In some embodiments, Ring B is substituted with 0-2 independently selected R c and 0-3 independently selected R 2c or C 1-6 aliphatic groups.
- the variables R 3 , R 4 , R 5 , R 6 , and R 7 are as defined above for Ring A, and R c and R 2c are defined below.
- Each R c independently is R 2c , an optionally substituted C 1-6 aliphatic, or an optionally substituted aryl, heteroaryl, or heterocyclyl group.
- Each R 2c independently is -halo, —NO 2 , —CN, —C(R 5 ) ⁇ C(R 5 ) 2 , —C(R 5 ) ⁇ C(R 5 )(R 10 ), —C ⁇ C—R 5 , —C ⁇ C—R 10 , —OR 5 , —SR 6 , —S(O)R 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , —N(R 4 ) 2 , —NR 4 C(O)R 5 , —NR 4 C(O)N(R 4 ) 2 , —NR 4 CO 2 R 6 , —O—CO 2 R 5 , —OC(O)N(R 4 ) 2 , —O—C(O)R 5 , —CO 2 R 5 , —C(O)—C(O)R 5 , —C(O)N(R 4 ) 2
- Ring B is a monocyclic 5- or 6-membered aryl or heteroaryl ring, substituted with 0-2 independently selected R c and 0-2 independently selected R 2c or C 1-6 aliphatic groups. In certain such embodiments, Ring B is a substituted or unsubstituted phenyl or pyridyl ring.
- Ring B is substituted with 0-2 substituents R c .
- each R c independently is C 1-3 aliphatic or R 2c , and each R 2c independently is selected from the group consisting of -halo, —NO 2 , —C(R 5 ) ⁇ C(R 5 ) 2 , —C ⁇ C—R 5 , —OR 5 , and —N(R 4 ) 2 .
- each R c independently is selected from the group consisting of -halo, C 1-3 aliphatic, C 1-3 haloaliphatic, and —OR 5 , where R 5 is hydrogen or C 1-3 aliphatic.
- Ring B is substituted with 0, 1, or 2 substituents, independently selected from the group consisting of chloro, fluoro, bromo, methyl, trifluoromethyl, and methoxy.
- Each substitutable saturated ring carbon atom in Ring C is unsubstituted or is substituted with ⁇ O, ⁇ S, ⁇ C(R 5 ) 2 , ⁇ N—N(R 4 ) 2 , ⁇ N—OR 5 , ⁇ N—NHC(O)R 5 , ⁇ N—NHCO 2 R 6 , ⁇ N—NHSO 2 R 6 , ⁇ N—R 5 or —R d .
- Each substitutable unsaturated ring carbon atom in Ring C is unsubstituted or substituted with —R d .
- Each substitutable ring nitrogen atom in Ring C is unsubstituted or is substituted with —R 9d , and one ring nitrogen atom in Ring C optionally is oxidized.
- Each R 9d independently is —C(O)R 5 , —C(O)N(R 4 ) 2 , —CO 2 R 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , or a C 1-4 aliphatic optionally substituted with R 3 or R 7 .
- Ring C may be unsubstituted or may be substituted on any one or more of its component rings, wherein the substituents may be the same or different. In some embodiments, Ring C is substituted with 0-2 independently selected R d and 0-3 independently selected R 2d or C 1-6 aliphatic groups.
- the variables R 3 , R 4 , R 5 , R 6 , and R 7 are as described above for Rings A and B.
- the variables R d and R 2d are described below.
- Each R d independently is R 2d , an optionally substituted aliphatic, or an optionally substituted aryl, heteroaryl, or heterocyclyl group.
- Each R 2d independently is -halo, —NO 2 , —CN, —C(R 5 ) ⁇ C(R 5 ) 2 , —C(R 5 ) ⁇ C(R 5 ) 2 (R 10 ), —C ⁇ C—R 5 , —C ⁇ C—R 10 , —OR 5 , —SR 6 , —S(O)R 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , —N(R 4 ) 2 , —NR 4 C(O)R 5 , —NR 4 C(O)N(R 4 ) 2 , —NR 4 CO 2 R 6 , —O—CO 2 R 5 , —OC(O)N(R 4 ) 2 , —O—C(O)R 5 , —CO 2 R 5 , —C(O)—C(O)R 5 , —C(O)N(R 4 )
- R 2d can be —SO 3 R 5 , —C(O)N(R 4 )C( ⁇ NR 4 )—N(R 4 ) 2 or —N(R 4 )C( ⁇ NR 4 )—N(R 4 )—C(O)R 5 .
- Ring C is a monocyclic 5- or 6-membered aryl or heteroaryl ring, which is substituted with 0-2 independently selected substituents R d and 0-2 independently selected R 2d or C 1-6 aliphatic groups.
- Ring C is an optionally substituted heteroaryl ring selected from the group consisting of pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, and oxazolyl.
- Ring C is a substituted or unsubstituted phenyl ring.
- Ring C is a monocyclic 5- or 6-membered aryl or heteroaryl ring, which is substituted with 0, 1, or 2 substituents Rd, as defined above.
- Ring C is a monocyclic 5- or 6-membered heterocyclyl or cycloaliphatic ring, which is substituted with 0-2 independently selected substituents R d and 0-2 independently selected R 2d or C 1-6 aliphatic groups.
- the Aurora kinase inhibitor is a compound represented by formula (II):
- Table 1 provides the chemical names for specific examples of compounds of formula (II).
- the Aurora kinase inhibitor is represented by formula (III):
- R 1 is a 5- or 6-membered aryl, heteroaryl, or heterocyclyl ring optionally substituted with one or two substituents independently selected from the group consisting of halo, C 1-3 aliphatic, and C 1-3 fluoroaliphatic.
- R 1 is a phenyl, furyl, pyrrolidinyl, or thienyl ring optionally substituted with one or two substituents independently selected from the group consisting of halo, C 1-3 aliphatic, and C 1-3 fluoroaliphatic.
- R 3 is hydrogen, C 1-3 aliphatic, C 1-3 fluoroaliphatic, or —CH 2 —OCH 3 .
- R 5 is hydrogen, C 1-3 aliphatic, or C 1-3 fluoroaliphatic.
- R a is halo, C 1-3 aliphatic, C 1-3 fluoroaliphatic, —OH, —O(C 1-3 aliphatic), —O(C 1-3 fluoroaliphatic), —CH ⁇ CH—R 3 , —CH ⁇ CH—R 3 , or an optionally substituted pyrrolidinyl, thienyl, furyl, or phenyl ring, wherein R 3 is hydrogen, C 1-3 aliphatic, C 1-3 fluoroaliphatic, or —CH 2 —OCH 3 .
- R a is selected from the group consisting of chloro, fluoro, C 1-3 aliphatic, C 1-3 fluoroaliphatic, —OCH 3 , —OCF 3 , —C ⁇ C—H, —C ⁇ C—CH 3 , —C ⁇ C—CH 2 OCH 3 , —CH ⁇ CH 2 , —CH ⁇ CHCH 3 , N-methylpyrrolidinyl, thienyl, methylthienyl, furyl, methylfuryl, phenyl, fluorophenyl, and tolyl.
- Table 2 provides the chemical names for specific examples of compounds of formula (III).
- the compound of formula (III) is 4- ⁇ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino ⁇ -2-methoxybenzoic acid or a pharmaceutically acceptable salt thereof.
- the compound of formula (III) is sodium 4- ⁇ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino ⁇ -2-methoxybenzoate.
- Antibodies which bind the CD20 antigen include, for example: C2B8 (rituximab; RITUXAN®) (U.S. Pat. No. 5,736,137, expressly incorporated herein by reference); the yttrium-[90]-labeled 2138 murine antibody designated Y2B8 (U.S. Pat. No. 5,736,137, expressly incorporated herein by reference); murine IgG2a 131 optionally labeled with 131 1 to generate the 131 1-B1 antibody (BEXXARTM®) (U.S. Pat. No.
- the anti-CD20 antibody is rituximab.
- Rituximab is a genetically engineered chimeric murine/human monoclonal antibody.
- Rituximab is an IgG, kappa immunoglobulin containing murine light and heavy chain variable region sequences and human constant region sequences.
- Rituximab has a binding affinity for the CD20 antigen of approximately 8.0 nM. It is commercially available, e.g., from Genentech (South San Francisco, Calif.).
- the anti-CD20 antibody used in the present invention may be administered along with standard of care chemotherapeutic agents/combinations, such as, for example, CHOP chemotherapy regimen, which is a regimen consisting of the combination of cyclophosphamide, doxorubicin, vincristine and prednisolone.
- CHOP chemotherapy regimen which is a regimen consisting of the combination of cyclophosphamide, doxorubicin, vincristine and prednisolone.
- Rituximab has been approved in combination with CHOP chemotherapy for the treatment of certain types of lymphomas and this combination has become known as RCHOP chemotherapy.
- the compounds can be assayed in vitro or in vivo for their ability to bind to and/or inhibit an Aurora kinase.
- In vitro assays include assays to determine inhibition of the ability of an Aurora kinase to phosphorylate a substrate protein or peptide. Alternate in vitro assays quantitate the ability of the compound to bind to an Aurora kinase. Inhibitor binding may be measured by radiolabelling the inhibitor prior to binding, isolating the inhibitor/Aurora kinase complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding may be determined by running a competition experiment in which new inhibitors are incubated with Aurora kinase bound to a known radioligand. The compounds also can be assayed for their ability to affect cellular or physiological functions mediated by Aurora kinase activity. Assays for each of these activities are known in the art.
- the invention provides a method for inhibiting cellular growth/cellular proliferation comprising contacting a cell with an Aurora kinase inhibitor in combination with an anti-CD20 antibody, such as, e.g., rituximab.
- an anti-CD20 antibody such as, e.g., rituximab.
- the invention provides a method for inhibiting cellular growth/cellular proliferation comprising contacting a cell with an Aurora kinase inhibitor in combination RCHOP chemotherapy.
- the method according to the invention causes an inhibition of cell proliferation of the contacted cells.
- inhibiting cell proliferation is used to denote an ability of an inhibitor of Aurora kinase and/or anti-CD20 antibody to inhibit cell number or cell growth in contacted cells as compared to cells not contacted with the inhibitor and/or antibody.
- An assessment of cell proliferation can be made by counting cells using a cell counter or by an assay of cell viability, e.g., a BrdU, MTT, XTT, or WST assay.
- such an assessment of cell proliferation can be made by measuring the growth, e.g., with calipers, and comparing the size of the growth of contacted cells with non-contacted cells.
- the growth of cells contacted with an Aurora kinase inhibitor and an anti-CD20 antibody is retarded by at least about 50% as compared to growth of non-contacted cells.
- cell proliferation of contacted cells is inhibited by at least about 75%, at least about 90%, or at least about 95% as compared to non-contacted cells.
- the phrase “inhibiting cell proliferation” includes a reduction in the number of contacted cells, as compare to non-contacted cells.
- an inhibitor of Aurora kinase and/or an anti-CD20 antibody that inhibits cell proliferation in a contacted cell may induce the contacted cell to undergo growth retardation, to undergo growth arrest, to undergo programmed cell death (i.e., apoptosis), or to undergo necrotic cell death.
- the invention provides a pharmaceutical composition comprising i) an Aurora kinase inhibitor; and ii) an anti-CD20 antibody.
- the Aurora kinase inhibitor is selected from the group consisting of i) the compounds of formulas (I), (II) and (III); ii) the compounds disclosed in, for example, WO 05/111039, US2005/0256102, US2007/0185087, WO 08/021038, US2008/0045501, WO 08/063525, US2008/0167292, WO 07/113212, EP1644376, US2005/0032839, WO 05/005427, WO 06/070192, WO 06/070198, WO 06/070202, WO 06/070195, WO 06/003440, WO 05/002576, WO 05/002552, WO 04/071507, WO 04/058781, WO 06/055528, WO 06/055561
- the salt preferably is derived from an inorganic or organic acid or base.
- suitable salts see, e.g., Berge et al, J. Pharm. Sci. 66:1-19 (1977) and Remington: The Science and Practice of Pharmacy, 20 th Ed ., ed. A. Gennaro, Lippincott Williams & Wilkins, 2000.
- Nonlimiting examples of suitable acid addition salts include the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, lucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenyl-propionate, picrate, pivalate, propionate, succinate, tartrate
- Suitable base addition salts include, without limitation, ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine, N-methyl-D-glucamine, t-butylamine, ethylene diamine, ethanolamine, and choline, and salts with amino acids such as arginine, lysine, and so forth.
- alkali metal salts such as sodium and potassium salts
- alkaline earth metal salts such as calcium and magnesium salts
- salts with organic bases such as dicyclohexylamine, N-methyl-D-glucamine, t-butylamine, ethylene diamine, ethanolamine, and choline
- salts with amino acids such as arginine, lysine, and so forth.
- basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
- lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
- dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates
- long chain halides such as
- pharmaceutically acceptable carrier is used herein to refer to a material that is compatible with a recipient subject, preferably a mammal, more preferably a human, and is suitable for delivering an active agent to the target site without terminating the activity of the agent.
- the toxicity or adverse effects, if any, associated with the carrier preferably are commensurate with a reasonable risk/benefit ratio for the intended use of the active agent.
- carrier include any and all solvents, diluents, and other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- Remington The Science and Practice of Pharmacy, 20 th Ed ., ed. A. Gennaro, Lippincott Williams & Wilkins, 2000 discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof.
- any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention.
- materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as disodium hydrogen phosphate, potassium hydrogen phosphate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium hydroxide and aluminum hydroxide, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, pyrogen-free water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose, sucrose, starches such as corn starch and potato starch, cellulose and
- compositions of the invention can be manufactured by methods well known in the art such as conventional granulating, mixing, dissolving, encapsulating, lyophilizing, or emulsifying processes, among others.
- Compositions may be produced in various forms, including granules, precipitates, or particulates, powders, including freeze dried, rotary dried or spray dried powders, amorphous powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions.
- Formulations may optionally contain solvents, diluents, and other liquid vehicles, dispersion or suspension aids, surface active agents, pH modifiers, isotonic agents, thickening or emulsifying agents, stabilizers and preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- compositions of this invention are formulated for pharmaceutical administration to a mammal, preferably a human being.
- Such pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
- parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
- the compositions are administered orally, intravenously, or subcutaneously.
- the formulations of the invention may be designed to be short-acting, fast-releasing, or long-acting.
- compounds can be administered in a local rather than systemic means, such as administration (e.g., by injection) at a tumor site.
- Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, cyclodextrins, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents such as, for example, water or
- sterile injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil can be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid are used in the preparation of injectables.
- the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
- Compositions formulated for parenteral administration may be injected by bolus injection or by timed push, or may be administered by continuous infusion.
- the rate of compound release can be controlled.
- biodegradable polymers include poly(orthoesters) and poly(anhydrides).
- Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
- compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and gly
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- the active compounds can also be in micro-encapsulated form with one or more excipients as noted above.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
- the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
- Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
- the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
- buffering agents include polymeric substances and waxes.
- Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
- the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
- Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention.
- the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body.
- Such dosage forms can be made by dissolving or dispensing the compound in the proper medium.
- Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
- Formulation of an antibody or fragment to be administered will vary according to the route of administration and formulation (e.g., solution, emulsion, capsule) selected.
- An appropriate pharmaceutical composition comprising an antibody or functional fragment thereof to be administered can be prepared in a physiologically acceptable vehicle or carrier.
- suitable carriers include, for example, aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- Parenteral vehicles can include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils.
- aqueous carriers include water, buffered water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol), dextrose solution and glycine.
- Intravenous vehicles can include various additives, preservatives, or fluid, nutrient or electrolyte replenishers (See, generally, Remington's Pharmaceutical Science, 16th Edition, Mack, Ed. 1980).
- the compositions can optionally contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents and toxicity adjusting agents, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride and sodium lactate.
- the antibodies and fragments of this invention can be lyophilized for storage and reconstituted in a suitable carrier prior to use according to art-known lyophilization and reconstitution techniques.
- the optimum concentration of the active ingredient(s) in the chosen medium can be determined empirically, according to procedures well known to the skilled artisan, and will depend on the ultimate pharmaceutical formulation desired.
- the antibody or fragment can be solubilized and loaded into a suitable dispenser for administration (e.g., an atomizer, nebulizer or pressurized aerosol dispenser).
- the antibody or fragment can be administered in a single dose or multiple doses.
- the dosage can be determined by methods known in the art and is dependent, for example, upon the antibody or fragment chosen, the subject's age, sensitivity and tolerance to drugs, and overall well-being.
- Antibodies and antigen-binding fragments thereof, such as human, humanized and chimeric antibodies and antigen-binding fragments can often be administered with less frequency than other types of therapeutics.
- an effective amount of an antibody can range from about 0.01 mg/kg to about 5 or 10 mg/kg administered daily, weekly, biweekly or monthly.
- hematological malignancies includes any malignancy associated with cells in the bloodstream; bone marrow; and the lymphoid system including in the liver, spleen, and lymph nodes.
- Nonlimiting examples of hematological malignancies include B and T cell lymphomas and leukemias.
- B and T cell lymphomas include, for example, low grade/follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, T or B prolymphocytic leukemia, diffuse large B cell NHL, peripheral T cell lymphomas, mantle cell lymphoma, marginal zone lymphomas, B or T cell lymphoblastic lymphoma, Burkitt's lymphoma, primary thyroid lymphoma, Waldenstrom's Macroglobulinemia or lymphoplasmacytic lymphoma.
- NHL low grade/follicular non-Hodgkin's lymphoma
- SL small lymphocytic
- T or B prolymphocytic leukemia diffuse large B cell NHL, peripheral T cell lymphomas, mantle cell lymphoma, marginal zone lymphomas, B or T cell lymphoblastic lymphoma, Burkitt's lymphoma, primary thyroid lymphoma, Waldenstrom's Macroglobulinemia or lymph
- leukemia include, for example, chronic leukocytic leukemia, acute myelogenous leukemia (AML), acute lymphoblastic leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia, lymphoblastic leukemia, lymphocytic leukemia, monocytic leukemia, myelogenous leukemia and promyelocytic leukemia.
- AML acute myelogenous leukemia
- CLL chronic lymphocytic leukemia
- chronic myelogenous leukemia chronic myelogenous leukemia
- lymphoblastic leukemia lymphoblastic leukemia
- lymphocytic leukemia monocytic leukemia
- myelogenous leukemia promyelocytic leukemia.
- Nonlimiting examples of hematological malignancies additionally include, for example, multiple myeloma, myelodysplastic syndromes (MDS), including refractory anemia (RA), refractory anemia with ringed siderblasts (RARS), (refractory anemia with excess blasts (RAEB), and RAEB in transformation (RAEB-T); and myeloproliferative syndromes.
- MDS myelodysplastic syndromes
- RA refractory anemia
- RARS refractory anemia with ringed siderblasts
- RAEB refractory anemia with excess blasts
- RAEB-T RAEB in transformation
- myeloproliferative syndromes myeloproliferative syndromes
- the hematological malignancy to be treated by the method of the invention is one in which the activity of an Aurora kinase is amplified and in which the CD20 antigen is expressed.
- the hematological malignancy is selected from the group consisting of lymphoma, leukemia and multiple myeloma.
- the lymphoma is selected from the group consisting of B cell lymphoma, non-Hodgkin's lymphoma and mantle cell lymphoma.
- patient means an animal, preferably a mammal, more preferably a human.
- the patient has been treated with an agent, e.g., an Aurora kinase inhibitor or an anti-CD20 antibody, prior to initiation of treatment according to the method of the invention.
- the patient is a patient at risk of developing or experiencing a recurrence of a hematological malignancy.
- terapéuticaally effective amount refers to an amount of a drug substance (e.g., Aurora kinase inhibitor and/or anti-CD20 antibody) effective for treatment or prophylaxis or amelioration of symptoms of a hematological malignancy discussed herein.
- a drug substance e.g., Aurora kinase inhibitor and/or anti-CD20 antibody
- compositions for use in the method of the invention may be formulated in unit dosage form for ease of administration and uniformity of dosage.
- unit dosage form refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
- a unit dosage form for parenteral administration may be in ampoules or in multi-dose containers.
- the Aurora kinase inhibitor may be administered with the anti-CD20 antibody in a single dosage form or as a separate dosage form.
- the anti-CD20 antibody may be administered prior to, at the same time as, or following administration of the Aurora kinase inhibitor of the invention.
- the instant invention includes the following methods: A method to treat a patient suffering from a hematological malignancy comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g., before or after) an anti-CD20 antibody; A method to treat a patient suffering from a hematological malignancy comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g. before or after) rituximab; A method to treat a patient suffering from lymphoma comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g.
- a method to treat a patient suffering from lymphoma comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g. before or after) rituximab;
- a method to treat a patient suffering from leukemia comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g. before or after) an anti-CD20 antibody;
- a method to treat a patient suffering from leukemia comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g.
- a method to treat a patient suffering from multiple myeloma comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g. before or after) an anti-CD20 antibody; and A method to treat a patient suffering from multiple myeloma comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g. before or after) rituximab.
- the method of the invention comprises administering to a patient suffering from a hematological malignancy a therapeutically effective amount of an Aurora kinase inhibitor of Formula (I), (II) or (III) as defined herein simultaneously with or consecutively with (e.g., before or after) rituximab.
- the invention relates to use of an Aurora kinase inhibitor for the manufacture of a medicament for the treatment of a hematological malignancy.
- the invention relates to the use of an Aurora kinase inhibitor of Formula (I), (II) or (III) as defined herein, in the manufacture of a medicament for use in combination therapy with rituximab for the treatment of a hematological malignancy.
- DLBCL diffuse large B-cell lymphoma
- the Ly19-Luc, WSU-DLBCL2-Luc and PHTX-22-06 models described in these studies are human DLBCL cell lines, transfected with luciferase. These models were grown in immunocompromised mice subcutaneously on the flank, or disseminated throughout the body by tail vain injection. 4- ⁇ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino ⁇ -2-methoxybenzoic acid (III-1) was administered orally in both daily and twice daily dosing regimens and rituximab was administered by IV injection QD7 ⁇ 3. The efficacy, tumor growth and post-treatment survival of mice treated with Compound III-1 and rituximab were compared as single agents or in combination.
- mice were inoculated with 4.0 ⁇ 10 6 cells from cell line Ly-19 at implant site Flank (cell suspension). Compounds were administered for 21 days, and tumor volumes were measured on days 0, 5, 13, 15, 18, and 21. After treatment ended, the surviving mice continued to be evaluated on days 25, 28, 33, 36, 40, 43, 47, 50, 54, 60, and 62.
- the primary goal was to determine whether the combination of Compound III-1 and rituximab was more effective at reducing tumor volume than either treatment alone.
- the second endpoint was to evaluate the rates of tumor regrowth among the groups after treatment was completed.
- Statistical analysis was performed using a linear mixed effects regression model. This model takes into account the differences in trends of tumor growth between control and treated samples.
- the statistical modeling was conducted in two steps: model fitting and model selection.
- a family of ten closely related mixed-effects regression models was fitted to the study data. Data from all time points in the study were used, including mice that were sacrificed before the end of the study.
- Each treatment group was fitted to a quadratic trend line for tumor growth that consisted of up to three terms for tumor growth: zero-order (intercept), first-order (slope) and second-order (curvature).
- Each drug treatment was then modeled by up to two interaction terms, one describing the difference in slope and the other describing the difference in curvature due to drug treatments.
- mouse-specific variability was accounted for by including random effects for each mouse with up to three terms: a mouse-specific intercept, slope or curvature effect.
- Repeated measurements of tumor growth for a given mouse were modeled using a compound symmetry covariance structure.
- Model selection was performed by first filtering models that the model-fitting algorithm was unable to fit in a numerically stable way (specifically by removing models that demonstrated sensitivity to the starting value of the autocorrelation coefficient, and those for whom the variance-covariance matrix of random effects was not positive definite). The best fit model was then selected using a statistical criterion called the Bayes Information Criterion (BIC), which is a measure of a model's goodness of fit that takes into account the number of parameters used by the model and the magnitude of the residuals—the difference between fitted and observed values.
- BIC Bayes Information Criterion
- the model fitting and selection procedure were performed twice, once on the original (untransformed) data, and once on log 10 -transformed data. Once the automated model-fitting and selection procedure were completed, two best-fit models were generated, one on log-transformed data and the other on untransformed data. An investigator then studied the diagnostic plots generated by the two statistical models and chose one of them as the appropriate model for the study. This choice was made on the basis of the distribution of the residuals as well as their behavior with respect to the fitted values. Obvious trends in the residuals were indicative of a poor model fit, suggesting trends remaining in the data that the model had failed to take into account.
- the effect size was calculated as the difference between areas under the model-fitted curves ( ⁇ AUC) for treated and control groups, relative to the area under the model-fitted curve for the control group.
- a ⁇ AUC of 0 meant that the curves for the treatment and control groups were the same, whereas a negative ⁇ AUC indicated tumor growth inhibition upon treatment.
- a ⁇ AUC of less than zero meant that a combination treatment led to a greater decrease in area under the curve than the sum of individual treatments, indicating a synergistic tumor growth inhibition.
- Permutation testing was performed to compare the difference between control and combination treatment against the difference that would have been observed if the treatments were purely additive. Synergy measures disclosed herein are provided based on ⁇ AUC calculations and based on TGI calculations. Because ⁇ AUC calculations capture the entire treatment period within an experiment, such calculations are deemed more comprehensive and more accurate than the TGI calculations.
- the average tumor volume in the vehicle group increased almost sixteen fold from 180 mm 3 at day 0 to over 2850 mm 3 on day 21, and this resulted in a mean area under the log(fold change) over time curve (AUC) of 12.9.
- the AUCs, and therefore the tumor volumes, were smaller in each of the treatment groups compared to vehicle (Table 3a).
- the results of the linear regression model revealed that all of these differences relative to the vehicle group were significant (Table 3b).
- the three combination groups showed consistent decreases in tumor volume and were all significantly lower than their respective single agents alone.
- the Compound III-1 (3 mg/kg qd)+rituximab (10 mg/kg) group was synergistic, while the other two combinations were additive when examining AUC values (Table 4). All three combinations were sub-additive when looking at tumor growth inhibition (Table 5, Table 6).
- the animals were inoculated with 4.0 ⁇ 10 6 cells from cell line WSU-DLCL2 at implant site Flank (cell suspension). Compounds were administered for 21 days, and tumor volumes were measured on days 0, 4, 7, 11, 15, 18, and 20. The primary goal was to investigate whether the combination of Compound III-1 and Rituximab was synergistic.
- the average tumor volume in the vehicle group increased over nine-fold from 201 mm 3 at day 0 to 1903 mm 3 on day 20.
- the tumor volumes were smaller in each of the treatment groups compared to vehicle (Table 8).
- Tumor Growth Inhibition (Day 20) Average percent decrease in tumor growth relative to the mean tumor volume of the vehicle group.
- Pct Tumor Growth Inhibition Treatment Relative to Vehicle Mean Vehicle Compound III-1 (3 mg/kg, PO, qd) 33.1 Compound III-1 (10 mg/kg, PO, qd) 68.9 Rituximab (10 mg/kg, IV, q7d) 67.1 Compound III-1 (3 mg/kg) + Rituximab 78.5 (10 mg/kg, IV, q7d) Compound III-1 (10 mg/kg) + Rituximab 95.5 (10 mg/kg, IV, q7d)
- Compound III-1 in combination with rituximab upon tumor volumes were investigated in an in vivo sub-cutaneous xenograft study. 3 mg/kg and 10 mg/kg Compound III-1, dosed PO and qd, and 10 mg/kg rituximab, dosed IV and q7d, were administered as both single agents and in combination. Neither combination group showed a synergistic interaction relative to their respective single agents when looking at AUC or tumor growth inhibition.
- the animals were inoculated with 2 ⁇ 5 mm 3 tumor mass from primary PHTX-22L-6 tumor chunk at implant site Flank (trocar). Compounds were administered for 21 days, and tumor volumes taken on days 0, 3, 7, 10, 14, 17, 21, 24, and 27 were analyzed. The primary goal was to investigate whether the combination of Compound III-1 and rituximab was synergistic.
- the average tumor volume in the vehicle group increased over nine-fold from 268 mm 3 at day 0 to 2563 mm 3 on day 27.
- the tumor volumes were smaller in each of the treatment groups compared to vehicle (Table 12).
- Compound III-1 in combination with rituximab upon tumor volumes were investigated in an in vivo sub-cutaneous xenograft study. 10 mg/kg and 20 mg/kg Compound III-1, dosed PO and bid, and 10 mg/kg rituximab, dosed IV and q7d, were administered as both single agents and in combination. Neither combination examined showed a synergistic interaction relative to their respective single agents when looking at AUC or tumor growth inhibition, which may be attributable to the significant single agent activity observed in this model.
- the in vivo experiments using the disseminated Ly19-Luc lymphoma model were performed in duplicate. The experiments consisted of looking at tumor volume after treatment with the combination of Compound III-1 and rituximab. Tumor volumes were estimated once weekly throughout the inoculation and treatment period using the Xenogen IVIS® imaging system (Xenogen Corporation, Alameda, Calif.). To image the mice, an intraperitoneal (IP) injection of luciferase (15 mg/ml), was administered 10 minutes prior to procedure and mice were anesthetized with 2% isofluorane 2-5 minutes throughout the scanning procedure. For Xenogen imaging, each mouse was imaged on dorsal and ventral views. The sum of 2 photon flux measurements was used for the analysis.
- IP intraperitoneal
- the antitumor effects of each treatment group were determined by calculating the percent TGI([ ⁇ control mean tumor volume ⁇ 4 treated mean tumor volume] ⁇ 100/ ⁇ control mean tumor volume) at the end of treatment. Mice were weighed once weekly for the duration of the study and the maximal percent body weight change was determined during the treatment period. Animals were monitored for survival up to 132 days following treatment. Animals were removed from the study when they reached humane endpoints (>20%, body weight loss or paralysis of either both front or hind limbs), the medial survival for each group was determined and the survival rate of treatment groups were compared to control. Treatment groups were evaluated to determine if the effects of combination treatment were synergistic, additive or sub-additive relative to control.
- TGI Tumor Growth Inhibition
- the photon flux data was log 10 transformed, and these values over the treatment period were compared across treatment groups to assess if the differences in the trends over time were statistically significant.
- a mixed-effects linear regression model using a restricted maximum likelihood was fit to the data.
- An ANOVA test was performed to determine if there was a statistically significant difference between the treatment groups and control.
- AUC Area Under the Curve
- Log 10 -transformed fold change photon flux values (tumor burden) from baseline were also used to calculate AUC values for each animal.
- the AUC values from the mice in a given treatment group were then averaged together to generate mean AUC values and associated standard errors.
- a synergy score calculation was used to address the question of whether the effects of the combination treatment were synergistic, additive, or sub-additive relative to the individual treatments.
- the effect of the combination treatment was considered synergistic if the synergy score was less than 0, additive if the synergy score equaled 0, and sub-additive if the synergy score was greater than 0.
- Standard errors and 95% confidence intervals were used to determine if the synergy scores were significantly different from zero.
- the survival rates of the animals in each treatment group were plotted using Kaplan-Meier curves and the log rank test was used to compare survival rates among pairs of treatment groups.
- mice received 100 ⁇ L of Compound III-1 and/or rituximab dosing solution prepared at 0.75, 2.5, 5.0 and 7.5 mg/mL (3, 10, 20, 30 mg/kg Compound III-1) or 2.0 mg/mL (10 mg/kg rituximab). These dosing solutions were prepared routinely based on historical mouse body weights of 25 or 20 grams respectively. All doses were approximate.
- c Mean tumor volumes, and TGI values were calculated on Day 24 of treatment.
- p values were calculated with an ANOVA, p ⁇ 0.05 considered statistically significant.
- TGI values will be greater than 100% when the average volume of the treatment group is smaller at the end of treatment than at the beginning of treatment e
- Log-rank analysis was used to compare the survival rate of each treatment group to the vehicle group test, p ⁇ 0.05 considered statistically significant.
- * Combination treatment groups had significantly longer survival than the corresponding individual treatment groups (p ⁇ 0.004).
- the vehicle used in TG1 and the treatment groups was 10% HP- ⁇ -CD plus 1% NaHCO 3 .
- the vehicle used in the rituximab treatment groups was 0.9% saline
- Photon flux values (tumor burden) from baseline to Day 24 were also used to calculate AUC values for each animal and the percent decrease in the AUC relative to the mean vehicle AUC was calculated (Table 17a).
- a synergy score calculation was applied to the AUC data to determine whether the effects of the combination treatment were synergistic, additive or sub-additive relative to the individual treatments. This analysis showed that the combination treatment of Compound III-1 at 3 mg/kg QD with rituximab at 10 mg/kg QW was synergistic when comparing the log 10 -transformed fold changes and the combination treatment of Compound III-1 at 10 mg/kg with rituximab at 10 mg/kg QW displayed an additive effect (Table 17b).
- mice reached the pre-defined endpoint of paralysis and were euthanized between Day 21 and Day 31, however all mice in the two combination treatment groups were alive up to Day 132.
- Day 132 the number of mice remaining in the single agent Compound III-13 mg/kg, Compound III-1 10 mg/kg and rituximab 10 mg/kg groups was 1 out of 10, 3 out of 10 and 1 out of 10 respectively.
- the median survival in days for each group is presented in Table 18. Log rank analysis, conducted to compare the survival rates between groups, showed that all treatment groups had significantly longer survival than the vehicle group, and all combination groups had significantly longer survival than each of the individual treatments (Table 16). Table 16 also shows the mean maximum body weight change of the groups from Day 0 to Day 24.
- the maximum body weight loss for vehicle group was 5.9% on Day 24. All other treatment groups gained weight during the study, including the single agent and combination agent groups. Treatment with Compound III-1 at 3 or 10 mg/kg on a QD schedule or rituximab at 10 mg/kg on a QW schedule was well tolerated.
- mice were dosed according to the following treatment groups:
- mice were weighed and tumor volumes were estimated with Xenogen signal (average photon flux) calculation once a week throughout the inoculation and the treatment period and after the treatment until the end of study.
- Treatment started 7 days following the inoculation of tumor cells into the tail vein, with an average photon flux measurement of 1 ⁇ 10 7 on treatment Day 0.
- the TGI, calculated on Day 23 (2 days post dose) was similar between treatment groups (75.8-100%).
- Tumor growth was significantly inhibited (P ⁇ 0.001) in all groups including the single agents (Compound III-1 or rituximab) the combination of Compound III-1+rituximab treatment group when compared to control (Table 20).
- the combination treatment group (Compound III-1 3 mg/kg+rituximab 10 mg/kg) showed a consistent decrease in tumor burden ( ⁇ 20.0), that was significantly lower than either of the respective single agents alone (Compound III-13 mg/kg and rituximab 10 mg/kg, P ⁇ 0.01).
- mice reached the pre-defined endpoint of paralysis and were euthanized between Day 21 and Day 31.
- a dose response was observed in the survival rate of rituximab treated mice with 3/10, 1/10, 1/10 and 0/10 mice remaining by Day 125 in the 10, 5, 1 and 0.5 mg/kg groups respectively.
- Log rank analysis conducted to compare the survival rates between groups, demonstrates that all treatment groups had significantly longer survival than the vehicle group, and the combination group had significantly longer survival than each of the individual treatments. None of the mice in the combination treatment group were removed during the 125 days of the study
- Table 24 shows the mean maximum body weight change of the groups from Day 0 to Day 22 of the study.
- the maximum body weight loss for vehicle group was 1.75% on Day 22. All other treatment groups gained weight during the study, including the single agent and combination agent groups.
- Combination treatment with Compound III-1 at 3 mg/kg and rituximab at 10 mg/kg appears to provide a synergistic effect that significantly lowered tumor burden when compared to either of the agents alone, thereby corroborating the synergistic effect observed in the sub-cutaneous Ly19 lymphoma model discussed above (refer to Example 1).
- the survival of the animals was significantly higher in each of the treatment groups compared to the vehicle group and significantly higher in the combination groups compared to the respective individual treatments. Following treatment, there were no significant changes in tumor growth rates in any of the groups up to 52 days in the first replicate and 125 days in the second replicate.
- results from the two experiments are consistent with one another and these data confirm that a combination of Compound III-1 and rituximab is the most effective treatment for disseminated Ly19-Luc lymphoma in SCID mice, resulting in a reduction of tumor burden to undetectable levels.
- Compound III-1 was administered initially at low doses (3 or 10 mg/kg on a QD schedule) alone and in combination with rituximab, or at higher doses (10 or 20 mg/kg on a BID schedule) alone or in combination with rituximab. After treatment, animals were monitored up to Day 132 to compare the survival between treatment groups and vehicle.
- mice received 100 ⁇ L of Compound III-1 and/or rituximab dosing solution prepared at 0.75, 2.5, 5.0 and 7.5 mg/mL (3, 10, 20, 30 mg/kg Compound III-1) or 2.0 mg/mL (10 mg/kg rituximab). These dosing solutions were prepared routinely based on historical mouse body weights of 25 or 20 grams respectively. All doses were approximate.
- c Mean tumor volumes, and TGI values were calculated on Day 21 (1 st study) and Day 22 (2 nd study) of treatment.
- mice remaining at the end of the study was 1 out of 10 in the 10 mg/kg single agent Compound III-1 and rituximab groups, 5 out of 10 in the 20 mg/kg Compound III-1 single agent group and the 10 mg/kg Compound III-1 combination group, and 8 out of 10 mice in the 20 mg/kg Compound III-1 combination group.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention relates to methods for the treatment of hematological malignancies. In particular, the invention provides methods for treatment of hematological malignancies by administering Aurora kinase inhibitors in combination with anti-CD20 antibodies.
Description
- The present application claims the benefit of U.S. Provisional Application Ser. No. 61/203,509, filed Dec. 22, 2008 (pending), the contents of which are incorporated herein by reference.
- This invention relates to methods for the treatment of hematological malignancies. In particular, the invention provides methods for treatment of hematological malignancies by administering Aurora kinase inhibitors in combination with anti-CD20 antibodies.
- According to the American Cancer Society, an estimated 1.4 million Americans were newly-diagnosed with cancer in 2004 and about 560,000 victims died from the disease. While medical advance have improved cancer survival rates, there is a continuing need for new and more effective treatment.
- Cancer is characterized by uncontrolled cell reproduction. Mitosis is a stage in the cell cycle during which a series of complex events ensure the fidelity of chromosome separation into two daughter cells. Several current cancer therapies, including the taxanes and vinca alkaloids, act to inhibit the mitotic machinery. Mitotic progression is largely regulated by proteolysis and by phosphorylation events that are mediated by mitotic kinases. Aurora kinase family members (e.g., Aurora A, Aurora B, Aurora C) regulate mitotic progression through modulation of centrosome separation, spindle dynamics, spindle assembly checkpoint, chromosome alignment/segregation, and cytokinesis (Dutertre et al., Oncogene, 21: 6175 (2002); Berdnik et al., Curr. Biol., 12: 640 (2002)). Overexpression and/or amplification of Aurora kinases have been linked to oncogenesis in several tumor types including those of colon and breast (Warner et al., Mol. Cancer Ther., 2: 589 (2003); Bischoff et al., EMBO, 17: 3062 (1998); Sen et al., Cancer Res., 94: 1320 (2002)). Moreover, Aurora kinase inhibition in tumor cells results in mitotic arrest and apoptosis, suggesting that these kinases are important targets for cancer therapy (Manfredi et al., PNAS., 104: 4106 (2007); Ditchfield, J. Cell Biol., 161: 267 (2003); Harrington et al., Nature Med., 1 (2004)). Given the central role of mitosis in the progression of virtually all malignancies, inhibitors of the Aurora kinases are expected to have application across a broad range of human tumors.
- CD20 (also known as Bp35) is a B-lymphocyte-restricted differentiation antigen that is expressed during early pre-B-cell development and remains until plasma cell differentiation. CD20 is a useful target for B-cell lymphomas as this antigen is expressed at very high densities on the surface of malignant B-cells, i.e., B-cells wherein unabated proliferation can lead to B-cell lymphomas. The Food and Drug Administration has approved the therapeutic use of an anti-CD20 antibody, rituximab (RITUXAN®), for use in relapsed and previously treated low-grade non-Hodgkin's lymphoma (NHL). Rituximab acts by binding to the CD20 antigen on B cells which results in the lysis of the B cell by a mechanism thought to involve complement-dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).
- However, while anti-CD20 antibodies and, in particular, rituximab, have been reported to be effective for treatment of B-cell lymphomas, such as non-Hodgkin's lymphoma, the treated patients are often subject to disease relapse. Therefore, it would be beneficial if more effective treatment regimens could be developed. Combined treatment regimens could be helpful for patients suffering from B cell related tumors or other hematological malignancies, and might potentially even decrease the rate of relapse or overcome the resistance to a particular anticancer agent sometime seen in these patients. Additionally, combinations of anticancer agents may have additive, or even synergistic, therapeutic effects.
- There is thus a need for new cancer treatment regimens, including combination therapies.
- The present invention provides new combination therapies for the treatment of hematological malignancies. In particular, the present invention provides a method to treat a patient suffering from a hematological malignancy comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g., before or after) an anti-CD20 antibody.
- Terms used herein shall be accorded the following defined meanings, unless otherwise indicated.
- As used herein, the term “Aurora kinase” refers to any one of a family of related serine/threonine kinases involved in mitotic progression. A variety of cellular proteins that play a role in cell division are substrates for phosphorylation by Aurora kinase enzymes, including, without limitation, histone H3, p53, CENP-A, myosin II regulatory light chain, protein phosphatase-1, TPX-2, INCENP, survivin, topoisomerase II alpha, vimentin, MBD-3, MgcRacGAP, desmin, Ajuba, XIEg5 (in Xenopus), Ndc10p (in budding yeast), and D-TACC (in Drosophila). Aurora kinase enzymes also are themselves substrates for autophosphorylation, e.g., at Thr288. Unless otherwise indicated by context, the term “Aurora kinase” is meant to refer to any Aurora kinase protein from any species, including, without limitation, Aurora A, Aurora B, and Aurora C, preferably Aurora A or B. Preferably, the Aurora kinase is a human Aurora kinase.
- The term “Aurora kinase inhibitor” or “inhibitor of Aurora kinase” is used to signify a compound which is capable of interacting with an Aurora kinase and inhibiting its enzymatic activity. Inhibiting Aurora kinase enzymatic activity means reducing the ability of an Aurora kinase to phosphorylate a substrate peptide or protein. In various embodiments, such reduction of Aurora kinase activity is at least about 50%, at least about 75%, at least about 90%, at least about 95%, or at least about 99%. In various embodiments, the concentration of Aurora kinase inhibitor required to reduce an Aurora kinase enzymatic activity is less than about 1 μM, less than about 500 nM, less than about 100 nM, or less than about 50 nM.
- In some embodiments, such inhibition is selective, i.e., the Aurora kinase inhibitor reduces the ability of an Aurora kinase to phosphorylate a substrate peptide or protein at a concentration that is lower than the concentration of the inhibitor that is required to produce another, unrelated biological effect, e.g., reduction of the enzymatic activity of a different kinase. In some embodiments, the Aurora kinase inhibitor also reduces the enzymatic activity of another kinase, preferably one that is implicated in cancer.
- The term “about” is used herein to mean approximately, in the region of, roughly, or around. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term “about” is used herein to modify a numerical value above and below the stated value by a variance of 10%.
- As used herein, the term “comprises” means “includes, but is not limited to.”
- A “CD20” antigen is a 35 kDa, non-glycosylated phosphoprotein found on the surface of greater than 90% of B cells from peripheral blood or lymphoid organs. CD20 is expressed during early pre-B cell development and remains until plasma cell differentiation. CD20 is present on both normal B cells as well as malignant B cells. Other names for CD20 in the literature include “B-lymphocyte-restricted antigen” and “Bp35”.
- The CD20 antigen is described in, e.g., Clark et al. PNAS (USA) 82:1766 (1985).
- The term “antibody” herein is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, humanized antibodies, human antibodies, chimeric antibodies, multispecific antibodies (e.g., bispecific antibodies) formed from at least two intact antibodies, and antibody fragments, so long as they exhibit the desired biological activity. Antibodies may be produced by one of skill in the art using conventional methods.
- The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567). The “monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson et al., Nature, 352:624-628 (1991) and Marks et al, J. MoL Biol., 222:581-597 (1991), for example. The monoclonal antibodies herein specifically include but are not limited to “chimeric” or “humanized” forms.
- The term “aliphatic” or “aliphatic group”, as used herein, means a substituted or unsubstituted straight-chain, branched or cyclic C1-12 hydrocarbon, which is completely saturated or which contains one or more units of unsaturation, but which is not aromatic. For example, suitable aliphatic groups include substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl, alkynyl groups and hybrids thereof, such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
- The terms “alkyl”, “alkenyl”, and “alkynyl”, used alone or as part of a larger moiety, refer to a straight and branched chain aliphatic group having from 1 to 12 carbon atoms. For purposes of the present invention, the term “alkyl” will be used when the carbon atom attaching the aliphatic group to the rest of the molecule is a saturated carbon atom. However, an alkyl group may include unsaturation at other carbon atoms. Thus, alkyl groups include, without limitation, methyl, ethyl, propyl, allyl, propargyl, butyl, pentyl, and hexyl.
- For purposes of the present invention, the term “alkenyl” will be used when the carbon atom attaching the aliphatic group to the rest of the molecule forms part of a carbon-carbon double bond. Alkenyl groups include, without limitation, vinyl, 1-propenyl, 1-butenyl, 1-pentenyl, and 1-hexenyl.
- For purposes of the present invention, the term “alkynyl” will be used when the carbon atom attaching the aliphatic group to the rest of the molecule forms part of a carbon-carbon triple bond. Alkynyl groups include, without limitation, ethynyl, 1-propynyl, 1-butynyl, 1-pentynyl, and 1-hexynyl.
- The term “cycloaliphatic”, used alone or as part of a larger moiety, refers to a saturated or partially unsaturated cyclic aliphatic ring system having from 3 to about 14 members, wherein the aliphatic ring system is optionally substituted. In some embodiments, the cycloaliphatic is a monocyclic hydrocarbon having 3-8 or 3-6 ring carbon atoms. Nonlimiting examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, and cyclooctadienyl. In some embodiments, the cycloaliphatic is a bridged or fused bicyclic hydrocarbon having 6-12, 6-10, or 6-8 ring carbon atoms, wherein any individual ring in the bicyclic ring system has 3-8 members.
- In some embodiments, two adjacent substituents on the cycloaliphatic ring, taken together with the intervening ring atoms, form an optionally substituted fused 5- to 6-membered aromatic or 3- to 8-membered non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S. Thus, the term “cycloaliphatic” includes aliphatic rings that are fused to one or more aryl, heteroaryl, or heterocyclyl rings. Nonlimiting examples include indanyl, 5,6,7,8-tetrahydroquinoxalinyl, decahydronaphthyl, or tetrahydronaphthyl, where the radical or point of attachment is on the aliphatic ring. The term “cycloaliphatic” may be used interchangeably with the terms “carbocycle”, “carbocyclyl”, “carbocyclo”, or “carbocyclic”.
- The terms “aryl” and “ar-”, used alone or as part of a larger moiety, e.g., “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refer to a C6 to C14 aromatic hydrocarbon, comprising one to three rings, each of which is optionally substituted. Preferably, the aryl group is a C6-10 aryl group. Aryl groups include, without limitation, phenyl, naphthyl, and anthracenyl. In some embodiments, two adjacent substituents on the aryl ring, taken together with the intervening ring atoms, form an optionally substituted fused 5- to 6-membered aromatic or 4- to 8-membered non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S. Thus, the term “aryl”, as used herein, includes groups in which an aromatic ring is fused to one or more heteroaryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the aromatic ring. Nonlimiting examples of such fused ring systems include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, fluorenyl, indanyl, phenanthridinyl, tetrahydronaphthyl, indolinyl, phenoxazinyl, benzodioxanyl, and benzodioxolyl. An aryl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic. The term “aryl” may be used interchangeably with the terms “aryl group”, “aryl moiety”, and “aryl ring”.
- An “aralkyl” or “arylalkyl” group comprises an aryl group covalently attached to an alkyl group, either of which independently is optionally substituted. Preferably, the aralkyl group is C6-10 aryl(C1-6)alkyl, C6-10 aryl(C1-4)alkyl, or C6-10 aryl(C1-3)alkyl, including, without limitation, benzyl, phenethyl, and naphthylmethyl.
- The terms “heteroaryl” and “heteroar-”, used alone or as part of a larger moiety, e.g., heteroaralkyl, or “heteroaralkoxy”, refer to groups having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 π electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to four heteroatoms. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. In some embodiments, two adjacent substituents on the heteroaryl, taken together with the intervening ring atoms, form an optionally substituted fused 5- to 6-membered aromatic or 4- to 8-membered non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S. Thus, the terms “heteroaryl” and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. A heteroaryl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring”, “heteroaryl group”, or “heteroaromatic”, any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
- As used herein, the terms “heterocycle”, “heterocyclyl”, “heterocyclic radical”, and “heterocyclic ring” are used interchangeably and refer to a stable 3- to 7-membered monocyclic, or to a fused 7- to 10-membered or bridged 6- to 10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term “nitrogen” includes a substituted nitrogen. As an example, in a heterocyclyl ring having 1-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or +NR (as in N-substituted pyrrolidinyl). A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl.
- In some embodiments, two adjacent substituents on a heterocyclic ring, taken together with the intervening ring atoms, for an optionally substituted fused 5- to 6-membered aromatic or 3- to 8-membered non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S. Thus, the terms “heterocycle”, “heterocyclyl”, “heterocyclyl ring”, “heterocyclic group”, “heterocyclic moiety”, and “heterocyclic radical”, are used interchangeably herein, and include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the heterocyclyl ring. A heterocyclyl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
- As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond between ring atoms. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
- The terms “haloaliphatic”, “haloalkyl”, “haloalkenyl” and “haloalkoxy” refer to an aliphatic, alkyl, alkenyl or alkoxy group, as the case may be, which is substituted with one or more halogen atoms. As used herein, the term “halogen” or “halo” means F, Cl, Br, or I. The term “fluoroaliphatic” refers to a haloaliphatic wherein the halogen is fluoro.
- The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, i.e., —(CH2)n—, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms is replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group. An alkylene chain also may be substituted at one or more positions with an aliphatic group or a substituted aliphatic group.
- The term “substituted”, as used herein, means that a hydrogen radical of the designated moiety is replaced with the radical of a specified substituent, provided that the substitution results in a stable or chemically feasible compound. The phrase “one or more substituents”, as used herein, refers to a number of substituents that equals from one to the maximum number of substituents possible based on the number of available bonding sites, provided that the above conditions of stability and chemical feasibility are met. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and the substituents may be either the same or different.
- An aryl (including the aryl moiety in aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including the heteroaryl moiety in heteroaralkyl and heteroaralkoxy and the like) group may contain one or more substituents. Examples of suitable substituents on the unsaturated carbon atom of an aryl or heteroaryl group include -halo, —NO2, —CN, —R*, —C(R*)═C(R*)2, —C≡C—R*, —OR*, —SRo, —S(O)Ro, —SO2Ro, —SO3Ro, —SO2N(R+)2, —N(R+)2, —NR+C(O)R*, —NR+C(O)N(R+)2, —NR+CO2Ro, —O—CO2R*, —OC(O)N(R+)2, —O—C(O)R*, —CO2R*, —C(O)—C(O)R*, —C(O)R*, —C(O)N(R+)2, —C(O)N(R+)C(═NR+)—N(R+)2, —N(R+)C(═NR+)—N(R+)—C(O)R*, —C(═NR+)—N(R+)2, —C(═NR+)—OR*, —N(R+)—N(R+)2, —N(R+)C(═NR+)—N(R+)2, —NR+SO2Ro, —NR+SO2N(R+)2, —P(O)(R*)2, —P(O)(OR*)2, —O—P(O)—OR*, and —P(O)(NR+)—N(R+)2; or two adjacent substituents, taken together with their intervening atoms, form a 5-6 membered unsaturated or partially unsaturated ring having 0-3 ring atoms selected from the group consisting of N, O, and S.
- An aryl (including the aryl moiety in aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including the heteroaryl moiety in heteroaralkyl and heteroaralkoxy and the like) group may contain one or more substituents. Examples of suitable substituents on the unsaturated carbon atom of an aryl or heteroaryl group include -halo, —NO2, —CN, —R*, —C(R*)═C(R*)2, —C≡C—R*, —OR*, —SRo, —S(O)Ro, —SO2Ro, —SO3Ro, —SO2N(R+)2, —N(R+)2, —NR+C(O)R*, —NR+C(O)N(R+)2, —NR+CO2Ro, —O—CO2R*, —OC(O)N(R+)2, —O—C(O)R*, —CO2R*, —C(O)—C(O)R*, —C(O)R*, —C(O)N(R+)2, —C(O)N(R+)C(═NR+)—N(R+)2, —N(R+)C(═NR+)—N(R+)—C(O)R*, —C(═NR+)—N(R+)2, —C(═NR+)—OR*, —N(R+)—N(R+)2, —N(R+)C(═NR+)—N(R+)2, —NR+SO2Ro, —NR+SO2N(R+)2, —P(O)(R*)2, —P(O)(OR*)2, —O—P(O)—OR*, and —P(O)(NR+)—N(R+)2; or two adjacent substituents, taken together with their intervening atoms, form a 5-6 membered unsaturated or partially unsaturated ring having 0-3 ring atoms selected from the group consisting of N, O, and S.
- Each R+, independently, is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group, or two R+ on the same nitrogen atom, taken together with the nitrogen atom, form a 5-8 membered aromatic or non-aromatic ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S. Each R* independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group. Each Ro is an optionally substituted aliphatic or aryl group.
- An aliphatic group or a non-aromatic heterocyclic ring may be substituted with one or more substituents. Examples of suitable substituents on the saturated carbon of an aliphatic group or of a non-aromatic heterocyclic ring include, without limitation, those listed above for the unsaturated carbon of an aryl or heteroaryl group and the following: ═O, ═S, ═C(R*)2, ═N—N(R*)2, ═N—OR*, ═N—NHC(O)R*, ═N—NHCO2Ro, ═N—NHSO2Ro, or ═N—R*, where each R* and Ro is as defined above.
- Suitable substituents on the nitrogen atom of a non-aromatic heterocyclic ring include —R*, —N(R*)2, —C(O)R*, —CO2R*, —C(O)—C(O)R*—C(O)CH2C(O)R*, —SO2R*, —SO2N(R*)2, —C(═S)N(R*)2, —C(═NH)—N(R*)2, and —NR*SO2R*; wherein each R* is as defined above.
- Unless otherwise stated, structures depicted herein are meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structure except for the replacement of a hydrogen atom by a deuterium or tritium, or the replacement of a carbon atom by a 13C- or 14C-enriched carbon are within the scope of the invention.
- It will be apparent to one skilled in the art that certain compounds described herein may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the invention. Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.
- Any compound capable of inhibiting the enzymatic activity of an Aurora kinase may be used in the methods of the instant invention. In particular, Aurora kinase inhibitors include the compounds described herein, as well as compounds disclosed in, for example, WO 05/111039, US2005/0256102, US2007/0185087, WO 08/021038, US2008/0045501, WO 08/063525, US2008/0167292, WO 07/113212, EP1644376, US2005/0032839, WO 05/005427, WO 06/070192, WO 06/070198, WO 06/070202, WO 06/070195, WO 06/003440, WO 05/002576, WO 05/002552, WO 04/071507, WO 04/058781, WO 06/055528, WO 06/055561, WO 05/118544, WO 05/013996, WO 06/036266, US2006/0160874, US2007/0142368, WO 04/043953, WO 07/132220, WO 07/132221, WO 07/132228, WO 04/00833 and WO 07/056164, each of which is hereby incorporated by reference in its entirety. Also suitable for use in the methods of the invention are solvated and hydrated forms of any of these compounds. Also suitable for use in the methods of the invention are pharmaceutically acceptable salts of any of the compounds, and solvated and hydrated forms of such salts. These Aurora kinase inhibitors can be prepared in a number of ways well known to one skilled in the art of organic synthesis, including, but not limited to, the methods of synthesis described in detail in the above references.
- In some embodiments, the Aurora kinase inhibitor is a compound represented by formula (I):
- or a pharmaceutically acceptable salt thereof;
- wherein:
-
- Ring A is a substituted or unsubstituted 5- or 6-membered aryl, heteroaryl, cycloaliphatic, or heterocyclyl ring;
- Ring B is a substituted or unsubstituted aryl, heteroaryl, cycloaliphatic, or heterocyclyl ring;
- Ring C is a substituted or unsubstituted aryl, heteroaryl, heterocyclyl, or cycloaliphatic ring;
- Re is hydrogen, —OR5, —N(R4)2, —SR5, or a C1-3 aliphatic optionally substituted with R3 or R7;
- each of Rx and Ry independently is hydrogen, fluoro, or an optionally substituted
- C1-6 aliphatic; or Rx and Ry, taken together with the carbon atom to which they are attached, form an optionally substituted 3- to 6-membered cycloaliphatic ring;
- each R3 independently is selected from the group consisting of -halo, —OH, —O(C1-3 alkyl), —CN, —N(R4)2, —C(O)(C1-3 alkyl), —CO2H, —CO2(C1-3 alkyl), —C(O)NH2, and —C(O)NH(C1-3 alkyl);
- each R4 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R4 on the same nitrogen atom, taken together with the nitrogen atom, form an optionally substituted 5- to 6-membered heteroaryl or 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S;
- each R5 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; and
- each R7 independently is an optionally substituted aryl, heterocyclyl, or heteroaryl group.
- Ring A is a substituted or unsubstituted 5- or 6-membered aryl, heteroaryl, cycloaliphatic, or heterocyclyl ring. Examples of Ring A include furano, dihydrofurano, thieno, dihydrothieno, cyclopenteno, cyclohexeno, 2H-pyrrolo, pyrrolo, pyrrolino, pyrrolidino, oxazolo, thiazolo, imidazolo, imidazolino, imidazolidino, pyrazolo, pyrazolino, pyrazolidino, isoxazolo, isothiazolo, oxadiazolo, triazolo, thiadiazolo, 2H-pyrano, 4H-pyrano, benzo, pyridino, piperidino, dioxano, morpholino, dithiano, thiomorpholino, pyridazino, pyrimidino, pyrazino, piperazino, and triazino, any of which groups may be substituted or unsubstituted. Preferred values for Ring A include, without limitation, substituted or unsubstituted rings selected from the group consisting of furano, thieno, pyrrolo, oxazolo, thiazolo, imidazolo, pyrazolo, isoxazolo, isothiazolo, triazolo, benzo, pyridino, pyridazino, pyrimidino, and pyrazino.
- Ring A may be substituted or unsubstituted. In some embodiments, each substitutable saturated ring carbon atom in Ring A is unsubstituted or is substituted with ═O, ═S, ═C(R5)2, ═N—N(R4)2, ═N—OR5, ═N—NHC(O)R5, ═N—NHCO2R6, ═N—NHSO2R6, ═N—R5 or —Rb, where Rb, R4, R5, and R6 are as defined below. Each substitutable unsaturated ring carbon atom in Ring A is unsubstituted or substituted with —Rb. Each substitutable ring nitrogen atom in Ring A is unsubstituted or is substituted with —R9b, and one ring nitrogen atom in Ring A optionally is oxidized. Each R9b independently is —C(O)R5, —C(O)N(R4)2, —CO2R6, —SO2R6, —SO2N(R4)2, or a C1-4 aliphatic optionally substituted with R3 or R7.
- Each Rb independently is R2b, an optionally substituted aliphatic, or an optionally substituted aryl, heterocyclyl, or heteroaryl group; or two adjacent Rb, taken together with the intervening ring atoms, form an optionally substituted fused 4- to 8-membered aromatic or non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S.
- Each R2b independently is -halo, —NO2, —CN, —C(R5)═C(R5)2, —C(R5)═C(R5)(R10), —C≡C—R5, —C≡C—R10, —OR5, —SR6, —S(O)R6, —SO2R6, —SO2N(R4)2, —N(R4)2, —NR4C(O)R5, —NR4C(O)N(R4)2, —NR4CO2R6, —O—CO2R5, —OC(O)N(R4)2, —O—C(O)R5, —CO2R5, —C(O)—C(O)R5, —C(O)R5, —C(O)N(R4)2, —C(═NR4)—N(R4)2, —C(═NR4)—OR5, —N(R4)—N(R4)2, N(R4)C(═NR4)—N(R4)2, —N(R4)SO2R6, —N(R4)SO2N(R4)2, —P(O)(R5)2, or —P(O)(OR5)2, where the variables R4, R5, and R7 have the values described above; each R6 independently is an optionally substituted aliphatic or aryl group; and each Rim independently is —CO2R5 or —C(O)N(R4)2.
- In some embodiments, Ring A is substituted by 0-2 substituents Rb. In some such embodiments, each Rb independently is C1-3 aliphatic or R2b, and each R2b independently is selected from the group consisting of -halo, —NO2, —C(R5)═C(R5)2, —OR5, and —N(R4)2. In some embodiments, each Rb independently is selected from the group consisting of -halo, C1-3 aliphatic, C1-3 fluoroaliphatic, and —OR5, where R5 is hydrogen or C1-3 aliphatic. In certain preferred embodiments, Ring A is substituted with 0, 1, or 2 substituents, preferably 0 or 1 substituents, independently selected from the group consisting of chloro, fluoro, bromo, methyl, trifluoromethyl, and methoxy.
- In some embodiments, Ring B is a substituted or unsubstituted mono- or bicyclic aryl or heteroaryl ring selected from the group consisting of furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indolyl, isoindolyl, indazolyl, benzo[b]furanyl, benzo[b]thienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, purinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and pteridinyl.
- Each substitutable saturated ring carbon atom in Ring B is unsubstituted or is substituted with ═O, ═S, ═C(R5)2, ═N—N(R4)2, ═N—OR5, ═N—NHC(O)R5, ═N—NHCO2R6, ═N—NHSO2R6, ═N—R5 or —Rc. Each substitutable unsaturated ring carbon atom in Ring B is unsubstituted or substituted with —Rc. Each substitutable ring nitrogen atom in Ring B is unsubstituted or is substituted with —R9c, and one ring nitrogen atom in Ring B optionally is oxidized. Each R9c independently is —C(O)R5, —C(O)N(R4)2, —CO2R6, —SO2R6, —SO2N(R4)2, or a C1-4 aliphatic optionally substituted with R3 or R7. Ring B may be unsubstituted or may be substituted on any one or more of its component rings, wherein the substituents may be the same or different. In some embodiments, Ring B is substituted with 0-2 independently selected Rc and 0-3 independently selected R2c or C1-6 aliphatic groups. The variables R3, R4, R5, R6, and R7 are as defined above for Ring A, and Rc and R2c are defined below.
- Each Rc independently is R2c, an optionally substituted C1-6 aliphatic, or an optionally substituted aryl, heteroaryl, or heterocyclyl group.
- Each R2c independently is -halo, —NO2, —CN, —C(R5)═C(R5)2, —C(R5)═C(R5)(R10), —C≡C—R5, —C≡C—R10, —OR5, —SR6, —S(O)R6, —SO2R6, —SO2N(R4)2, —N(R4)2, —NR4C(O)R5, —NR4C(O)N(R4)2, —NR4CO2R6, —O—CO2R5, —OC(O)N(R4)2, —O—C(O)R5, —CO2R5, —C(O)—C(O)R5, —C(O)R5, —C(O)N(R4)2, —C(═NR4)—N(R4)2, —C(═NR4)—OR5, —N(R4)—N(R4)2, —N(R4)C(═NR4)—N(R4)2, —N(R4)SO2R6, —N(R4)SO2N(R4)2, —P(O)(R5)2, or —P(O)(OR5)2.
- In some embodiments, Ring B is a monocyclic 5- or 6-membered aryl or heteroaryl ring, substituted with 0-2 independently selected Rc and 0-2 independently selected R2c or C1-6 aliphatic groups. In certain such embodiments, Ring B is a substituted or unsubstituted phenyl or pyridyl ring.
- In some embodiments, Ring B is substituted with 0-2 substituents Rc. In some such embodiments, each Rc independently is C1-3 aliphatic or R2c, and each R2c independently is selected from the group consisting of -halo, —NO2, —C(R5)═C(R5)2, —C≡C—R5, —OR5, and —N(R4)2. In some embodiments, each Rc independently is selected from the group consisting of -halo, C1-3 aliphatic, C1-3 haloaliphatic, and —OR5, where R5 is hydrogen or C1-3 aliphatic. In certain preferred embodiments, Ring B is substituted with 0, 1, or 2 substituents, independently selected from the group consisting of chloro, fluoro, bromo, methyl, trifluoromethyl, and methoxy.
- Each substitutable saturated ring carbon atom in Ring C is unsubstituted or is substituted with ═O, ═S, ═C(R5)2, ═N—N(R4)2, ═N—OR5, ═N—NHC(O)R5, ═N—NHCO2R6, ═N—NHSO2R6, ═N—R5 or —Rd. Each substitutable unsaturated ring carbon atom in Ring C is unsubstituted or substituted with —Rd. Each substitutable ring nitrogen atom in Ring C is unsubstituted or is substituted with —R9d, and one ring nitrogen atom in Ring C optionally is oxidized. Each R9d independently is —C(O)R5, —C(O)N(R4)2, —CO2R6, —SO2R6, —SO2N(R4)2, or a C1-4 aliphatic optionally substituted with R3 or R7. Ring C may be unsubstituted or may be substituted on any one or more of its component rings, wherein the substituents may be the same or different. In some embodiments, Ring C is substituted with 0-2 independently selected Rd and 0-3 independently selected R2d or C1-6 aliphatic groups. The variables R3, R4, R5, R6, and R7 are as described above for Rings A and B. The variables Rd and R2d are described below.
- Each Rd independently is R2d, an optionally substituted aliphatic, or an optionally substituted aryl, heteroaryl, or heterocyclyl group.
- Each R2d independently is -halo, —NO2, —CN, —C(R5)═C(R5)2, —C(R5)═C(R5)2(R10), —C≡C—R5, —C≡C—R10, —OR5, —SR6, —S(O)R6, —SO2R6, —SO2N(R4)2, —N(R4)2, —NR4C(O)R5, —NR4C(O)N(R4)2, —NR4CO2R6, —O—CO2R5, —OC(O)N(R4)2, —O—C(O)R5, —CO2R5, —C(O)—C(O)R5, —C(O)R5, —C(O)N(R4)2, —C(═NR4)—N(R4)2, —C(═NR4)—OR5, —N(R4)—N(R4)2, —N(R4)C(═NR4)—N(R4)2, —N(R4)SO2R6, —N(R4)SO2N(R4)2, —P(O)(R5)2, or —P(O)(OR5)2. Additionally, R2d can be —SO3R5, —C(O)N(R4)C(═NR4)—N(R4)2 or —N(R4)C(═NR4)—N(R4)—C(O)R5.
- In some embodiments, Ring C is a monocyclic 5- or 6-membered aryl or heteroaryl ring, which is substituted with 0-2 independently selected substituents Rd and 0-2 independently selected R2d or C1-6 aliphatic groups. In some such embodiments, Ring C is an optionally substituted heteroaryl ring selected from the group consisting of pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, and oxazolyl. In some other embodiments, Ring C is a substituted or unsubstituted phenyl ring. In some embodiments, Ring C is a monocyclic 5- or 6-membered aryl or heteroaryl ring, which is substituted with 0, 1, or 2 substituents Rd, as defined above.
- In some other embodiments, Ring C is a monocyclic 5- or 6-membered heterocyclyl or cycloaliphatic ring, which is substituted with 0-2 independently selected substituents Rd and 0-2 independently selected R2d or C1-6 aliphatic groups.
- In some embodiments, the Aurora kinase inhibitor is a compound represented by formula (II):
- or a pharmaceutically acceptable salt thereof;
- wherein:
-
- Re is hydrogen or a C1-3 aliphatic optionally substituted with R3 or R7;
- Ring A is substituted with 0-3 Rb;
- each Rb independently is selected from the group consisting of C1-6 aliphatic, R2b, R7b, -T1-R2b, and -T1-R7b;
- each R2b independently is -halo, —NO2, —CN, —C(R5)═C(R5)2, —C≡C—R5, —OR5, —SR6, —S(O)R6, —SO2R6, —SO2N(R4)2, —N(R4)2, —NR4C(O)R5, —NR4C(O)N(R4)2, —NR4CO2R6, —O—CO2R5, —OC(O)N(R4)2, —O—C(O)R5, —CO2R5, —C(O)—C(O)R5, —C(O)R5, —C(O)N(R4)2, —C(═NR4)—N(R4)2, —C(═NR4)—OR5, —N(R4)—N(R4)2, —N(R4)C(═NR4)—N(R4)2, —N(R4)SO2R6, —N(R4)SO2N(R4)2, —P(O)(R5)2, or —P(O)(OR5)2;
- each R7b independently is an optionally substituted aryl, heterocyclyl, or heteroaryl group;
- Ring B is substituted with 0-2 independently selected Rc and 0-2 independently selected R2c or C1-6 aliphatic groups;
- each Rc independently is selected from the group consisting of C1-6 aliphatic, R2c, R7c, -T1-R2c, and -T1-R7c;
- each R2c independently is -halo, —NO2, —CN, —C(R5)═C(R5)2, —C≡C—R5, —OR5, —SR6, —S(O)R6, —SO2R6, —SO2N(R4)2, —N(R4)2, —NR4C(O)R5, —NR4C(O)N(R4)2, —NR4CO2R6, —O—CO2R5, —OC(O)N(R4)2, —O—C(O)R5, —CO2R5, —C(O)—C(O)R5, —C(O)R5, —C(O)N(R4)2, —C(═NR4)—N(R4)2, —C(═NR4)—OR5, —N(R4)—N(R4)2, —N(R4)C(═NR4)—N(R4)2, —N(R4)SO2R6, —N(R4)SO2N(R4)2, —P(O)(R5)2, or —P(O)(OR5)2;
- each R7c independently is an optionally substituted aryl, heterocyclyl, or heteroaryl group;
- T1 is a C1-6 alkylene chain optionally substituted with R3 or R3b, wherein T1 or a portion thereof optionally forms part of a 3- to 7-membered ring;
- Ring C is substituted with 0-2 independently selected Rd and 0-3 independently selected R2d or C1-6 aliphatic groups;
- each Rd independently is selected from the group consisting of C1-6 aliphatic, R2d, R7d, -T2-R2d, -T2-R7d, —V-T3-R2d, and —V-T3-R7d;
- T2 is a C1-6 alkylene chain optionally substituted with R3 or R3b, wherein the alkylene chain optionally is interrupted by —C(R5)═C(R5)—, —C≡C—, —O—, —S—, —S(O)—, —S(O)2—, —SO2N(R4)—, —N(R4)—, —N(R4)C(O)—, —NR4C(O)N(R4)—, —N(R4)CO2—, —C(O)N(R4)—, —C(O)—, —C(O)—C(O)—, —OC2—, —OC(O)—, —OC(O)O—, —OC(O)N(R4)—, —N(R4)—N(R4)—, —N(R4)SO2—, or —SO2N(R4)—, and wherein T2 or a portion thereof optionally forms part of a 3-7 membered ring;
- T3 is a C1-6 alkylene chain optionally substituted with R3 or R3b, wherein the alkylene chain optionally is interrupted by —C(R5)═C(R5)—, —C≡C—, —O—, —S—, —S(O)—, —S(O)2—, —SO2N(R4)—, —N(R4)—, —N(R4)C(O)—, —NR4C(O)N(R4)—, —N(R4)CO2—, —C(O)N(R4)—, —C(O)—, —C(O)—C(O)—, —CO2—, —OC(O)—, —OC(O)O—, —OC(O)N(R4)—, —N(R4)—N(R4)—, —N(R4)SO2—, or —SO2N(R4)—, and wherein T3 or a portion thereof optionally forms part of a 3-7 membered ring;
- V is —C(R5)═C(R5)—, —C≡C—, —O—, —S—, —S(O)—, —S(O)2—, —SO2N(R4)—, —N(R4)—, —N(R4)C(O)—, —NR4C(O)N(R4)—, —N(R4)CO2—, —C(O)N(R4)—, —C(O)—, —C(O)—C(O)—, —CO2—, —OC(O)—, —OC(O)O—, —OC(O)N(R4)—, —C(NR4)═N—, —C(OR5)═N—, —N(R4)—N(R4)—, —N(R4)SO2—, —N(R4)SO2N(R4)—, —P(O)(R5)—, —P(O)(OR5)—O—, —P(O)—O—, or —P(O)(NR5)—N(R5)—;
- R2d is -halo, —NO2, —CN, —C(R5)═C(R5)2, —C≡C—R5, —OR5, —SR6, —S(O)R6, —SO2R6, —SO2N(R4)2, —N(R4)2, —NR4C(O)R5, —NR4C(O)N(R4)2, —NR4CO2R6, —O—CO2R5, —OC(O)N(R4)2, —O—C(O)R5, —CO2R5, —C(O)—C(O)R5, —C(O)R5, —C(O)N(R4)2, —C(═NR4)—N(R4)2, —C(═NR4)—OR5, —N(R4)—N(R4)2, —N(R4)C(═NR4)—N(R4)2, —N(R4)SO2R6, —N(R4)SO2N(R4)2, —P(O)(R5)2, or —P(O)(OR5)2; and
- each R7d independently is an optionally substituted aryl, heterocyclyl, or heteroaryl group.
- each R3 independently is selected from the group consisting of -halo, —OH, —O(C1-3 alkyl), —CN, —N(R4)2, —C(O)(C1-3 alkyl), —CO2H, —CO2(C1-3 alkyl), —C(O)NH2, and —C(O)NH(C1-3 alkyl);
- each R3b independently is a C1-3 aliphatic optionally substituted with R3 or R7, or two substituents R3b on the same carbon atom, taken together with the carbon atom to which they are attached, form a 3- to 6-membered carbocyclic ring;
- each R4 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R4 on the same nitrogen atom, taken together with the nitrogen atom, form an optionally substituted 5- to 8-membered heteroaryl or heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S;
- each R5 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group;
- each R6 independently is an optionally substituted aliphatic or aryl group; and
- each R7 independently is an optionally substituted aryl, heterocyclyl, or heteroaryl group.
- Table 1 provides the chemical names for specific examples of compounds of formula (II).
-
TABLE 1 Examples of Compounds of Formula (II) II-1: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(2-methylamino-ethyl)-benzamide II-2: N-(2-Amino-ethyl)-4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-N-methyl-benzamide II-3: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-methyl-N-(2-methylamino-ethyl)-benzamide II-4: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(2-dimethylamino-ethyl)-benzamide II-5: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(2-dimethylamino-ethyl)-N-methyl-benzamide II-6: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(3-dimethylamino-propyl)-benzamide II-7: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(3-dimethylamino-propyl)-N-methyl-benzamide II-8: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-piperazin-1-yl-methanone II-9: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone II-10: {4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone II-11: [4-(9-Chloro-7-o-tolyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)- phenyl]-(4-methyl-piperazin-1-yl)-methanone II-12: {4-[9-Chloro-7-(2-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone II-13: {4-[9-Chloro-7-(4-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone II-14: {4-[7-(2-Fluoro-phenyl)-9-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone II-15: 2-{3-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-1-(4-methyl-piperazin-1-yl)-ethanone II-16: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-piperidin-4-yl-benzamide II-17: (4-Amino-piperidin-1-yl)-{4-[9-chloro-7-(2-fluoro-phenyl)-5H- benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone II-18: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-(4-dimethylamino-piperidin-1-yl)-methanone II-19: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide II-20: 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide II-21: 4-(9-Chloro-7-o-tolyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-N-[3- (4-methyl-piperazin-1-yl)-propyl]-benzamide II-22: 4-[9-Chloro-7-(2-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide II-23: 4-[9-Chloro-7-(4-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide II-24: 4-[7-(2-Fluoro-phenyl)-9-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide II-25: 2-{3-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-N-[3-(4-methyl-piperazin-1-yl)-propyl]-acetamide II-26: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-morpholin-4-yl-methanone II-27: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N,N-bis-(2-hydroxy-ethyl)-benzamide II-28: {4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-morpholin-4-yl-methanone II-29: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(2-morpholin-4-yl-ethyl)-benzamide II-30: 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(2-morpholin-4-yl-ethyl)-benzamide II-31: 4-(9-Chloro-7-o-tolyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-N-(2- morpholin-4-yl-ethyl)-benzamide II-32: 4-[9-Chloro-7-(2-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(3-morpholin-4-yl-propyl)-benzamide II-33: 4-[9-Chloro-7-(4-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(2-morpholin-4-yl-ethyl)-benzamide II-34: 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-2-hydroxy-N-(2-morpholin-4-yl-ethyl)-benzamide II-35: [9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]- pyridin-2-yl-amine II-36: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]- (3,5-dichloro-phenyl)-amine II-37: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- methoxy-phenyl)-amine II-38: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- ethoxy-phenyl)-amine II-39: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3- methoxy-phenyl)-amine II-40: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(2- methoxy-phenyl)-amine II-41: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- chloro-phenyl)-amine II-42: [9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- chloro-phenyl)-amine II-43: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3- chloro-phenyl)-amine II-44: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(2- chloro-phenyl)-amine II-45: 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenol II-46: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- morpholin-4-yl-phenyl)-amine II-47: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-[4- (4-methyl-piperazin-1-yl)-phenyl]-amine II-48: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- pyridin-4-ylmethyl-phenyl)-amine II-49: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzonitrile II-50: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- nitro-phenyl)-amine II-51: 4-[7-(2-Fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- benzoic acid II-52: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-53: 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-54: 4-(9-Chloro-7-o-tolyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)- benzoic acid II-55: 4-[9-Chloro-7-(2-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-56: 4-[9-Chloro-7-(4-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-57: 4-[9-Fluoro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-58: 4-[7-(2-Fluoro-phenyl)-9-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-59: 4-[10-Fluoro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-60: 4-[10-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-61: 4-[10-Bromo-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-62: 4-[7-(2-Fluoro-phenyl)-10-methoxy-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-63: 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzamide II-64: 3-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzamide II-65: {3-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-acetic acid II-66: 2-{3-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-acetamide II-67: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzenesulfonic acid II-68: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzenesulfonamide II-69: 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide II-70: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- trifluoromethanesulfonyl-phenyl)-amine II-71: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]- (3,4-dimethoxy-phenyl)-amine II-72: [9-Chloro-7-(2-fluoro-phenyl)-6,7-dihydro-5H-benzo[c]pyrimido- [4,5-e]azepin-2-yl]-(3,4-dimethoxy-phenyl)-amine II-73: [9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]- (3,4-dimethoxy-phenyl)-amine II-74: (9-Chloro-7-o-tolyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)-(3,4- dimethoxy-phenyl)-amine II-75: (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-9-methyl-5H- benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine II-76: (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-9-isopropyl-5H- benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine II-77: (3,4-Dimethoxy-phenyl)-[10-fluoro-7-(2-fluoro-phenyl)-5H- benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine II-78: [10-Bromo-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]- (3,4-dimethoxy-phenyl)-amine II-79: (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-10-trifluoromethyl-5H- benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine II-80: (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-10-methyl-5H- benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine II-81: (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-10-methoxy-5H- benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine II-82: (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-11-methyl-5H- benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine II-83: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]- (2,3-dihydro-benzo[1,4]dioxin-6-yl)-amine II-84: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- fluoro-3-methoxy-phenyl)-amine II-85: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-2-hydroxy-benzoic acid II-86: 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-2-hydroxy-benzoic acid II-87: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]- (3,4-dichloro-phenyl)-amine II-88: [9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]- (3,5-dimethoxy-phenyl)-amine II-89: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]- (3,5-dimethyl-phenyl)-amine II-90: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]- phenyl-amine II-91: 4-[9-Chloro-7-(2,5-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-92: 4-[9-Chloro-7-(2,3-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-93: (3-Dimethylamino-pyrrolidin-1-yl)-{4-[7-(2-fluoro-phenyl)-9-methoxy- 5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone II-94: 4-[9-Chloro-7-(2,5-dimethoxy-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-95: 4-[7-(2-Fluoro-phenyl)-9-methoxy-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N,N-bis-(2-hydroxy-ethyl)-benzamide II-96: 4-[9-Chloro-7-(2,4-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-97: 4-[9-Chloro-7-(2,4-difluoro-phenyl)-7H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-98: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-(3-dimethylamino-azetidin-1-yl)-methanone II-99: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-methyl-N-(1-methyl-pyrrolidin-3-yl)-benzamide II-100: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-(3-dimethylamino-pyrrolidin-1-yl)-methanone II-101: 4-[9-Chloro-7-(2,4-dimethoxy-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-102: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-(3-methylamino-pyrrolidin-1-yl)-methanone II-103: (3-Amino-pyrrolidin-1-yl)-{4-[9-chloro-7-(2-fluoro-phenyl)-5H- benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone II-104: 4-[9-Chloro-7-(2,3-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid methyl ester II-105: 4-[9-Chloro-7-(2,5-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid methyl ester II-106: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-phosphonic acid II-107: N-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-methanesulfonamide II-108: N-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-N-methyl-acetamide II-109: 2-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoylamino}-succinic acid II-110: [9-Chloro-7-(2-fluoro-phenyl)-4-methyl-5H-benzo[c]pyrimido- [4,5-e]azepin-2-yl]-(3,4-dimethoxy-phenyl)-amine II-111: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-(3,5-dimethyl-piperazin-1-yl)-methanone II-112: 1-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoyl}-pyrrolidine-2-carboxylic acid II-113: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-(3-methyl-piperazin-1-yl)-methanone II-114: [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-[4- (2H-tetrazol-5-yl)-phenyl]-amine II-115: N-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-acetamide II-116: 5-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-2-fluoro-benzoic acid II-117: N-(3-Amino-propyl)-4-[9-chloro-7-(2-fluoro-phenyl)-5H- benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-methyl-benzamide II-118: 2-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoylamino}-propionic acid II-119: 5-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-pyridine-2-carboxylic acid II-120: 2-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-N-(2-morpholin-4-yl-ethyl)-acetamide II-121: 5-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-2-methoxy-benzoic acid II-122: 5-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-2-methyl-benzoic acid II-123: 6-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-nicotinic acid II-124: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(2-morpholin-4-yl-ethyl)-benzenesulfonamide II-125: 2-Chloro-5-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-126: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-acetic acid II-127: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-2-trifluoromethyl-benzoic acid II-128: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-methyl-N-(1-methyl-piperidin-4-yl)-benzamide II-129: N-(3-Amino-propyl)-4-[9-chloro-7-(2-fluoro-phenyl)-5H- benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzamide II-130: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(3-methylamino-propyl)-benzamide II-131: N-(2-Amino-2-methyl-propyl)-4-[9-chloro-7-(2-fluoro-phenyl)-5H- benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzamide II-132: 2-(3,4-Dimethoxy-phenylamino)-7-(2-fluoro-phenyl)-5H- benzo[c]pyrimido[4,5-e]azepine-10-carboxylic acid II-133: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-2-methyl-benzoic acid II-134: 2-Chloro-4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-135: 4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-136: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-2-fluoro-benzoic acid II-137: 4-[7-(2-Fluoro-phenyl)-9-methoxy-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-138: (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-9-methoxy-5H- benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine II-139: [9,10-Dichloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- yl]-(3,4-dimethoxy-phenyl)-amine II-140: 4-[9,10-Dichloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin- 2-ylamino]-benzoic acid II-141: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-2-methoxy-benzoic acid II-142: N-(2-Amino-ethyl)-4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzamide II-143: 4-(9-Chloro-7-phenyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)- benzoic acid II-144: [7-(2-Bromo-phenyl)-9-chloro-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]- (3,4-dimethoxy-phenyl)-amine II-145: 2-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-1-(4-methyl-piperazin-1-yl)-ethanone II-146: 3-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-147: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-[2-(1H-imidazol-4-yl)-ethyl]-benzamide II-148: 4-[7-(2-Fluoro-phenyl)-9-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(2-morpholin-4-yl-ethyl)-benzamide II-149: {3-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-acetic acid II-150: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(2-pyridin-4-yl-ethyl)-benzamide II-151: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(2-pyridin-3-yl-ethyl)-benzamide II-152: (9-Chloro-7-phenyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)-(3,4- dimethoxy-phenyl)-amine II-153: 4-[7-(2-Fluoro-phenyl)-10-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-154: (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-yl]-amine II-155: 4-[9-Chloro-7-(4-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-156: 4-[9-Chloro-7-(3-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-157: 4-[9-Chloro-7-(3-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide II-158: 4-[9-Chloro-7-(3-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(2-morpholin-4-yl-ethyl)-benzamide II-159: {4-[9-Chloro-7-(3-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone II-160: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-methyl-N-(2-pyridin-2-yl-ethyl)-benzamide II-161: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(2-pyridin-2-yl-ethyl)-benzamide II-162: 4-[9-Chloro-7-(3-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-163: {3-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone II-164: 9-Chloro-7-(2-fluorophenyl)-N-{4-[(4-pyridin-2-ylpiperazin-1- yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-165: 9-Chloro-7-(2-fluorophenyl)-N-(4-{[4-(2-morpholin-4-yl-2- oxoethyl)piperazin-1-yl]carbonyl}phenyl)-5H-pyrimido- [5,4-d][2]benzazepin-2-amine II-166: 9-Chloro-7-(2-fluorophenyl-N-(4-{[4-(2-furoyl)piperazin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-167: Benzyl-4-(4-{[9-chloro-7-(2-fluorophenyl)-5H-pyrimido- [5,4-d][2]benzazepin-2-yl]amino}benzoyl)piperazine-1-carboxylate II-168: Ethyl-4-(4-{[9-chloro-7-(2-fluorophenyl)-5H-pyrimido- [5,4-d][2]benzazepin-2-yl]amino}benzoyl)piperazine-1-carboxylate II-169: 2-[4-(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}benzoyl)piperazin-1-yl]benzoic acid II-170: 2-[4-(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}benzoyl)piperazin-1-yl]-N-isopropylacetamide II-171: 9-Chloro-7-(2-fluorophenyl)-N-(4-{[4-(2-pyrrolidin-1-ylethyl)piperazin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-172: N-[2-(aminocarbonyl)phenyl]-4-{[9-chloro-7-(2-fluorophenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzamide II-173: 9-Chloro-7-(2-fluorophenyl)-N-{4-[(4-pyrimidin-2-ylpiperazin-1- yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-174: 4-{[9-Chloro-7-(2-chloro-6-fluorophenyl)-5H-pyrimido- [5,4-d][2]benzazepin-2-yl]amino}benzoic acid II-175: 9-Chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1- yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-176: 9-Chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(dimethylamino)pyrrolidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-177: 9-Chloro-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-7-(2-fluoro- 6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-178: 9-Chloro-N-(4-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7-(2- fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-179: 9-Chloro-N-(4-{[3-(dimethylamino)azetidin-1-yl]carbonyl}phenyl)-7-(2- fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-180: 9-Chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(dimethylamino)azetidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-181: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-[4-(3-piperidin-1-yl-propyl)-piperazin-1-yl]-methanone II-182: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-[4-(2-piperidin-1-yl-ethyl)-piperazin-1-yl]-methanone II-183: {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin- 2-ylamino]-phenyl}-(4-dimethylamino-piperidin-1-yl)-methanone II-184: {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin- 2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone II-185: 4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-(3-dimethylamino-propyl)-N-methyl-benzamide II-186: {4-[9-Chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-phenyl}-(4-dimethylamino-piperidin-1-yl)- methanone II-187: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-[4-(2-dipropylamino-ethyl)-piperazin-1-yl]-methanone II-188: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-[4-(3-pyrrolidin-1-yl-propyl)-piperazin-1-yl]- methanone II-189: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-[4-(2-morpholin-4-yl-ethyl)-piperazin-1-yl]-methanone II-190: 4-[9-Chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5- e]azepin-2-ylamino]-benzoic acid II-191: {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin- 2-ylamino]-phenyl}-(3(S)-methyl-piperazin-1-yl)-methanone II-192: (3-Amino-azetidin-1-yl)-{4-[9-chloro-7-(2-fluoro-phenyl)-5H- benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone II-193: {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-(3-dimethylaminomethyl-azetidin-1-yl)-methanone II-194: {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin- 2-ylamino]-phenyl}-(3(R)-methyl-piperazin-1-yl)-methanone II-195: {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin- 2-ylamino]-phenyl}-piperazin-1-yl-methanone II-196: (3-Amino-pyrrolidin-1-yl)-{4-[9-chloro-7-(2,6-difluoro-phenyl)-5H- benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone II-197: {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin- 2-ylamino]-phenyl}-(3-methylamino-pyrrolidin-1-yl)-methanone II-198: 4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-methyl-N-(3-methylamino-propyl)-benzamide II-199: {4-[9-Chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5- e]azepin-2-ylamino]-phenyl}-(3-methylamino-pyrrolidin-1-yl)- methanone II-200: 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-cyclohexanecarboxylic acid II-201: 9-chloro-N-(4-{[4-(2-ethoxyphenyl)piperazin-1-yl]carbonyl}phenyl)-7-(2- fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-202: N-[amino(imino)methyl]-4-{[9-chloro-7-(2,6-difluorophenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzamide II-203: 3-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}benzoic acid II-204: 9-chloro-7-(2,6-difluorophenyl)-N-(3-{[3-(dimethylamino)azetidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-205: 9-chloro-7-(2,6-difluorophenyl)-N-(3-{[4-(dimethylamino)piperidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-206: 9-chloro-7-(2,6-difluorophenyl)-N-(3-{[3-(dimethylamino)pyrrolidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-207: N-[2-(aminomethyl)-1,3-benzoxazol-5-yl]-9-chloro-7-(2,6-difluorophenyl)- 5H-pyrimido[5,4-d][2]benzazepin-2-amine II-208: 9-chloro-N-[4-({4-[3-(diethylamino)propyl]piperazin-1- yl}carbonyl)phenyl]-7-(2-fluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-209: 9-chloro-N-[4-({4-[2-(diethylamino)ethyl]piperazin-1- yl}carbonyl)phenyl]-7-(2-fluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-210: 9-chloro-N-[4-({4-[3-(dimethylamino)propyl]piperazin-1- yl}carbonyl)phenyl]-7-(2-fluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-211: 9-chloro-7-(2-fluorophenyl)-N-[4-({4-[(1-methylpiperidin-3- yl)methyl]piperazin-1-yl}carbonyl)phenyl]-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-212: 9-chloro-7-(2,6-difluorophenyl)-N-(4-nitrophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-213: 9-chloro-N-(3-chloro-4-{[4-(2-pyrrolidin-1-ylethyl)piperazin-1- yl]carbonyl}phenyl)-7-(2-fluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-214: 9-chloro-N-{3-chloro-4-[(3-methylpiperazin-1-yl)carbonyl]phenyl}-7-(2- fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-215: 9-chloro-N-(3-chloro-4-{[3-(dimethylamino)pyrrolidin-1- yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-216: 9-chloro-N-{3-chloro-4-[(3-methylpiperazin-1-yl)carbonyl]phenyl}-7-(2,6- difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-217: N-[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]benzene-1,4-diamine II-218: methyl 2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoate II-219: 1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}benzoyl)piperazine-2-carboxylic acid II-220: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[4-(methylamino)piperidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-221: N-{4-[(3-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2,6- difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-222: 9-chloro-7-(2,6-difluorophenyl)-N-{3-[(3,5-dimethylpiperazin-1- yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-223: 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[[4-(dimethylamino)piperidin-1- yl](imino)methyl]benzamide II-224: 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[imino(piperazin-1-yl)methyl]benzamide II-225: 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}-N-[3-(dimethylamino)propyl]-N- methylbenzamide II-226: 3-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}-N-[3-(dimethylamino)propyl]-N- methylbenzamide II-227: 9-chloro-N-(3-{[3-(dimethylamino)azetidin-1-yl]carbonyl}phenyl)-7-(2- fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-228: 9-chloro-N-{3-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-7-(2-fluoro- 6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-229: 9-chloro-N-(3-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-7-(2- fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-230: N-(4-{[3-(aminomethyl)azetidin-1-yl]carbonyl}phenyl)-9-chloro-7-(2- fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-231: 9-chloro-N-(3-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7-(2- fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-232: 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-{4-[(3-methylpiperazin-1- yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-233: 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-{4-[(4-methylpiperazin-1- yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-234: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)azetidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-235: 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[3-(methylamino)azetidin- 1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-236: 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}benzonitrile II-237: 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[[3-(dimethylamino)pyrrolidin-1- yl](imino)methyl]benzamide II-238: 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[(3,5-dimethylpiperazin-1-yl)(imino)methyl]benzamide II-239: N-{4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2,6- difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-240: N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2-fluoro-6- methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-241: N-{4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2-fluoro-6- methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-242: 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[4-(methylamino)piperidin- 1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-243: 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-[4-(piperazin-1- ylcarbonyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-244: 9-chloro-7-(2,6-difluorophenyl)-N-{4-[[4-(dimethylamino)piperidin-1- yl](imino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-245: N-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}phenyl)guanidine II-246: 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-methyl-N-[2-(methylamino)ethyl]benzamide II-247: 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[2-(dimethylamino)ethyl]-N-methylbenzamide II-248: methyl 4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoyl)piperazine-2-carboxylate II-249: 2-[(4-carboxyphenyl)amino]-7-(2-fluorophenyl)-5H-pyrimido[5,4- d][2]benzazepine-9-carboxylic acid II-250: 9-chloro-7-(2,6-difluorophenyl)-N-{4-[[3-(dimethylamino)pyrrolidin-1- yl](imino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-251: 9-chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1- yl)(imino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-252: N-(2-aminoethyl)-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}-N-methylbenzamide II-253: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)piperidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-254: 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}-N-methyl-N-[2- (methylamino)ethyl]benzamide II-255: 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}-N-[2-(dimethylamino)ethyl]-N- methylbenzamide II-256: 7-(2-fluorophenyl)-2-[(3-methoxyphenyl)amino]-5H-pyrimido[5,4- d][2]benzazepine-9-carboxylic acid II-257: N-(3-aminopropyl)-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}-N-methylbenzamide II-258: 2-chloro-5-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoic acid II-259: 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[[3-(dimethylamino)azetidin-1-yl](imino)methyl]benzamide II-260: N-(2-amino-2-methylpropyl)-4-{[9-chloro-7-(2,6-difluorophenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzamide II-261: 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}-N-methyl-N-[3- (methylamino)propyl]benzamide II-262: N-{4-[(3-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2-fluoro-6- methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-263: 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[3-(methylamino)piperidin- 1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-264: N-(3-aminopropyl)-4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide II-265: N-(2-aminoethyl)-4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide II-266: 4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}benzoyl)piperazine-2-carboxylic acid II-267: 9-chloro-7-(2,6-difluorophenyl)-N-{4-[[3-(dimethylamino)azetidin-1- yl](imino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-268: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{imino[3-(methylamino)pyrrolidin- 1-yl]methyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-269: 9-chloro-N-(4-chloro-3-{[4-(dimethylamino)piperidin-1- yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-270: 9-chloro-7-(2,6-difluorophenyl)-N-[4-(5,5-dimethyl-4,5-dihydro-1H- imidazol-2-yl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-271: N-[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]-N′-pyrimidin-2-ylbenzene-1,4-diamine II-272: 4-{[9-(3-aminoprop-1-yn-1-yl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoic acid II-273: 9-bromo-7-(2,6-difluorophenyl)-N-(3-methoxyphenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-274: 4-{[9-bromo-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}benzoic acid II-275: 7-(2,6-difluorophenyl)-N-(3-methoxyphenyl)-9-(3-pyrrolidin-1-ylprop-1- yn-1-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-276: 9-(3-aminoprop-1-yn-1-yl)-7-(2,6-difluorophenyl)-N-(3-methoxyphenyl)- 5H-pyrimido[5,4-d][2]benzazepin-2-amine II-277: 4-({9-chloro-7-[2-(trifluoromethyl)phenyl]-5H-pyrimido[5,4- d][2]benzazepin-2-yl}amino)benzoic acid II-278: N-{4-[(3-aminoazetidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2,6- difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-279: 4-[(9-chloro-7-pyridin-2-yl-5H-pyrimido[5,4-d][2]benzazepin-2- yl)amino]benzoic acid II-280: N-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}phenyl)-4-methylpiperazine-1-carboxamide II-281: 9-chloro-N-(4-chloro-3-{[3-(methylamino)pyrrolidin-1- yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-282: 9-chloro-N-(4-chloro-3-{[4-(methylamino)piperidin-1- yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-283: 2-chloro-5-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}-N-methyl-N-[2- (methylamino)ethyl]benzamide II-284: N-{4-[(3-aminopyrrolidin-1-yl)(imino)methyl]phenyl}-9-chloro-7-(2,6- difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-285: 2-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}phenyl)-1,4,5,6-tetrahydropyrimidin-5-ol II-286: N-{4-[(3-aminoazetidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2-fluoro-6- methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-287: N-{4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-[2- (trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-288: 9-chloro-N-(4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-7-[2- (trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-289: N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-[2- (trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-290: 9-chloro-N-(4-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7-[2- (trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-291: 9-chloro-N-(4-chloro-3-{[3-(methylamino)azetidin-1-yl]carbonyl}phenyl)- 7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-292: N-{3-[(4-aminopiperidin-1-yl)carbonyl]-4-chlorophenyl}-9-chloro-7-(2,6- difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-293: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(dimethylamino)piperidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-294: methyl 4-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoyl)piperidine-4-carboxylate II-295: 4-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoyl)piperidine-4-carboxylic acid II-296: N-{4-[(3-aminoazetidin-1-yl)carbonyl]phenyl}-9-chloro-7-[2- (trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-297: 9-chloro-N-(4-{[3-(methylamino)azetidin-1-yl]carbonyl}phenyl)-7-[2- (trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-298: N-{4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-pyridin-2-yl- 5H-pyrimido[5,4-d][2]benzazepin-2-amine II-299: N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-pyridin-2-yl- 5H-pyrimido[5,4-d][2]benzazepin-2-amine II-300: ethyl 2-amino-4-[(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoyl)amino]butanoate II-301: 4-{[9-chloro-7-(3-fluoropyridin-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}benzoic acid II-302: 9-{[3-(dimethylamino)azetidin-1-yl]carbonyl}-7-(2-fluorophenyl)-N-(3- methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-303: 7-(2-fluorophenyl)-2-[(3-methoxyphenyl)amino]-N-methyl-N-[3- (methylamino)propyl]-5H-pyrimido[5,4-d][2]benzazepine-9-carboxamide II-304: N-{(4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(3- fluoropyridin-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-305: N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-(3- fluoropyridin-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-306: 2-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}phenyl)-4,5-dihydro-1H-imidazole-5-carboxylic acid II-307: N-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}phenyl)-2-(dimethylamino)acetamide II-308: 2-amino-N-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}phenyl)-2-methylpropanamide II-309: ethyl (2R)-4-amino-2-[(4-{[9-chloro-7-(2,6-difluorophenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)amino]butanoate II-310: 4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}benzoyl)-N-methylpiperazine-2-carboxamide II-311: 7-(2-fluorophenyl)-2-[(3-methoxyphenyl)amino]-N-(3-morpholin-4- ylpropyl)-5H-pyrimido[5,4-d][2]benzazepine-9-carboxamide II-312: 9-[(3,5-dimethylpiperazin-1-yl)carbonyl]-7-(2-fluorophenyl)-N-(3- methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-313: 9-chloro-N-(3-chloro-4-{[4-(dimethylamino)piperidin-1- yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-314: ethyl 2-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}phenyl)-4,5-dihydro-1H-imidazole-5- carboxylate II-315: 9-chloro-N-(4-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7- pyridin-2-yl-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-316: 9-chloro-N-(4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-7- pyridin-2-yl-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-317: 4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}benzoyl)piperazine-2-carboxamide II-318: N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]-3-chlorophenyl}-9-chloro-7-(2,6- difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-319: N-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}phenyl)piperidine-4-carboxamide II-320: 4-{[9-chloro-7-(2-fluoro-6-{methyl[2-(methylamino)ethyl]amino}phenyl)- 5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic acid II-321: 9-chloro-7-(2,4-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1- yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-322: 9-chloro-7-(2,4-dimethoxyphenyl)-N-{4-[(3,5-dimethylpiperazin-1- yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-323: 9-chloro-7-(2-chloro-6-fluorophenyl)-N-{4-[(3-methylpiperazin-1- yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-324: 9-chloro-7-(2-chloro-6-fluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1- yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-325: 9-chloro-7-(2-chloro-6-fluorophenyl)-N-(4-{[4-(methylamino)piperidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-326: 9-chloro-7-(2-chloro-6-fluorophenyl)-N-(4-{[3-(methylamino)piperidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-327: 9-chloro-7-(2-chloro-6-fluorophenyl)-N-(4-{[3-(methylamino)pyrrolidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-328: 9-chloro-N-(3,4-dimethoxyphenyl)-7-{2- [(dimethylamino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2- amine II-329: 9-chloro-7-(2-methoxyphenyl)-N-{4-[(3-methylpiperazin-1- yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-330: 9-chloro-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-7-(2- methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-331: 9-chloro-7-(2-methoxyphenyl)-N-(4-{[4-(methylamino)piperidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-332: 9-chloro-7-(2-methoxyphenyl)-N-(4-{[3-(methylamino)pyrrolidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-333: 9-chloro-7-(2-methoxyphenyl)-N-(4-{[3-(methylamino)piperidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-334: 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-methylbenzamide II-335: 4-{[9-chloro-7-(2-fluoro-6-{methyl[3- (methylamino)propyl]amino}phenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}benzoic acid II-336: 4-{[9-chloro-7-(2-fluoro-6-{methyl[3- (methylamino)propyl]amino}phenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}-N-methylbenzamide II-337: 1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}phenyl)ethanone II-338: N-[3-(3-aminoprop-1-yn-1-yl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-amine II-339: 4-[(9-chloro-7-{2-fluoro-6-[(2-hydroxyethyl)amino]phenyl}-5H- pyrimido[5,4-d][2]benzazepin-2-yl)amino]-N-methylbenzamide II-340: 4-[(7-{2-[(2-aminoethyl)amino]-6-fluorophenyl}-9-chloro-5H- pyrimido[5,4-d][2]benzazepin-2-yl)amino]-N-methylbenzamide II-341: 4-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoyl)-N-methylpiperidine-4-carboxamide II-342: 4-[(9-chloro-7-{2-[4-(dimethylamino)piperidin-1-yl]-6-fluorophenyl}-5H- pyrimido[5,4-d][2]benzazepin-2-yl)amino]-N-methylbenzamide II-343: 9-chloro-7-(2,6-difluorophenyl)-N-{3-[3-(dimethylamino)prop-1-yn-1- yl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-344: 9-chloro-7-(2,6-difluorophenyl)-N-(3-iodophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-345: 4-{[9-chloro-7-(2-{[2-(dimethylamino)ethyl]amino}-6-fluorophenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide II-346: 4-[(9-chloro-7-{2-[[2-(dimethylamino)ethyl](methyl)amino]-6- fluorophenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-yl)amino]-N- methylbenzamide II-347: 4-{[9-chloro-7-(2-fluoro-6-{methyl[2-(methylamino)ethyl]amino}phenyl)- 5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide II-348: 4-({7-[2-(4-aminopiperidin-1-yl)-6-fluorophenyl]-9-chloro-5H- pyrimido[5,4-d][2]benzazepin-2-yl}amino)-N-methylbenzamide II-349: 7-(2-fluorophenyl)-2-[(3-methoxyphenyl)amino]-N-methyl-N-[2- (methylamino)ethyl]-5H-pyrimido[5,4-d][2]benzazepine-9-carboxamide II-350: 4-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoyl)piperidine-4-carboxamide II-351: 9-chloro-7-(2-chloro-6-fluorophenyl)-N-(4-{[3-(methylamino)azetidin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-352: 9-chloro-7-(2,6-difluorophenyl)-N-(4-methyl-1,3-thiazol-2-yl)-5H- pyrimido[5,4-d][2]benzazepin-2-amine II-353: 7-(2,6-difluorophenyl)-2-[(3-methoxyphenyl)amino]-5H-pyrimido[5,4- d][2]benzazepine-9-carboxylic acid II-354: 4-({9-chloro-7-[2-fluoro-6-(methylamino)phenyl]-5H-pyrimido[5,4- d][2]benzazepin-2-yl}amino)-N-methylbenzamide II-355: 2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-methyl-1,3-thiazole-4-carboxamide II-356: N-1H-benzimidazol-2-yl-9-chloro-7-(2,6-difluorophenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-amine II-357: 7-(2,6-difluorophenyl)-2-[(4-methyl-1,3-thiazol-2-yl)amino]-5H- pyrimido[5,4-d][2]benzazepine-9-carboxylic acid II-358: 3-amino-1-(3-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}phenyl)propan-1-one II-359: 1-(3-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}phenyl)-3-(dimethylamino)propan-1-one II-360: 2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-1,3-thiazole-4-carboxylic acid II-361: ethyl 2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}-1,3-thiazole-4-carboxylate II-362: 9-chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1- yl)carbonyl]-1,3-thiazol-2-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-363: ethyl 2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}-1,3-oxazole-5-carboxylate II-364: 2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-1,3-oxazole-5-carboxylic acid II-365: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[(3R)-3-methylpiperazin-1- yl]carbonyl}-1,3-thiazol-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-366: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[(2R)-2-methylpiperazin-1- yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-367: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)pyrrolidin-1- yl]carbonyl}-1,3-thiazol-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-368: 2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-1,3-oxazole-4-carboxylic acid II-369: 9-chloro-7-(2,6-difluorophenyl)-N-{5-[(3,5-dimethylpiperazin-1- yl)carbonyl]-1,3-oxazol-2-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-370: 9-chloro-7-(2,6-difluorophenyl)-N-(5-{[3-(methylamino)pyrrolidin-1- yl]carbonyl}-1,3-oxazol-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-371: 4-{[9-chloro-7-(2,6-difluorophenyl)-5-methyl-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoic acid II-372: 9-chloro-7-(2,6-difluorophenyl)-N-{3-[3-(dimethylamino)propyl]phenyl}- 5H-pyrimido[5,4-d][2]benzazepin-2-amine II-373: N-[3-(3-aminopropyl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-amine II-374: 9-chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1- yl)carbonyl]-1,3-oxazol-2-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-375: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)pyrrolidin-1- yl]carbonyl}-1,3-oxazol-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-376: 7-(2,6-difluorophenyl)-2-({4-[(3,5-dimethylpiperazin-1- yl)carbonyl]phenyl}amino)-N-methyl-5H-pyrimido[5,4-d][2]benzazepine- 9-carboxamide II-377: 2-{[4-(aminocarbonyl)phenyl]amino}-7-(2,6-difluorophenyl)-5H- pyrimido[5,4-d][2]benzazepine-9-carboxylic acid II-378: 1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4d][2]benzazepin-2- yl]amino}benzoyl)-N-methyl-4-(methylamino)piperidine-4-carboxamide II-379: N-{4-[(3-amino-3-methylpyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2,6- difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-380: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-methyl-3- (methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-381: 1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}benzoyl)-4-(methylamino)piperidine-4-carboxamide II-382: 9-chloro-7-(2,6-difluorophenyl)-N-{4-[(3,3,5-trimethylpiperazin-1- yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-383: N-1-azabicyclo[2.2.2]oct-3-yl-4-{[9-chloro-7-(2,6-difluorophenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide II-384: N-1-azabicyclo[2.2.2]oct-3-yl-4-{[9-chloro-7-(2,6-difluorophenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzamide II-385: 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-hydroxybenzamide II-386: N-{4-[(aminooxy)carbonyl]phenyl}-9-chloro-7-(2,6-difluorophenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-amine II-387: 4-{[9-chloro-7-(2,6-difluorophenyl)-7H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}benzoic acid II-388: 4-{[9-chloro-7-(2,3-difluorophenyl)-7H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}benzoic acid II-389: 3-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoyl)-N-methylpyrrolidine-3- carboxamide II-390: 3-amino-1-(2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoyl)pyrrolidine-3-carboxamide II-391: 9-chloro-7-(2,6-difluorophenyl)-N-{4-[(3,3-dimethylpiperazin-1- yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-392: 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)benzamide II-393: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(dimethylamino)-3- methylpyrrolidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-394: 9-chloro-7-(2,6-difluorophenyl)-N-(3-methyl-1H-pyrazol-5-yl)-5H- pyrimido[5,4-d][2]benzazepin-2-amine II-395: 2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoic acid II-396: 4-amino-1-(2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoyl)-N-methylpiperidine-4- carboxamide II-397: 4-amino-1-(2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoyl)-N,N-dimethylpiperidine-4- carboxamide II-398: 4-[(9-methoxy-7-oxo-6,7-dihydro-5H-pyrimido[5,4-d][2]benzazepin-2- yl)amino]benzoic acid II-399: 2-({4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}amino)-9-methoxy- 5,6-dihydro-7H-pyrimido[5,4-d][2]benzazepin-7-one II-400: 9-methoxy-2-[(4-{[3-(methylamino)pyrrolidin-1- yl]carbonyl}phenyl)amino]-5,6-dihydro-7H-pyrimido[5,4- d][2]benzazepin-7-one II-401: 4-[(8-methyl-7-oxo-5,6,7,8-tetrahydropyrimido[5,4-c]pyrrolo[3,2- e]azepin-2-yl)amino]benzoic acid II-402: 2-({4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}amino)-8-methyl-5,8- dihydropyrimido[5,4-c]pyrrolo[3,2-e]azepin-7(6H)-one II-403: 2-[(3-methoxyphenyl)amino]-8-methyl-5,8-dihydropyrimido[5,4- c]pyrrolo[3,2-e]azepin-7(6H)-one II-404: 9-chloro-2-[(3,4-dimethoxyphenyl)amino]-5,6-dihydro-7H-pyrimido[5,4- d][2]benzazepin-7-one II-405: 4-{[4-amino-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoic acid II-406: 9-chloro-N-(3-chloro-4-{[4-(methylamino)piperidin-1- yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-407: 9-chloro-N-(3-chloro-4-{[4-(methylamino)piperidin-1- yl]carbonyl}phenyl)-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-408: 4-{[9-chloro-7-(2-fluoro-6-hydroxyphenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoic acid II-409: 9-chloro-N-[4-(1,7-diazaspiro[4.4]non-7-ylcarbonyl)phenyl]-7-(2,6- difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-410: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[2-(methylamino)-7- azabicyclo[2.2.1]hept-7-yl]carbonyl}phenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-411: 1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}benzoyl)-N-methyl-3-(methylamino)pyrrolidine-3- carboxamide II-412: 1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}benzoyl)-3-(methylamino)pyrrolidine-3-carboxamide II-413: 1-(2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}benzoyl)-N-methyl-3- (methylamino)piperidine-3-carboxamide II-414: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-methyl-3- (methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-415: 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[3-methyl-3- (methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-416: {2-Chloro-4-[9-chloro-7-(2-fluoro-6-methoxy-phenyl)-5H- benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3-methyl-3- methylamino-piperidin-1-yl)-methanone II-417: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[4-methyl-4- (methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-418: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[4-(dimethylamino)-4- methylpiperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-419: N-{4-[(4-amino-4-methylpiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2,6- difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-420: 9-chloro-N-(3-chloro-4-{[4-methyl-4-(methylamino)piperidin-1- yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-421: 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[4-methyl-4- (methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-422: 2-Chloro-4-[9-chloro-7-(2-fluoro-6-methoxy-phenyl)-5H- benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(4-methyl-4- methylamino-piperidin-1-yl)-methanone II-423: 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(3-fluoro-4-{[4-methyl-4- (methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-424: 9-chloro-N-{3-chloro-4-[(3,3,5,5-tetramethylpiperazin-1- yl)carbonyl]phenyl}-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-425: N-1-azabicyclo[2.2.2]oct-3-yl-4-{[9-chloro-7-(2,6-difluorophenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-fluoro-N-methylbenzamide II-426: N-1-azabicyclo[2.2.2]oct-3-yl-4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)- 5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide II-427: N-8-azabicyclo[3.2.1]oct-3-yl-4-{[9-chloro-7-(2,6-difluorophenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide II-428: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)-8- azabicyclo[3.2.1]oct-8-yl]carbonyl}phenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-429: 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[3-(methylamino)-8- azabicyclo[3.2.1]oct-8-yl]carbonyl}phenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-amine II-430: 4-{[7-(2,6-difluorophenyl)-9-methyl-5H-pyrimido[5,4-c]thieno[2,3- e]azepin-2-yl]amino}benzoic acid II-431: 7-(2,6-difluorophenyl)-N-{4-[(3,3,5,5-tetramethylpiperazin-1- yl)carbonyl]phenyl}-5H-pyrimido[5,4-c]thieno[2,3-e]azepin-2-amine II-432: N-{4-[(3-amino-3-methylpyrrolidin-1-yl)carbonyl]phenyl}-7-(2,6- difluorophenyl)-10-methyl-5,10-dihydropyrimido[5,4-c]pyrrolo[2,3- e]azepin-2-amine II-433: 7-(2,6-difluorophenyl)-9-methyl-N-(4-{[3-(methylamino)pyrrolidin-1- yl]carbonyl}phenyl)-5H-furo[2,3-c]pyrimido[4,5-e]azepin-2-amine II-434: 4-(2,6-difluorophenyl)-2-methyl-N-(4-{[3-methyl-3- (methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-6H-pyrimido[5,4- c][1,3]thiazolo[4,5-e]azepin-9-amine II-435: N-{4-[(3-amino-3-methylpyrrolidin-1-yl)carbonyl]phenyl}-7-(2-fluoro-6- methoxyphenyl)-5,9-dihydropyrimido[5,4-c]pyrrolo[3,4-e]azepin-2-amine II-436: 4-{[4-(2,6-difluorophenyl)-1-methyl-1,6-dihydropyrazolo[4,3- c]pyrimido[4,5-e]azepin-9-yl]amino}benzoic acid II-437: 1-{4-[4-(2,6-Difluoro-phenyl)-2-methyl-6H-3-thia-5,8,10-triaza- benzo[e]azulen-9-ylamino]-benzoyl}-4-dimethylamino-piperidine-4- carboxylic acid methylamide II-438: 4-(4-{[7-(2,6-difluorophenyl)-5H-furo[3,2-c]pyrimido[4,5-e]azepin-2- yl]amino}benzoyl)-N-methylpiperazine-2-carboxamide II-439: 4-(4-{[4-(2,6-difluorophenyl)-6H-isoxazolo[4,5-c]pyrimido[4,5-e]azepin-9- yl]amino}benzoyl)-N-methylpiperazine-2-carboxamide II-440: 4-(2,6-difluorophenyl)-9-[(4-{[3-methyl-3-(methylamino)pyrrolidin-1- yl]carbonyl}phenyl)amino]-3,6-dihydroimidazo[4,5-c]pyrimido[4,5- e]azepin-2(1H)-one II-441: 2-amino-N-(3-{[7-(2,6-difluorophenyl)-8,10-dimethyl-5H-pyrimido[5,4- c]thieno[3,4-e]azepin-2-yl]amino}phenyl)-N,2-dimethylpropanamide II-442: 9-chloro-7-(2,6-difluorophenyl)-N-{3-[(2,2,6,6-tetramethylpiperidin-4- yl)oxy]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-443: 4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}phenyl)-N-methyl-1-(methylamino)cyclohexanecarboxamide II-444: 7-(3-{[7-(2-fluoro-6-methoxyphenyl)-9-methoxy-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}phenyl)-1,7-diazaspiro[4.4]nonan-6-one II-445: 9-chloro-N-[4-(3,8-diazabicyclo[3.2.1]oct-3-ylcarbonyl)phenyl]-7-(2,6- difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-446: 1-(3-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}phenyl)-3,5,5-trimethylpiperazin-2-one II-447: 9-chloro-N-[4-(2,6-dimethylpiperidin-4-yl)phenyl]-7-(2-fluoro-6- methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-448: N-[4-(1-amino-1-methylethyl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5H- pyrimido[5,4-d][2]benzazepin-2-amine II-449: N-[4-(2,5-diazaspiro[3.4]oct-2-ylcarbonyl)phenyl]-7-(2,6-difluorophenyl)- 10-methyl-5H-isothiazolo[5,4-c]pyrimido[4,5-e]azepin-2-amine II-450: 4-(2,6-difluorophenyl)-1-methyl-9-[(4-{[4-methyl-4- (methylamino)piperidin-1-yl]carbonyl}phenyl)amino]-1,6-dihydro-2H- pyrimido[5,4-c][1,3]thiazolo[4,5-e]azepin-2-one II-451: 4-(2,6-difluorophenyl)-N-[4-(1H-imidazol-2-yl)phenyl]-1-methyl-1,6- dihydroimidazo[4,5-c]pyrimido[4,5-e]azepin-9-amine II-452: 4-{[7-(2,6-difluorophenyl)-5H-[1]benzofuro[2,3-c]pyrimido[4,5-e]azepin-2- yl]amino}benzoic acid II-453: 7-(2-fluorophenyl)-N-{4-[(3,3,5,5-tetramethylpiperazin-1- yl)carbonyl]phenyl}-8,9,10,11-tetrahydro-5H-pyrido[4′,3′:4,5]thieno[3,2- c]pyrimido[4,5-e]azepin-2-amine II-454: 9-bromo-7-(2-fluorophenyl)-N-(4-{[3-(methylamino)pyrrolidin-1- yl]carbonyl}phenyl)-5,8-dihydropyrimido[5,4-c]pyrrolo[3,2-e]azepin-2- amine II-455: 7-(2-fluorophenyl)-N-(3-methyl-1H-indazol-6-yl)-5,12- dihydropyrimido[4′,5′:5,6]azepino[4,3-b]indol-2-amine II-456: 1-(4-{[7-(2,6-difluorophenyl)-9,10-dimethyl-5,8-dihydropyrimido[5,4- c]pyrrolo[3,2-e]azepin-2-yl]amino}benzoyl)-3-(methylamino)pyrrolidine- 3-carboxamide II-457: {3-[9-Chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone II-458: [9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- yl]-(2-methylaminomethyl-benzothiazol-6-yl)-amine II-459: 4-[9-Chloro-7-(2-isopropoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin- 2-ylamino]-benzoic acid II-460: 4-[9-Chloro-7-(2-fluoro-6-isopropoxy-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-461: 4-[9-Chloro-7-(2-ethoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-462: 4-[9-Chloro-7-(2-ethoxy-6-fluoro-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-463: 4-[9-Chloro-7-(2-fluoro-6-methyl-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-464: 4-[9-Chloro-7-(2-trifluoromethoxy-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-465: 4-[9-Chloro-7-(2-fluoro-6-trifluoromethoxy-phenyl)-5H- benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic acid II-466: 4-[9-Chloro-7-(3-fluoro-2-trifluoromethoxy-phenyl)-5H- benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic acid II-467: 4-[9-Chloro-7-(2,3-dimethoxy-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-468: 4-[9-Chloro-7-(2-isobutyl-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-469: 4-(7-Benzofuran-2-yl-9-chloro-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino)-benzoic acid II-470: 4-[9-Chloro-7-(1-methyl-1H-pyrrol-2-yl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-471: 4-[9-Chloro-7-(1-methyl-1H-imidazol-2-yl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-472: 4-(9-Chloro-7-thiophen-2-yl-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino)-benzoic acid II-473: 4-[9-Chloro-7-(2H-pyrazol-3-yl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-474: 4-[9-Chloro-7-(2-ethynyl-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-475: 4-[7-(2-Aminomethyl-phenyl)-9-chloro-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-476: 4-[9-Chloro-7-(5-fluoro-2-methoxy-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-477: 4-[9-Chloro-7-(3-methoxy-pyridin-2-yl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-478: 4-[8-Fluoro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-479: 4-[8-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-480: 4-[11-Fluoro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-481: 4-[11-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-benzoic acid II-482: 6-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-pyridazine-3-carboxylic acid II-483: 2-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-1H-imidazole-4-carboxylic acid II-484: 4-[9-Chloro-7-(2-fluoro-phenyl)-4-methyl-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-485: 4-[4-Aminomethyl-9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido- [4,5-e]azepin-2-ylamino]-benzoic acid II-486: 4-(9-Aminomethyl-7-phenyl-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino)-benzoic acid II-487: 9-Chloro-7-(2-fluorophenyl)-N-{4-[(2-methylpiperazin-1- yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-488: 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[{3-[(dimethylamino)methyl]azetidin-1- yl}(imino)methyl]benzamide II-489: 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[imino(piperazin-1-yl)methyl]benzamide II-490: 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[imino(3-methylpiperazin-1-yl)methyl]benzamide II-491: 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[[3-(dimethylamino)pyrrolidin-1- yl](imino)methyl]benzamide II-492: 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[imino(4-methylpiperazin-1-yl)methyl]benzamide II-493: 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[(3,5-dimethylpiperazin-1-yl)(imino)methyl]benzamide II-494: 1-[[(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}benzoyl)amino](imino)methyl]pyrrolidine-3-carboxamide II-495: 1-[[(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}benzoyl)amino](imino)methyl]piperidine-3-carboxamide II-496: 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[{4-[(cyclopropylcarbonyl)amino]piperidin-1- yl}(imino)methyl]benzamide II-497: 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[(dimethylamino)(imino)methyl]benzamide II-498: N-[[(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}phenyl)amino](imino)methyl]cyclopropanecarboxamide II-499: N-[[(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}phenyl)amino](imino)methyl]-3- (dimethylamino)cyclopentanecarboxamide II-500: 4-({9-Chloro-7-[2-fluoro-6-(trifluoromethyl)phenyl]-5H-pyrimido- [5,4-d][2]benzazepin-2-yl}amino)benzoic acid II-501: 4-{[9-Chloro-7-(2,6-dichlorophenyl)-5H>-pyrimido[5,4-d][2]benzazepin-2- yl]amino}benzoic acid II-502: 4-{[9-Chloro-7-(2-fluoro-6-methylphenyl)-5H-pyrimido- [5,4-d][2]benzazepin-2-yl]amino}benzoic acid II-503: 4-{[7-(2-Bromo-6-chlorophenyl)-9-chloro-5H-pyrimido- [5,4-d][2]benzazepin-2-yl]amino}benzoic acid II-504: 9-Chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1- yl)carbonyl]-3-fluorophenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-505: 4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[(3,5-dimethylpiperazin-1-yl)(imino)methyl]-N- methylbenzamide II-506: 4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[[3-(dimethylamino)azetidin-1-yl](imino)methyl]-N- methylbenzamide II-507: 3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[(3,5-dimethylpiperazin-1-yl)(imino)methyl]benzamide II-508: 3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[[3-(dimethylamino)pyrrolidin-1- yl](imino)methyl]benzamide II-509: 9-Chloro-7-(2,6-difluorophenyl)-N-{3-[(3,5-dimethylpiperazin-1- yl)carbonyl]-4-fluorophenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-510: N-[[(4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido- [5,4-d][2]benzazepin-2-yl]amino}phenyl)amino](imino)methyl]-3- (dimethylamino)cyclopentanecarboxamide II-511: N-[[(4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido- [5,4-d][2]benzazepin-2-yl]amino}-2-fluorophenyl)amino](imino)methyl]- 3-(dimethylamino)cyclopentanecarboxamide II-512: N-[[(5-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido- [5,4-d][2]benzazepin-2-yl]amino)}-2-fluorophenyl)amino](imino)methyl]- 3-(dimethylamino)cyclopentanecarboxamide II-513: N-(4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}phenyl)-3,5-dimethylpiperazine-1-carboximidamide II-514: 4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[[3-(dimethylamino)pyrrolidin-1-yl](imino)methyl]-N- methylbenzamide II-515: N-(3-{[9-Chloro-7-(2,6-difluorophenyl)-5<i>H</i>-pyrimido- [5,4-d][2]benzazepin-2-yl]amino}phenyl)-3,5-dimethylpiperazine-1- carboximidamide II-516: N-(3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}phenyl)-N,3,5-trimethylpiperazine-1-carboximidamide II-517: 3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-N-[[3-(dimethylamino)azetidin-1-yl](imino)methyl]benzamide II-518: N-(5-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}-2-fluorophenyl)-N,3,5-trimethylpiperazine-1- carboximidamide II-519: N-[[(3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido- [5,4-d][2]benzazepin-2-yl]amino}phenyl)amino](imino)methyl]-3- (dimethylamino)cyclopentanecarboxamide II-520: 9-Chloro-7-(2,6-difluorophenyl)-N-{3-[(3,5-dimethylpiperazin-1- yl)(imino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-521: N-(4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}phenyl)-N,3,5-trimethylpiperazine-1-carboximidamide II-522: N-(4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}-2-fluorophenyl)-3,5-dimethylpiperazine-1-carboximidamide II-523: 9-Chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1- yl)(imino)methyl]-3-fluorophenyl}-5H-pyrimido[5,4-d][2]benzazepin-2- amine II-524: 5-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-2-(2,6-dimethylpiperidin-4-yl)-1H-isoindole-1,3(2H)-dione II-525: N-[2-(Aminomethyl)-1H-benzimidazol-6-yl]-9-chloro-7-(2-fluorophenyl)- 5H-pyrimido[5,4-d][2]benzazepin-2-amine II-526: 9-Chloro-7-(2-fluorophenyl)-N-{2-[(methylamino)methyl]-1H- benzimidazol-6-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-527: 9-Chloro-N-{2-[(dimethylamino)methyl]-1H-benzimidazol-6-yl}-7-(2- fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-528: 9-Chloro-7-(2-fluorophenyl)-N-{2-[(methylamino)methyl]-1,3- benzothiazol-6-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-529: 9-Chloro-7-(2,6-difluorophenyl)-N-{2-[(methylamino)methyl]-1H- benzimidazol-6-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-530: 9-Chloro-7-(2,6-difluorophenyl)-N-{2-[(methylamino)methyl]-1,3- benzoxazol-6-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-531: 9-Chloro-7-(2-fluorophenyl)-N-{2-[(methylamino)methyl]-1,3- benzoxazol-6-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-532: 9-Chloro-7-(2,6-difluorophenyl)-N-{3-[(3,5-dimethylpiperazin-1- yl)(imino)methyl]-4-fluorophenyl}-5H-pyrimido[5,4-d][2]benzazepin-2- amine II-533: 9-Chloro-7-(2,6-difluorophenyl)-N-{2-[(methylamino)methyl]-1,3- benzothiazol-6-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine II-534: {3-[9-Chloro-7-(2,6-difluorophenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone II-535: 3-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- ylamino]-N-methyl-N-(4-methyl-pentyl)-benzamide - In some embodiments, the Aurora kinase inhibitor is represented by formula (III):
- or a pharmaceutically acceptable salt thereof;
- wherein:
-
- Ra is selected from the group consisting of C1-3 aliphatic, C1-3 fluoroaliphatic, —R1, -T-R1, —R2, and -T-R2;
- T is a C1-3 alkylene chain optionally substituted with fluoro;
- R1 is an optionally substituted aryl, heteroaryl, or heterocyclyl group;
- R2 is selected from the group consisting of halo, —C≡C—R3, —CH═CH—R3, —N(R4)2, and —OR5;
- R3 is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group;
- each R4 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R4 on the same nitrogen atom, taken together with the nitrogen atom form an optionally substituted 5- to 6-membered heteroaryl or 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S;
- R5 is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; and
- Rb is selected from the group consisting of fluoro, chloro, —CH3, —CF3, —OH, —OCH3, —OCF3, —OCH2CH3, and —OCH2CF3.
- Ra is selected from the group consisting of C1-3 aliphatic, C1-3 fluoroaliphatic, —R1, -T-R1, —R2, and -T-R2;
- In some embodiments, R1 is a 5- or 6-membered aryl, heteroaryl, or heterocyclyl ring optionally substituted with one or two substituents independently selected from the group consisting of halo, C1-3 aliphatic, and C1-3 fluoroaliphatic. In certain embodiments, R1 is a phenyl, furyl, pyrrolidinyl, or thienyl ring optionally substituted with one or two substituents independently selected from the group consisting of halo, C1-3 aliphatic, and C1-3 fluoroaliphatic.
- In some embodiments, R3 is hydrogen, C1-3 aliphatic, C1-3 fluoroaliphatic, or —CH2—OCH3.
- In some embodiments, R5 is hydrogen, C1-3 aliphatic, or C1-3 fluoroaliphatic.
- In certain embodiments, Ra is halo, C1-3 aliphatic, C1-3 fluoroaliphatic, —OH, —O(C1-3 aliphatic), —O(C1-3 fluoroaliphatic), —CH≡CH—R3, —CH═CH—R3, or an optionally substituted pyrrolidinyl, thienyl, furyl, or phenyl ring, wherein R3 is hydrogen, C1-3 aliphatic, C1-3 fluoroaliphatic, or —CH2—OCH3. In certain particular embodiments, Ra is selected from the group consisting of chloro, fluoro, C1-3 aliphatic, C1-3 fluoroaliphatic, —OCH3, —OCF3, —C≡C—H, —C≡C—CH3, —C≡C—CH2OCH3, —CH═CH2, —CH═CHCH3, N-methylpyrrolidinyl, thienyl, methylthienyl, furyl, methylfuryl, phenyl, fluorophenyl, and tolyl.
- Table 2 provides the chemical names for specific examples of compounds of formula (III).
-
TABLE 2 Examples of Compounds of Formula (III) Chemical Name III-1 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-2-methoxybenzoic acid III-2 4-{[9-ethynyl-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}-2-methoxybenzoic acid III-3 4-({9-chloro-7-[2-fluoro-6-(trifluoromethoxy)phenyl]-5H-pyrimido[5,4- d][2]benzazepin-2-yl}amino)-2-methoxybenzoic acid III-4 4-{[7-(2-fluoro-6-methoxyphenyl)-9-(1-methyl-1H-pyrrol-2-yl)-5H- pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid III-5 4-{[7-(2-fluoro-6-methoxyphenyl)-9-(4-methyl-3-thienyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid III-6 4-{[7-(2-fluoro-6-methoxyphenyl)-9-(3-methyl-2-furyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid III-7 4-({9-ethynyl-7-[2-fluoro-6-(2,2,2-trifluoroethoxy)phenyl]-5H-pyrimido[5,4- d][2]benzazepin-2-yl}amino)-2-methoxybenzoic acid III-8 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-2-methoxybenzoic acid III-9 4-{[7-(2-fluoro-6-methoxyphenyl)-9-(2-methylphenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid III-10 4-{[7-(2-fluoro-6-methoxyphenyl)-9-prop-1-yn-1-yl-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid III-11 4-{[7-(2-fluoro-6-methoxyphenyl)-9-vinyl-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-2-methoxybenzoic acid III-12 4-{[7-(2-fluoro-6-methoxyphenyl)-9-(2-fluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid III-13 4-{[7-(2-fluoro-6-methoxyphenyl)-9-(3-methoxyprop-1-yn-1-yl)-5H- pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid III-14 4-({7-(2-fluoro-6-methoxyphenyl)-9-[(1E)-prop-1-en-1-yl]-5H-pyrimido[5,4- d][2]benzazepin-2-yl}amino)-2-methoxybenzoic acid III-15 4-({9-chloro-7-[2-fluoro-6-(2,2,2-trifluoroethoxy)phenyl]-5H-pyrimido[5,4- d][2]benzazepin-2-yl}amino)-2-methoxybenzoic acid III-16 4-{[7-(2-fluoro-6-methoxyphenyl)-9-(2-furyl)-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}-2-methoxybenzoic acid III-17 4-{[9-chloro-7-(2-fluoro-6-hydroxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- yl]amino}-2-methoxybenzoic acid III-18 4-{[7-(2-fluoro-6-methoxyphenyl)-9-phenyl-5H-pyrimido[5,4-d][2]benzazepin- 2-yl]amino}-2-methoxybenzoic acid - In one embodiment, the compound of formula (III) is 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt thereof. In a particular embodiment, the compound of formula (III) is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate.
- Any antibody capable of binding the CD20 antigen may be used in the methods of the instant invention. Antibodies which bind the CD20 antigen include, for example: C2B8 (rituximab; RITUXAN®) (U.S. Pat. No. 5,736,137, expressly incorporated herein by reference); the yttrium-[90]-labeled 2138 murine antibody designated Y2B8 (U.S. Pat. No. 5,736,137, expressly incorporated herein by reference); murine IgG2a 131 optionally labeled with 131 1 to generate the 131 1-B1 antibody (BEXXARTM®) (U.S. Pat. No. 5,595,721, expressly incorporated herein by reference); murine monoclonal antibody 1F5 (Press et al. Blood 69(2): 584-591 (1987)); chimeric 2H7 antibody (U.S. Pat. No. 5,677,180 expressly incorporated herein by reference); and monoclonal antibodies L27, G28-2, 93-1 133, B—Cl or NU-B2 available from the International Leukocyte Typing Workshop (Valentine et al., In: Leukocyte TypingIII (McMichael, Ed., p. 440, Oxford University Press (1987)).
- In some embodiments, the anti-CD20 antibody is rituximab. Rituximab is a genetically engineered chimeric murine/human monoclonal antibody. Rituximab is an IgG, kappa immunoglobulin containing murine light and heavy chain variable region sequences and human constant region sequences. Rituximab has a binding affinity for the CD20 antigen of approximately 8.0 nM. It is commercially available, e.g., from Genentech (South San Francisco, Calif.).
- In some embodiments, the anti-CD20 antibody used in the present invention may be administered along with standard of care chemotherapeutic agents/combinations, such as, for example, CHOP chemotherapy regimen, which is a regimen consisting of the combination of cyclophosphamide, doxorubicin, vincristine and prednisolone. Rituximab has been approved in combination with CHOP chemotherapy for the treatment of certain types of lymphomas and this combination has become known as RCHOP chemotherapy.
- Compounds of formulas (I), (II) and (III), as well as compounds disclosed in, for example, WO 05/111039, US2005/0256102, US2007/0185087, WO 08/021038, US2008/0045501, WO 08/063525, US2008/0167292, WO 07/113212, EP1644376, US2005/0032839, WO 05/005427, WO 06/070192, WO 06/070198, WO 06/070202, WO 06/070195, WO 06/003440, WO 05/002576, WO 05/002552, WO 04/071507, WO 04/058781, WO 06/055528, WO 06/055561, WO 05/118544, WO 05/013996, WO 06/036266, US2006/0160874, US2007/0142368, WO 04/043953, WO 07/132220, WO 07/132221, WO 07/132228, WO 04/00833 and WO 07/056164 are inhibitors of Aurora kinase. The compounds can be assayed in vitro or in vivo for their ability to bind to and/or inhibit an Aurora kinase. In vitro assays include assays to determine inhibition of the ability of an Aurora kinase to phosphorylate a substrate protein or peptide. Alternate in vitro assays quantitate the ability of the compound to bind to an Aurora kinase. Inhibitor binding may be measured by radiolabelling the inhibitor prior to binding, isolating the inhibitor/Aurora kinase complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding may be determined by running a competition experiment in which new inhibitors are incubated with Aurora kinase bound to a known radioligand. The compounds also can be assayed for their ability to affect cellular or physiological functions mediated by Aurora kinase activity. Assays for each of these activities are known in the art.
- In another aspect, therefore, the invention provides a method for inhibiting cellular growth/cellular proliferation comprising contacting a cell with an Aurora kinase inhibitor in combination with an anti-CD20 antibody, such as, e.g., rituximab. In an another embodiment, the invention provides a method for inhibiting cellular growth/cellular proliferation comprising contacting a cell with an Aurora kinase inhibitor in combination RCHOP chemotherapy.
- Preferably, the method according to the invention causes an inhibition of cell proliferation of the contacted cells. The phrase “inhibiting cell proliferation” is used to denote an ability of an inhibitor of Aurora kinase and/or anti-CD20 antibody to inhibit cell number or cell growth in contacted cells as compared to cells not contacted with the inhibitor and/or antibody. An assessment of cell proliferation can be made by counting cells using a cell counter or by an assay of cell viability, e.g., a BrdU, MTT, XTT, or WST assay. Where the cells are in a solid growth (e.g., a solid tumor or organ), such an assessment of cell proliferation can be made by measuring the growth, e.g., with calipers, and comparing the size of the growth of contacted cells with non-contacted cells.
- Preferably, the growth of cells contacted with an Aurora kinase inhibitor and an anti-CD20 antibody is retarded by at least about 50% as compared to growth of non-contacted cells. In various embodiments, cell proliferation of contacted cells is inhibited by at least about 75%, at least about 90%, or at least about 95% as compared to non-contacted cells. In some embodiments, the phrase “inhibiting cell proliferation” includes a reduction in the number of contacted cells, as compare to non-contacted cells. Thus, an inhibitor of Aurora kinase and/or an anti-CD20 antibody that inhibits cell proliferation in a contacted cell may induce the contacted cell to undergo growth retardation, to undergo growth arrest, to undergo programmed cell death (i.e., apoptosis), or to undergo necrotic cell death.
- In another aspect, the invention provides a pharmaceutical composition comprising i) an Aurora kinase inhibitor; and ii) an anti-CD20 antibody. In some embodiments the Aurora kinase inhibitor is selected from the group consisting of i) the compounds of formulas (I), (II) and (III); ii) the compounds disclosed in, for example, WO 05/111039, US2005/0256102, US2007/0185087, WO 08/021038, US2008/0045501, WO 08/063525, US2008/0167292, WO 07/113212, EP1644376, US2005/0032839, WO 05/005427, WO 06/070192, WO 06/070198, WO 06/070202, WO 06/070195, WO 06/003440, WO 05/002576, WO 05/002552, WO 04/071507, WO 04/058781, WO 06/055528, WO 06/055561, WO 05/118544, WO 05/013996, WO 06/036266, US2006/0160874, US2007/0142368, WO 04/043953, WO 07/132220, WO 07/132221, WO 07/132228, WO 04/00833 and WO 07/056164; and pharmaceutically acceptable salts thereof.
- If a pharmaceutically acceptable salt of the Aurora kinase inhibitor is utilized in these compositions, the salt preferably is derived from an inorganic or organic acid or base. For reviews of suitable salts, see, e.g., Berge et al, J. Pharm. Sci. 66:1-19 (1977) and Remington: The Science and Practice of Pharmacy, 20th Ed., ed. A. Gennaro, Lippincott Williams & Wilkins, 2000.
- Nonlimiting examples of suitable acid addition salts include the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, lucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenyl-propionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate.
- Suitable base addition salts include, without limitation, ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine, N-methyl-D-glucamine, t-butylamine, ethylene diamine, ethanolamine, and choline, and salts with amino acids such as arginine, lysine, and so forth.
- Also, basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
- The term “pharmaceutically acceptable carrier” is used herein to refer to a material that is compatible with a recipient subject, preferably a mammal, more preferably a human, and is suitable for delivering an active agent to the target site without terminating the activity of the agent. The toxicity or adverse effects, if any, associated with the carrier preferably are commensurate with a reasonable risk/benefit ratio for the intended use of the active agent.
- The terms “carrier”, “adjuvant”, or “vehicle” are used interchangeably herein, and include any and all solvents, diluents, and other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington: The Science and Practice of Pharmacy, 20th Ed., ed. A. Gennaro, Lippincott Williams & Wilkins, 2000 discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as disodium hydrogen phosphate, potassium hydrogen phosphate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium hydroxide and aluminum hydroxide, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, pyrogen-free water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose, sucrose, starches such as corn starch and potato starch, cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate, powdered tragacanth; malt, gelatin, talc, excipients such as cocoa butter and suppository waxes, oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil, glycols such as propylene glycol and polyethylene glycol, esters such as ethyl oleate and ethyl laurate, agar, alginic acid, isotonic saline, Ringer's solution, alcohols such as ethanol, isopropyl alcohol, hexadecyl alcohol, and glycerol, cyclodextrins, lubricants such as sodium lauryl sulfate and magnesium stearate, petroleum hydrocarbons such as mineral oil and petrolatum. Coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
- The pharmaceutical compositions of the invention can be manufactured by methods well known in the art such as conventional granulating, mixing, dissolving, encapsulating, lyophilizing, or emulsifying processes, among others. Compositions may be produced in various forms, including granules, precipitates, or particulates, powders, including freeze dried, rotary dried or spray dried powders, amorphous powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions. Formulations may optionally contain solvents, diluents, and other liquid vehicles, dispersion or suspension aids, surface active agents, pH modifiers, isotonic agents, thickening or emulsifying agents, stabilizers and preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- According to a preferred embodiment, the compositions of this invention are formulated for pharmaceutical administration to a mammal, preferably a human being. Such pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intravenously, or subcutaneously. The formulations of the invention may be designed to be short-acting, fast-releasing, or long-acting. Still further, compounds can be administered in a local rather than systemic means, such as administration (e.g., by injection) at a tumor site.
- Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, cyclodextrins, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use. Compositions formulated for parenteral administration may be injected by bolus injection or by timed push, or may be administered by continuous infusion.
- In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
- Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents such as phosphates or carbonates.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
- Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
- Formulation of an antibody or fragment to be administered will vary according to the route of administration and formulation (e.g., solution, emulsion, capsule) selected. An appropriate pharmaceutical composition comprising an antibody or functional fragment thereof to be administered can be prepared in a physiologically acceptable vehicle or carrier. A mixture of antibodies and/or fragments can also be used. For solutions or emulsions, suitable carriers include, for example, aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles can include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. A variety of appropriate aqueous carriers are known to the skilled artisan, including water, buffered water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol), dextrose solution and glycine. Intravenous vehicles can include various additives, preservatives, or fluid, nutrient or electrolyte replenishers (See, generally, Remington's Pharmaceutical Science, 16th Edition, Mack, Ed. 1980). The compositions can optionally contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents and toxicity adjusting agents, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride and sodium lactate. The antibodies and fragments of this invention can be lyophilized for storage and reconstituted in a suitable carrier prior to use according to art-known lyophilization and reconstitution techniques. The optimum concentration of the active ingredient(s) in the chosen medium can be determined empirically, according to procedures well known to the skilled artisan, and will depend on the ultimate pharmaceutical formulation desired. For inhalation, the antibody or fragment can be solubilized and loaded into a suitable dispenser for administration (e.g., an atomizer, nebulizer or pressurized aerosol dispenser).
- The antibody or fragment can be administered in a single dose or multiple doses. The dosage can be determined by methods known in the art and is dependent, for example, upon the antibody or fragment chosen, the subject's age, sensitivity and tolerance to drugs, and overall well-being. Antibodies and antigen-binding fragments thereof, such as human, humanized and chimeric antibodies and antigen-binding fragments can often be administered with less frequency than other types of therapeutics. For example, an effective amount of an antibody can range from about 0.01 mg/kg to about 5 or 10 mg/kg administered daily, weekly, biweekly or monthly.
- The present invention provides new combination therapies for the treatment of hematological malignancies. As used herein, the term “hematological malignancies” includes any malignancy associated with cells in the bloodstream; bone marrow; and the lymphoid system including in the liver, spleen, and lymph nodes. Nonlimiting examples of hematological malignancies include B and T cell lymphomas and leukemias. Nonlimiting examples of B and T cell lymphomas include, for example, low grade/follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, T or B prolymphocytic leukemia, diffuse large B cell NHL, peripheral T cell lymphomas, mantle cell lymphoma, marginal zone lymphomas, B or T cell lymphoblastic lymphoma, Burkitt's lymphoma, primary thyroid lymphoma, Waldenstrom's Macroglobulinemia or lymphoplasmacytic lymphoma. Nonlimiting examples of leukemia include, for example, chronic leukocytic leukemia, acute myelogenous leukemia (AML), acute lymphoblastic leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia, lymphoblastic leukemia, lymphocytic leukemia, monocytic leukemia, myelogenous leukemia and promyelocytic leukemia. Nonlimiting examples of hematological malignancies additionally include, for example, multiple myeloma, myelodysplastic syndromes (MDS), including refractory anemia (RA), refractory anemia with ringed siderblasts (RARS), (refractory anemia with excess blasts (RAEB), and RAEB in transformation (RAEB-T); and myeloproliferative syndromes. It should be clear to those of skill in the art that these pathological conditions may often have different names due to differing/changing classification systems.
- In some embodiments, the hematological malignancy to be treated by the method of the invention is one in which the activity of an Aurora kinase is amplified and in which the CD20 antigen is expressed. In some embodiments, the hematological malignancy is selected from the group consisting of lymphoma, leukemia and multiple myeloma. In certain embodiments, the lymphoma is selected from the group consisting of B cell lymphoma, non-Hodgkin's lymphoma and mantle cell lymphoma.
- The term “patient”, as used herein, means an animal, preferably a mammal, more preferably a human. In some embodiments, the patient has been treated with an agent, e.g., an Aurora kinase inhibitor or an anti-CD20 antibody, prior to initiation of treatment according to the method of the invention. In some embodiments, the patient is a patient at risk of developing or experiencing a recurrence of a hematological malignancy.
- The expression “therapeutically effective amount” refers to an amount of a drug substance (e.g., Aurora kinase inhibitor and/or anti-CD20 antibody) effective for treatment or prophylaxis or amelioration of symptoms of a hematological malignancy discussed herein.
- Compositions for use in the method of the invention may be formulated in unit dosage form for ease of administration and uniformity of dosage. The expression “unit dosage form” as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. A unit dosage form for parenteral administration may be in ampoules or in multi-dose containers.
- The Aurora kinase inhibitor may be administered with the anti-CD20 antibody in a single dosage form or as a separate dosage form. When administered as a separate dosage form, the anti-CD20 antibody may be administered prior to, at the same time as, or following administration of the Aurora kinase inhibitor of the invention.
- As specifically contemplated herein, the instant invention includes the following methods: A method to treat a patient suffering from a hematological malignancy comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g., before or after) an anti-CD20 antibody; A method to treat a patient suffering from a hematological malignancy comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g. before or after) rituximab; A method to treat a patient suffering from lymphoma comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g. before or after) an anti-CD20 antibody; A method to treat a patient suffering from lymphoma comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g. before or after) rituximab; A method to treat a patient suffering from leukemia comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g. before or after) an anti-CD20 antibody; A method to treat a patient suffering from leukemia comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g. before or after) rituximab; A method to treat a patient suffering from multiple myeloma comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g. before or after) an anti-CD20 antibody; and A method to treat a patient suffering from multiple myeloma comprising administering to said patient a therapeutically effective amount of a Aurora kinase inhibitor simultaneously with or consecutively with (e.g. before or after) rituximab.
- In some particular embodiments, the method of the invention comprises administering to a patient suffering from a hematological malignancy a therapeutically effective amount of an Aurora kinase inhibitor of Formula (I), (II) or (III) as defined herein simultaneously with or consecutively with (e.g., before or after) rituximab.
- Additionally, the invention relates to use of an Aurora kinase inhibitor for the manufacture of a medicament for the treatment of a hematological malignancy. In other particular embodiments, the invention relates to the use of an Aurora kinase inhibitor of Formula (I), (II) or (III) as defined herein, in the manufacture of a medicament for use in combination therapy with rituximab for the treatment of a hematological malignancy.
- Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices and materials are herein described. All publications mentioned herein are hereby incorporated by reference in their entirety for the purpose of describing and disclosing the materials and methodologies that are reported in the publication which might be used in connection with the invention.
- ANOVA Analysis of variance
- ΔAUC difference in the area under the curve
- BID twice daily
- DLBCL diffuse large B-cell lymphoma
- IV intravenous(ly)
- MTD maximum tolerated dose
- SCID severe combined immunodeficiency
- po. Orally (by mouth, per os)
- QD once daily
- QW or Q7D once weekly
- SC subcutaneous(ly)
- TG treatment group
- TGI tumor growth inhibition
- The Ly19-Luc, WSU-DLBCL2-Luc and PHTX-22-06 models described in these studies are human DLBCL cell lines, transfected with luciferase. These models were grown in immunocompromised mice subcutaneously on the flank, or disseminated throughout the body by tail vain injection. 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid (III-1) was administered orally in both daily and twice daily dosing regimens and rituximab was administered by IV injection QD7×3. The efficacy, tumor growth and post-treatment survival of mice treated with Compound III-1 and rituximab were compared as single agents or in combination.
- This is an in vivo experiment looking at tumor volume after treatment with the combination of Compound III-1 and rituximab. Tumor growth was monitored with vernier calipers. The mean tumor volume was calculated using the formula V=W2×L/2. When the mean tumor volume reached approximately 200 mm3, the animals were randomized into the following eight treatment groups, with each cohort made up of ten mice:
- Vehicle
- 3 mg/kg Compound III-1 (qd)
- 10 mg/kg Compound III-1 (qd)
- 10 mg/kg Compound III-1 (bid)
- 10 mg/kg rituximab (qw)
- 3 mg/kg Compound III-1 (qd)+10 mg/kg rituximab (qw)
- 10 mg/kg Compound III-1 (qd)+10 mg/kg rituximab (qw)
- 10 mg/kg Compound III-1 (bid)+10 mg/kg rituximab (qw)
- The animals were inoculated with 4.0×106 cells from cell line Ly-19 at implant site Flank (cell suspension). Compounds were administered for 21 days, and tumor volumes were measured on days 0, 5, 13, 15, 18, and 21. After treatment ended, the surviving mice continued to be evaluated on days 25, 28, 33, 36, 40, 43, 47, 50, 54, 60, and 62.
- There were several endpoints in this experiment. The primary goal was to determine whether the combination of Compound III-1 and rituximab was more effective at reducing tumor volume than either treatment alone. The second endpoint was to evaluate the rates of tumor regrowth among the groups after treatment was completed.
- Statistical analysis was performed using a linear mixed effects regression model. This model takes into account the differences in trends of tumor growth between control and treated samples. The statistical modeling was conducted in two steps: model fitting and model selection. In the first step, a family of ten closely related mixed-effects regression models was fitted to the study data. Data from all time points in the study were used, including mice that were sacrificed before the end of the study. Each treatment group was fitted to a quadratic trend line for tumor growth that consisted of up to three terms for tumor growth: zero-order (intercept), first-order (slope) and second-order (curvature). Each drug treatment was then modeled by up to two interaction terms, one describing the difference in slope and the other describing the difference in curvature due to drug treatments. In addition, mouse-specific variability was accounted for by including random effects for each mouse with up to three terms: a mouse-specific intercept, slope or curvature effect. Repeated measurements of tumor growth for a given mouse were modeled using a compound symmetry covariance structure.
- Model selection was performed by first filtering models that the model-fitting algorithm was unable to fit in a numerically stable way (specifically by removing models that demonstrated sensitivity to the starting value of the autocorrelation coefficient, and those for whom the variance-covariance matrix of random effects was not positive definite). The best fit model was then selected using a statistical criterion called the Bayes Information Criterion (BIC), which is a measure of a model's goodness of fit that takes into account the number of parameters used by the model and the magnitude of the residuals—the difference between fitted and observed values. The BIC favors models that are parsimonious and that fit the underlying data well.
- The model fitting and selection procedure were performed twice, once on the original (untransformed) data, and once on log10-transformed data. Once the automated model-fitting and selection procedure were completed, two best-fit models were generated, one on log-transformed data and the other on untransformed data. An investigator then studied the diagnostic plots generated by the two statistical models and chose one of them as the appropriate model for the study. This choice was made on the basis of the distribution of the residuals as well as their behavior with respect to the fitted values. Obvious trends in the residuals were indicative of a poor model fit, suggesting trends remaining in the data that the model had failed to take into account.
- Once an appropriate statistical model was selected, the effect size was calculated as the difference between areas under the model-fitted curves (ΔAUC) for treated and control groups, relative to the area under the model-fitted curve for the control group. A ΔAUC of 0 meant that the curves for the treatment and control groups were the same, whereas a negative ΔAUC indicated tumor growth inhibition upon treatment.
- The significance of an effect size for a given pairwise comparison was assessed using permutation analysis. During this procedure, the assignment of mice to treatment and control groups were randomly shuffled. The ΔAUC metric was calculated for comparisons between these new simulated groups, and the process was repeated ˜2000 times. This gave rise to an empirical distribution of the ΔAUC values for the null hypothesis, which stated that there was no difference in ΔAUC values between treatment and control groups. The reported p-value was the proportion of permuted ΔAUC values which were greater than the ΔAUC of the original group assignments. P-values<0.05 were considered significant.
- For combination studies a synergy measure was also reported (in addition to the measures of tumor growth inhibition for each arm of the trial relative to control). For the synergy measure, the approach and the results described here were essentially equivalent, except that effect size was defined differently and permutation testing was performed over four groups rather than two. The effect size for combinations was defined as: ΔAUC=[AUCA×B-AUCctl-(AUCA-AUCctl+AUCB-AUCctl)]/AUCctl (where A×B is the combination treatment, ctl is the control, and A and B are the agents used singly). A ΔAUC of less than zero meant that a combination treatment led to a greater decrease in area under the curve than the sum of individual treatments, indicating a synergistic tumor growth inhibition. Permutation testing was performed to compare the difference between control and combination treatment against the difference that would have been observed if the treatments were purely additive. Synergy measures disclosed herein are provided based on ΔAUC calculations and based on TGI calculations. Because ΔAUC calculations capture the entire treatment period within an experiment, such calculations are deemed more comprehensive and more accurate than the TGI calculations.
- In this study, all animals in all of the treatment groups endured the 21 days of treatment.
- The average tumor volume in the vehicle group increased almost sixteen fold from 180 mm3 at day 0 to over 2850 mm3 on day 21, and this resulted in a mean area under the log(fold change) over time curve (AUC) of 12.9. The AUCs, and therefore the tumor volumes, were smaller in each of the treatment groups compared to vehicle (Table 3a). The results of the linear regression model revealed that all of these differences relative to the vehicle group were significant (Table 3b).
-
TABLE 3a Efficacy Analysis (Days 0 through 21) Average percent change in the area under the log10 fold change vs day curves (AUC) relative to the mean AUC of the vehicle group. Pct Decrease in AUC Relative to Mean Vehicle Treatment AUC Vehicle — Compound III-1 (3 mg/kg qd) 22.9 Compound III-1 (10 mg/kg qd) 79.3 Compound III-1 (10 mg/kg bid) 105.6 Rituximab (10 mg/kg) 71.8 Compound III-1 (3 mg/kg qd) + Rituximab 130.0 (10 mg/kg) Compound III-1 (10 mg/kg qd) + Rituximab 151.4 (10 mg/kg) Compound III-1 (10 mg/kg bid) + Rituximab 186.2 (10 mg/kg) -
TABLE 3b Efficacy Analysis (Days 0 through 21) Treatment Group Reference P-value Compound III-1 (3 mg/kg qd) Vehicle <0.01 Compound III-1 (10 mg/kg qd) <0.01 Compound III-1 (10 mg/kg bid) <0.01 Rituximab (10 mg/kg) <0.01 Compound III-1 (3 mg/kg qd) + Rituximab <0.01 (10 mg/kg) Compound III-1 (10 mg/kg qd) + Rituximab <0.01 (10 mg/kg) Compound III-1 (10 mg/kg bid) + Rituximab <0.01 (10 mg/kg) Compound III-1 (3 mg/kg) + Compound III-1 <0.01 Rituximab (10 mg/kg) (3 mg/kg) Rituximab <0.01 (10 mg/kg) Compound III-1 (10 mg/kg qd) + Rituximab Compound III-1 <0.01 (10 mg/kg) (10 mg/kg qd) Rituximab <0.01 (10 mg/kg) Compound III-1 (10 mg/kg bid) + Rituximab Compound III-1 <0.01 (10 mg/kg) (10 mg/kg bid) Rituximab <0.01 (10 mg/kg) - The three combination groups showed consistent decreases in tumor volume and were all significantly lower than their respective single agents alone. The Compound III-1 (3 mg/kg qd)+rituximab (10 mg/kg) group was synergistic, while the other two combinations were additive when examining AUC values (Table 4). All three combinations were sub-additive when looking at tumor growth inhibition (Table 5, Table 6).
-
TABLE 4 Synergy Analysis (AUC, Days 0 through 21) Synergistic: score <0, Additive: score = 0, Sub-additive: score >0. Assessment based on whether 95% confidence interval included the value 0. Synergy 95% Confidence Combination Score Interval Assessment Compound III-1 −0.35 (−0.55, −0.15) Synergistic (3 mg/kg qd) + Rituximab (10 mg/kg) Compound III-1 0.00 (−0.19, 0.18) Additive (10 mg/kg qd) + Rituximab (10 mg/kg) Compound III-1 −0.09 (−0.32, 0.14) Additive (10 mg/kg bid) + Rituximab (10 mg/kg) -
TABLE 5 Tumor Growth Inhibition (Day 21) Average percent decrease in tumor growth relative to the mean tumor volume of the vehicle group. Pct Tumor Growth Inhibition Relative Treatment to Vehicle Mean Vehicle — Compound III-1 (3 mg/kg qd) 54.7 Compound III-1 (10 mg/kg qd) 97.1 Compound III-1 (10 mg/kg bid) 102.2 Rituximab (10 mg/kg) 94.5 Compound III-1 (3 mg/kg qd) + Rituximab 103.7 (10 mg/kg) Compound III-1 (10 mg/kg qd) + Rituximab 105.3 (10 mg/kg) Compound III-1 (10 mg/kg bid) + Rituximab 105.8 (10 mg/kg) -
TABLE 6 Synergy Analysis (Tumor Growth Inhibition, Day 21 Synergistic: score <0, Additive: score = 0, Sub-additive: score >0. Assessment based on whether 95% confidence interval included the value 0. Synergy 95% Confidence Combination Score Interval Assessment Compound III-1 0.46 (0.35, 0.56) Sub-Additive (3 mg/kg qd) + Rituximab (10 mg/kg) Compound III-1 0.86 (0.81, 0.91) Sub-Additive (10 mg/kg qd) + Rituximab (10 mg/kg) Compound III-1 0.91 (0.86, 0.96) Sub-Additive (10 mg/kg bid) + Rituximab (10 mg/kg) - To determine if tumors began to regrow after treatment ended, mixed-effects piecewise linear regression models were built to compare the slope of the log tumor volume between days 9 and day 21 to the slope between days 21 and 62 (or earlier if all animals in a group died). All of the examined groups showed increases in slope after treatment which were at least marginally significant (Table 7), suggesting that tumor volumes stopped shrinking or, in the cases of Compound III-1 (10 mg/kg qd) and rituximab (10 mg/kg), began to grow again.
-
TABLE 7 Difference in Tumor Growth Rates Breakpoint was set at day 21. Change in slope was calculated as slope (day 21 to 62) − slope (day 13 to 21). P-values <0.05 indicate that the difference in slope was significantly different than zero. Change in Treatment Group Slope P-value Compound III-1 (10 mg/kg qd) 0.040 0.05 Compound III-1 (10 mg/kg bid) 0.018 <0.01 Rituximab (10 mg/kg) 0.039 <0.01 Compound III-1 (3 mg/kg qd) + Rituximab 0.012 0.02 (10 mg/kg) Compound III-1 (10 mg/kg qd) + Rituximab 0.053 <0.01 (10 mg/kg) Compound III-1 (10 mg/kg bid) + Rituximab 0.091 <0.01 (10 mg/kg) - The effects of Compound III-1 in combination with rituximab upon tumor volumes were investigated in an in vivo sub-cutaneous xenograft study. 3 mg/kg Compound III-1 dosed qd, 10 mg/kg Compound III-1 dosed qd, and 10 mg/kg Compound III-1 dosed bid were administered as both single agents and in combination with 10 mg/kg of rituximab. All treatment groups had significantly lower mean areas under the log(fold change) vs time curves relative to the vehicle group during the first 21 days. Additionally, the mean AUC of the 3 mg/kg Compound III-1+rituximab combination group was significantly lower than that for the respective individual treatment groups. Surprisingly, the combination of Compound III-1 with rituximab was demonstrated to have a synergistic therapeutic effect in this sub-cutaneous lymphoma model. Once treatment was completed, tumor volumes ceased to continue diminishing, and in some cases began to regrow.
- This is an in vivo experiment looking at tumor volume after treatment with the combination of Compound III-1 and rituximab. Tumor growth was monitored with vernier calipers. The mean tumor volume was calculated using the formula V=W2×L/2. When the mean tumor volume reached approximately 250 mm3, the animals were randomized into the following six treatment groups, with each group made up of ten mice:
- Vehicle
- 3 mg/kg Compound III-1 (P.O., qd)
- 10 mg/kg Compound III-1 (P.O., qd)
- 10 mg/kg rituximab (I.V., q7d)
- 3 mg/kg Compound III-1+10 mg/kg rituximab
- 10 mg/kg Compound III-1+10 mg/kg rituximab
- The animals were inoculated with 4.0×106 cells from cell line WSU-DLCL2 at implant site Flank (cell suspension). Compounds were administered for 21 days, and tumor volumes were measured on days 0, 4, 7, 11, 15, 18, and 20. The primary goal was to investigate whether the combination of Compound III-1 and Rituximab was synergistic.
- The statistical methodology used in these experiments was the same as that described in Example 1 above.
- The average tumor volume in the vehicle group increased over nine-fold from 201 mm3 at day 0 to 1903 mm3 on day 20. The tumor volumes were smaller in each of the treatment groups compared to vehicle (Table 8).
-
TABLE 8 Efficacy Analysis (Days 0 through 20) Average percent change in the area under the log10 fold change vs day curves (AUC) relative to the mean AUC of the vehicle group. Pct Decrease in AUC Relative to Treatment Mean Vehicle AUC Vehicle — Compound III-1 (3 mg/kg, PO, qd) 19.4 Compound III-1 (10 mg/kg, PO, 48.5 qd) Rituximab (10 mg/kg, IV, q7d) 43.2 Compound III-1 (3 mg/kg) + 60.5 Rituximab (10 mg/kg, IV, q7d) Compound III-1 (10 mg/kg) + 86.6 Rituximab (10 mg/kg, IV, q7d) - Both combination groups were additive relative to their respective individual treatments when comparing AUC values (Table 9).
-
TABLE 9 Synergy Analysis of AUC values (Days 0 through 20) Synergistic: score <0, Additive: score = 0, Sub-additive: score >0. Assessment based on whether 95% confidence interval included the value 0 Approx. 95% Synergy Confidence Combination Score Interval Assessment Compound III-1 (3 mg/kg) + 0.02 (−0.12, 0.16) Additive Rituximab (10 mg/kg, IV, q7d) Compound III-1 (10 mg/kg) + 0.05 (−0.08, 0.18) Additive Rituximab (10 mg/kg, IV, q7d) - Both treatment groups were sub-additive when looking at tumor growth inhibition (Table 10, and Table 11).
-
TABLE 10 Tumor Growth Inhibition (Day 20) Average percent decrease in tumor growth relative to the mean tumor volume of the vehicle group. Pct Tumor Growth Inhibition Treatment Relative to Vehicle Mean Vehicle — Compound III-1 (3 mg/kg, PO, qd) 33.1 Compound III-1 (10 mg/kg, PO, qd) 68.9 Rituximab (10 mg/kg, IV, q7d) 67.1 Compound III-1 (3 mg/kg) + Rituximab 78.5 (10 mg/kg, IV, q7d) Compound III-1 (10 mg/kg) + Rituximab 95.5 (10 mg/kg, IV, q7d) -
TABLE 11 Synergy Analysis of Tumor Growth Inhibition (Day 20) Synergistic: score <0, Additive: score = 0, Sub-additive: score >0. Assessment based on whether 95% confidence interval included the value 0. Synergy Approx. 95% Combination Score Confidence Interval Assessment Compound (3 mg/kg) + 0.21 (0.08, 0.35) Sub-Additive Rituximab (10 mg/kg, IV, q7d) Compound (10 mg/kg) + 0.40 (0.30, 0.51) Sub-Additive Rituximab (10 mg/kg, IV, q7d) - The effects of Compound III-1 in combination with rituximab upon tumor volumes were investigated in an in vivo sub-cutaneous xenograft study. 3 mg/kg and 10 mg/kg Compound III-1, dosed PO and qd, and 10 mg/kg rituximab, dosed IV and q7d, were administered as both single agents and in combination. Neither combination group showed a synergistic interaction relative to their respective single agents when looking at AUC or tumor growth inhibition.
- This is an in vivo experiment looking at tumor volume after treatment with the combination of Compound III-1, and rituximab. Tumor growth was monitored with vernier calipers. The mean tumor volume was calculated using the formula V=W2×L/2. When the mean tumor volume reached approximately 200 mm3, the animals were randomized into the following six treatment groups, with each group made up of ten mice:
- Vehicle
- 10 mg/kg Compound III-1 (P.O., bid)
- 20 mg/kg Compound III-1 (P.O., bid)
- 10 mg/kg rituximab (I.V., q7d)
- 10 mg/kg Compound III-1+10 mg/kg rituximab
- 20 mg/kg Compound III-1+10 mg/kg rituximab
- The animals were inoculated with 2×5 mm3 tumor mass from primary PHTX-22L-6 tumor chunk at implant site Flank (trocar). Compounds were administered for 21 days, and tumor volumes taken on days 0, 3, 7, 10, 14, 17, 21, 24, and 27 were analyzed. The primary goal was to investigate whether the combination of Compound III-1 and rituximab was synergistic.
- The statistical methodology used in these experiments was the same as that described in Example 1 above.
- The average tumor volume in the vehicle group increased over nine-fold from 268 mm3 at day 0 to 2563 mm3 on day 27. The tumor volumes were smaller in each of the treatment groups compared to vehicle (Table 12).
-
TABLE 12 Efficacy Analysis (Days 0 through 27) Average percent change in the area under the log10 fold change vs day curves (AUC) relative to the mean AUC of the vehicle group. Pct Decrease in AUC Relative Treatment to Mean Vehicle AUC Vehicle — Compound III-1 (10 mg/kg, PO, bid) 52.3 Compound III-1 (20 mg/kg, PO, bid) 79.3 Rituximab (10 mg/kg, IV, q7d) 41.9 Compound III-1 (10 mg/kg) + Rituximab 75.8 (10 mg/kg, IV, q7d) Compound III-1 (20 mg/kg) + Rituximab 146.8 (10 mg/kg, IV, q7d) - Both combinations groups were additive relative to their respective individual treatments when comparing AUC values (Table 13).
-
TABLE 13 Synergy Analysis of AUC values (Days 0 through 27) Synergistic: score <0, Additive: score = 0, Sub-additive: score >0. Assessment based on whether 95% confidence interval included the value 0. Approx. 95% Synergy Confidence Combination Score Interval Assessment Compound III-1 (3 mg/kg) + 0.18 (−0.05, 0.42) Additive Rituximab (10 mg/kg, IV, q7d) Compound III-1 (10 mg/kg) + −0.26 (−0.80, 0.29) Additive Rituximab (10 mg/kg, IV, q7d) - Both treatment groups were sub-additive when looking at tumor growth inhibition (Table 14, and Table 15).
-
TABLE 14 Tumor Growth Inhibition (Days 0 through 27) Average percent decrease in tumor growth relative to the mean tumor volume of the vehicle group. Pct Tumor Growth Inhibition Treatment Relative to Vehicle Mean Vehicle — Compound III-1 (10 mg/kg, PO, bid) 86.3 Compound III-1 (20 mg/kg, PO, bid) 95.1 Rituximab (10 mg/kg, IV, q7d) 57.3 Compound III-1 (10 mg/kg) + Rituximab 97.3 (10 mg/kg, IV, q7d) Compound III-1 (20 mg/kg) + Rituximab 105.1 (10 mg/kg, IV, q7d) -
TABLE 15 Synergy Analysis of Tumor Growth Inhibition (Days 0 through 27) Synergistic: score <0, Additive: score = 0, Sub-additive: score >0. Assessment based on whether 95% confidence interval included the value 0. Approx. 95% Synergy Confidence Combination Score Interval Assessment Compound III-1 (10 mg/kg) + 0.46 (0.26, 0.67) Sub- Rituximab (10 mg/kg, Additive IV, q7d) Compound III-1 (20 mg/kg) + 0.47 (0.27, 0.68) Sub- Rituximab (10 mg/kg, Additive IV, q7d) - The effects of Compound III-1 in combination with rituximab upon tumor volumes were investigated in an in vivo sub-cutaneous xenograft study. 10 mg/kg and 20 mg/kg Compound III-1, dosed PO and bid, and 10 mg/kg rituximab, dosed IV and q7d, were administered as both single agents and in combination. Neither combination examined showed a synergistic interaction relative to their respective single agents when looking at AUC or tumor growth inhibition, which may be attributable to the significant single agent activity observed in this model.
- The in vivo experiments using the disseminated Ly19-Luc lymphoma model were performed in duplicate. The experiments consisted of looking at tumor volume after treatment with the combination of Compound III-1 and rituximab. Tumor volumes were estimated once weekly throughout the inoculation and treatment period using the Xenogen IVIS® imaging system (Xenogen Corporation, Alameda, Calif.). To image the mice, an intraperitoneal (IP) injection of luciferase (15 mg/ml), was administered 10 minutes prior to procedure and mice were anesthetized with 2% isofluorane 2-5 minutes throughout the scanning procedure. For Xenogen imaging, each mouse was imaged on dorsal and ventral views. The sum of 2 photon flux measurements was used for the analysis.
- The antitumor effects of each treatment group were determined by calculating the percent TGI([Δ control mean tumor volume−4 treated mean tumor volume]×100/Δ control mean tumor volume) at the end of treatment. Mice were weighed once weekly for the duration of the study and the maximal percent body weight change was determined during the treatment period. Animals were monitored for survival up to 132 days following treatment. Animals were removed from the study when they reached humane endpoints (>20%, body weight loss or paralysis of either both front or hind limbs), the medial survival for each group was determined and the survival rate of treatment groups were compared to control. Treatment groups were evaluated to determine if the effects of combination treatment were synergistic, additive or sub-additive relative to control.
- Tumor Growth Inhibition (TGI):
- The photon flux data was log10 transformed, and these values over the treatment period were compared across treatment groups to assess if the differences in the trends over time were statistically significant. A mixed-effects linear regression model using a restricted maximum likelihood was fit to the data. An ANOVA test was performed to determine if there was a statistically significant difference between the treatment groups and control.
- Area Under the Curve (AUC):
- Log10-transformed fold change photon flux values (tumor burden) from baseline were also used to calculate AUC values for each animal. The AUC values from the mice in a given treatment group were then averaged together to generate mean AUC values and associated standard errors.
- Synergy Effects:
- A synergy score calculation was used to address the question of whether the effects of the combination treatment were synergistic, additive, or sub-additive relative to the individual treatments. The effect of the combination treatment was considered synergistic if the synergy score was less than 0, additive if the synergy score equaled 0, and sub-additive if the synergy score was greater than 0. Standard errors and 95% confidence intervals (calculated as 2*SE) were used to determine if the synergy scores were significantly different from zero.
- Tumor Regrowth:
- To compare the tumor regrowth rates after stopping treatment, mixed-effects piecewise linear regression models were built separately for each treatment group with mice monitored beyond treatment period. All P-values <0.05 were called significant in this report.
- Survival Rate:
- The survival rates of the animals in each treatment group were plotted using Kaplan-Meier curves and the log rank test was used to compare survival rates among pairs of treatment groups.
- Animals bearing Ly19-Luc xenografts were treated with Compound III-1 and rituximab as single agents and in combination. The TGI, calculated on Day 24 was similar between treatment groups (89.6%-100.3%). Tumor growth was significantly inhibited in all single agent and combination treatment groups compared to vehicle (p<0.001, Table 16).
-
TABLE 16 Dosing regimen for mice in first disseminated Ly19 experimental group Maximum Survival Percent Body TGI Median Study/ Dose Route and Weight Change Meanc p Survival p Treatment Groupa (mg/kg) b Dose Regimen (%) (%) Valued (Days) Valuee Vehicle 0 Po/QD × 21 days −5.9, Day 24 N/A N/A 25 N/A Compound III-1 3 Po/QD × 21 days +6.2, Day 24 89.6, Day 24 <0.001 40 <0.001 Compound III-1 10 Po/QD × 21 days +3.3, Day 24 100, Day 24 <0.001 63.5 <0.001 Compound III-1 3 po/QD × 21 days +8.7, Day 24 100, Day 24 <0.001 >100 <0.001* Rituximab 10 IV/QW × 3 doses Compound III-1 10 po/QD × 21 days +4.5, Day 24 100.3, Day 24 <0.001 >100 <0.001* Rituximab 10 IV/QW × 3 doses Rituximab 10 IV/QW × 3 doses +9.4, Day 24 99.6, Day 24 <0.001 66 <0.001 aThere were 10 mice in each treatment group. b For each dose, mice received 100 μL of Compound III-1 and/or rituximab dosing solution prepared at 0.75, 2.5, 5.0 and 7.5 mg/mL (3, 10, 20, 30 mg/kg Compound III-1) or 2.0 mg/mL (10 mg/kg rituximab). These dosing solutions were prepared routinely based on historical mouse body weights of 25 or 20 grams respectively. All doses were approximate. cMean tumor volumes, and TGI values were calculated on Day 24 of treatment. dTGI = TGI calculation B − tumor growth inhibition (TGI = [(Δ control average volume − Δ treated average volume) × 100/Δ control average volume]. p values were calculated with an ANOVA, p < 0.05 considered statistically significant. TGI values will be greater than 100% when the average volume of the treatment group is smaller at the end of treatment than at the beginning of treatment eLog-rank analysis was used to compare the survival rate of each treatment group to the vehicle group test, p < 0.05 considered statistically significant. *= Combination treatment groups had significantly longer survival than the corresponding individual treatment groups (p ≦ 0.004). fAnimals dosed with Compound III-1 at 10 mg/kg BID and 30 mg/kg QD received a 5 day dose holiday from Day 13 to Day 17. gThe vehicle used in TG1 and the treatment groups was 10% HP-β-CD plus 1% NaHCO3. The vehicle used in the rituximab treatment groups was 0.9% saline - Individual whole body bioluminescence images were taken of all mice in all treatment groups using the Xenogen IVIS® imaging system. Any bioluminescense observed in these whole body images represents tumor presence in the mouse model. Tumor presence/growth in each mouse was assessed using this system prior to treatment on Day 0; after the end of treatment on Day 24; and of mice remaining in the study on Day 52. On Day 24 there is a striking reduction in the fluorescent signal of the tumor as a result of treatment with Compound III-1 at 10 mg/kg, with the combination Compound III-1 at 3 mg/kg with rituximab and with the combination Compound III-1 at 10 mg/kg with rituximab. Mice receiving combination treatments show little or no evidence of the disseminated lymphoma tumor. At Day 52 however, tumor growth was evident in the mice remaining in the single agent Compound III-1 10 mg/kg and rituximab 10 mg/kg groups.
- Photon flux values (tumor burden) from baseline to Day 24 were also used to calculate AUC values for each animal and the percent decrease in the AUC relative to the mean vehicle AUC was calculated (Table 17a). A synergy score calculation was applied to the AUC data to determine whether the effects of the combination treatment were synergistic, additive or sub-additive relative to the individual treatments. This analysis showed that the combination treatment of Compound III-1 at 3 mg/kg QD with rituximab at 10 mg/kg QW was synergistic when comparing the log10-transformed fold changes and the combination treatment of Compound III-1 at 10 mg/kg with rituximab at 10 mg/kg QW displayed an additive effect (Table 17b).
-
TABLE 17a Average percent change in the area under the log10 fold change versus day curves (AUC) relative to the mean AUC of the vehicle group for each treatment group. Values greater than 100 indicate decreased tumor burden. Percent Decrease in AUC Treatment Relative to Mean Vehicle AUC Vehicle N/A Compound III-1 (3 mg/kg-QD) 59.3 Compound III-1 (10 mg/kg-QD) 108.2 Rituximab (10 mg/kg-QW) 103.3 Compound III-1 (3 mg/kg) + 121.2 Rituximab (10 mg/kg) Compound III-1 (10 mg/kg) + 121.4 Rituximab (10 mg/kg) -
TABLE 17b Synergistic: score <0, Additive: score = 0, Sub-Additive: score >0. Assessment based on whether 95% confidence interval included the value 0. Synergy 95% Confidence Combination Score Interval Assessment Compound III-1 (3 mg/kg) + −25.5 (−35.9, −15.0) Synergistic Rituximab (10 mg/kg) Compound III-1 (10 mg/kg) + −4.3 (−11.5, 2.9) Additive Rituximab (10 mg/kg) - All vehicle treated mice reached the pre-defined endpoint of paralysis and were euthanized between Day 21 and Day 31, however all mice in the two combination treatment groups were alive up to Day 132. By the end of the study (Day 132), the number of mice remaining in the single agent Compound III-13 mg/kg, Compound III-1 10 mg/kg and rituximab 10 mg/kg groups was 1 out of 10, 3 out of 10 and 1 out of 10 respectively. The median survival in days for each group is presented in Table 18. Log rank analysis, conducted to compare the survival rates between groups, showed that all treatment groups had significantly longer survival than the vehicle group, and all combination groups had significantly longer survival than each of the individual treatments (Table 16). Table 16 also shows the mean maximum body weight change of the groups from Day 0 to Day 24. The maximum body weight loss for vehicle group was 5.9% on Day 24. All other treatment groups gained weight during the study, including the single agent and combination agent groups. Treatment with Compound III-1 at 3 or 10 mg/kg on a QD schedule or rituximab at 10 mg/kg on a QW schedule was well tolerated.
-
TABLE 18 Method of Study/Cell Dose Administration/ Noteworthy Line/Treatment (mg/kg) Frequency Endpoints Findings Ly19-Luc 0 po/QD × 21 days TGIa N/A Vehicle (10% HP-β-CD Median Survival (Days) 25 plus 1% NaHCO3) BW changeb −5.9, Day 24 Compound III-1 3 po/QD × 21 days TGI 89.6, p < 0.001 Median Survival (Days) 40, p < 0.01c BW change +6.2, Day 24 Compound III-1 10 po/QD × 21 days TGI 100, p < 0.001 Median Survival (Days) 63.5, p < 0.01 BW change +3.3%, Day 24 Compound III-1 + 3 po/QD × 21 days TGI 100, p < 0.001 Rituximab 10 IV/QW × 3 doses Median Survival (Days) >100, p < 0.01 BW change +8.7%, Day 24 Compound III-1 + 10 po/QD × 21 days TGI 100.3, p < 0.001 Rituximab 10 IV/QW × 3 doses Median Survival (Days) >100, p < 0.01 BW change +4.5%, Day 24 Rituximab 10 IV/QW × 3 doses TGI 99.6, p < 0.001 Median Survival (Days) 66, p < 0.01 BW change +9.4%, Day 24 aTGI was calculated on Day 24, p values were calculated using a one-way ANOVA with p < 0.05 considered statistically significant bMaximum body-weight change. cLog-rank analysis was used to compare the survival rate of each treatment group to the vehicle group, p < 0.05 considered statistically significant, - Mice were dosed according to the following treatment groups:
-
TABLE 19 Dosing regimen for mice in second disseminated Ly19 experimental group. Dose Dose Animals/ Dose Dose Dose Solution Volume Group Test Article group Route (mg/kg) Regimen (mg/ml) (ml) 1 Vehicle 10 PO 0 QD 100 2 Compound III-1 10 PO 3 QD 0.75 100 3 Compound III-1 + 10 PO/IV 3/10 QD/ 0.75/2.5 100 Rituximab Q7D × 3 4 Rituximab 10 IV 10 Q7D × 3 2.5 100 5 Rituximab 10 IV 5 Q7D × 3 1.25 100 6 Rituximab 10 IV 1 Q7D × 3 0.25 100 7 Rituximab 10 IV 0.5 Q7D × 3 0.025 100 - Mice were weighed and tumor volumes were estimated with Xenogen signal (average photon flux) calculation once a week throughout the inoculation and the treatment period and after the treatment until the end of study.
- Treatment started 7 days following the inoculation of tumor cells into the tail vein, with an average photon flux measurement of 1×107 on treatment Day 0. The TGI, calculated on Day 23 (2 days post dose) was similar between treatment groups (75.8-100%). Tumor growth was significantly inhibited (P<0.001) in all groups including the single agents (Compound III-1 or rituximab) the combination of Compound III-1+rituximab treatment group when compared to control (Table 20).
-
TABLE 20 Mean Group/ Dose Route & Photon Flux TGI Test Article (mg/kg) N Schedule (Day 23) Day 23 P-value Group 1/ — 10 PO QD × 3 wks 1.84E+09 — Vehicle Group 2/ 3 mg/kg 10 PO QD × 3 wks 2.34E+08 87.7% P < 0.001 Compound III-1 Group 3/ 3/10 mg/kg 10 PO QD × 3 wks 9.13E+05 100% P < 0.001 Compound III-1/ IV Q7D × 3 wks Rituximab Group 4/ 10 mg/kg 10 IV Q7D × 3 dose 8.43E+07 95.9% P < 0.001 Rituximab Group 5/ 5 mg/kg 10 IV Q7D × 3 dose 1.57E+08 91.9% P < 0.001 Rituximab Group 6/ 1 mg/kg 10 IV Q7D × 3 dose 3.52E+08 81.3% P < 0.001 Rituximab Group 7/ 0.1 mg/kg 10 IV Q7D × 3 dose 4.52E+08 75.8 P < 0.001 Rituximab TGI, tumor growth inhibition (TGI = 100 − [(MTV treated/MTV control) × 100]; P < 0.001 as determined by ANOVA - To better compare tumor growth and the response to treatment between groups, mean AUC values were calculated for each group based on photon flux levels representing tumor burden. The AUC values from each group during the treatment period up to Day 23 (2 days post-treatment) are summarized in Table 21a.
-
TABLE 21a Mean area under the log10 fold change vs day curves (AUC) for each treatment group. Negative values indicate decreased tumor burden. Mean Treatment AUC Vehicle 30.4 Rituximab (0.5 mg/kg Q7D) 24.7 Rituximab (1 mg/kg Q7D) 18.8 Rituximab (5 mg/kg Q7D) 8.1 Rituximab (10 mg/kg Q7D)) 8.4 Compound III-1 (3 mg/kg QD) 18.2 Compound III-1 (3 mg/kg QD + −20.0 Rituximab 10 mg/kg Q7D) - Average photon flux measurements increased approximately two logs in the vehicle group during the 23-day period, which was an average increase in tumor burden of nearly two-fold and resulted in a mean AUC of 30.4 (Table 21a). The AUCs, and therefore the tumor burden, were smaller in each of the treatment groups compared to vehicle. A clear dose response in the AUC values was observed in the rituximab treatment groups. The results of the linear regression model revealed that all of these differences relative to the vehicle group were significant (P<0.01, Table 21b). Additionally, the combination treatment group (Compound III-1 3 mg/kg+rituximab 10 mg/kg) showed a consistent decrease in tumor burden (−20.0), that was significantly lower than either of the respective single agents alone (Compound III-13 mg/kg and rituximab 10 mg/kg, P<0.01). In fact, the mice in this group had photon flux values that were in the un-inoculated, baseline range (photon flux=4-7×10̂5), suggesting the tumors had disappeared.
-
TABLE 21b Summary of mixed-effects linear regression results Treatment Group Reference P-value Compound III-1 (3 mg/kg-QD) Vehicle <0.01 Rituximab (0.5 mg/kg Q7D) 0.02 Rituximab (1 mg/kg Q7D) 0.01 Rituximab (5 mg/kg Q7D) <0.01 Compound III-1 (3 mg/kg QD) + <0.01 Rituximab (10 mg/kg Q7D) Compound III-1 (3 mg/kg QD) + Compound III-1 (3 mg/kg <0.01 Rituximab (10 mg/kg Q7D) QD) Compound III-1 (3 mg/kg QD) + Rituximab (10 mg/kg Q7D) <0.01 Rituximab (10 mg/kg Q7D) - A synergy score calculation was applied to these data to determine whether the effects of the combination treatment were synergistic, additive or sub-additive relative to the individual treatments. This analysis showed that the combination treatment with Compound III-1 at 3 mg/kg plus rituximab at 10 mg/kg was synergistic when comparing the log10-transformed fold changes (Table 22).
-
TABLE 22 Synergistic: score <0, Additive: score = 0, Sub-Additive: score >0. Assessment based on whether 95% confidence interval included the value 0. Synergy 95% Confidence Combination Score Interval Assessment Compound III-1 (3 mg/kg + −46.6 (−56.2, −37.0) Synergistic Rituximab 10 mg/kg - Following treatment, tumor growth was monitored in remaining mice up to Day 125 to determine if tumors would re-grow after treatment ended. Mixed-effects piecewise linear regression models were built to compare the slope of the log flux between Days 9 and 23 to the slope between Days 23 and 125 (or earlier if all animals in a group died). Due to loss of mice from paralysis in many groups, only the combination Compound III-1 and rituximab group and the rituximab 10 and 5 mg/kg groups were evaluated. None of the groups had significantly different changes in slopes after treatment stopped on Day 23 (Table 23), indicating that tumor growth/inhibition did not significantly change following the cessation of treatment. These data suggest that the inhibitory effects of each of the respective treatments appear to continue up to 104 days following treatment.
-
TABLE 23 Breakpoint was set at Day 23. Difference was calculated as slope (Day 23 to 125) − slope (Day 9 to 23). P-values <0.05 indicate that the difference in slope was significantly different than zero. Treatment Group Difference in Slope P-value Rituximab (5 mg/kg) −0.01 0.49 Rituximab (10 mg/kg) −0.01 0.40 Compound III-1 (3 mg/kg + 0.00 0.86 Rituximab 10 mg/kg) - Individual whole body bioluminescence images were taken of all mice in all treatment groups using the Xenogen IVIS® imaging system. Tumor presence/growth in each mouse was assessed using this system prior to treatment on Day 0; 3 days before the end of treatment (Day 18); and 104 days following the end of treatment (Day 125). On Day 18 there is a striking reduction in the fluorescent signal of the tumor as a result of treatment with the combination Compound III-1 at 3 mg/kg with rituximab as compared to any of the other treatment groups or control group. Mice receiving combination treatments show little or no evidence of the disseminated lymphoma tumor, whereas tumor growth was evident in the single agent Compound III-13 mg/kg group and all of the single agent rituximab treatment groups. Bioluminescence images of mice in the combination treatment group, i.e., Compound III-1 at 3 mg/kg with rituximab, on Day 125, show no evidence of tumor growth. Due to the loss of mice from paralysis in the other treatment groups, bioluminescence imaging was not conducted in these groups.
- All vehicle treated mice reached the pre-defined endpoint of paralysis and were euthanized between Day 21 and Day 31. A dose response was observed in the survival rate of rituximab treated mice with 3/10, 1/10, 1/10 and 0/10 mice remaining by Day 125 in the 10, 5, 1 and 0.5 mg/kg groups respectively. Log rank analysis, conducted to compare the survival rates between groups, demonstrates that all treatment groups had significantly longer survival than the vehicle group, and the combination group had significantly longer survival than each of the individual treatments. None of the mice in the combination treatment group were removed during the 125 days of the study
- Table 24 shows the mean maximum body weight change of the groups from Day 0 to Day 22 of the study. The maximum body weight loss for vehicle group was 1.75% on Day 22. All other treatment groups gained weight during the study, including the single agent and combination agent groups. Treatment with Compound III-1 at 3 mg/kg on a QD schedule, or rituximab up to 10 mg/kg on a Q7D schedule, were well tolerated.
-
TABLE 24 Body weight (BW) change Maximum BW Dose Route & Mean BW Mean BW Change (%) Test Article (mg/kg) N Schedule Day 0 Day 22 Day 22 Vehicle — 10 PO QD × 3 wks 19.46 19.12 −1.75 Compound III-1 3 mg/kg 10 PO QD × 3 wks 19.20 19.81 +3.1 Compound III-1/ 3 mg/kg 10 PO QD × 3 wks/ 18.02 18.21 +1.05 Rituximab 10 mg/kg IV Q7D × 3 dose Rituximab 10 mg/kg 10 IV Q7D × 3 dose 19.11 19.72 +3.19 Rituximab 5 mg/kg 10 IV Q7D × 3 dose 18.55 19.55 +5.39 Rituximab 1 mg/kg 10 IV Q7D × 3 dose 19.43 20.25 +4.22 Rituximab 0.5 mg/kg 10 IV Q7D × 3 dose 19.30 20.27 +5.02 - In vivo imaging experiments in SCID mice bearing Ly19-Luc disseminated lymphoma tumors were performed in duplicate in order to confirm the effects of Compound III-1 and rituximab as single agents and as combination treatment. Tumor burden and TGI were determined using quantitative Xenogen imaging in mice receiving various doses of Compound III-1 with and without 10 mg/kg of rituximab. Tumor growth was significantly inhibited in all treatment groups (P<0.001). Tumor burden, presented as the AUC of photon flux values during the treatment period, was significantly lower in all treatment groups compared to control. Combination treatment with Compound III-1 at 3 mg/kg and rituximab at 10 mg/kg appears to provide a synergistic effect that significantly lowered tumor burden when compared to either of the agents alone, thereby corroborating the synergistic effect observed in the sub-cutaneous Ly19 lymphoma model discussed above (refer to Example 1). The survival of the animals was significantly higher in each of the treatment groups compared to the vehicle group and significantly higher in the combination groups compared to the respective individual treatments. Following treatment, there were no significant changes in tumor growth rates in any of the groups up to 52 days in the first replicate and 125 days in the second replicate. In summary, results from the two experiments are consistent with one another and these data confirm that a combination of Compound III-1 and rituximab is the most effective treatment for disseminated Ly19-Luc lymphoma in SCID mice, resulting in a reduction of tumor burden to undetectable levels.
- Two separate studies were conducted in the WSU-DLBCL2-luc model. Compound III-1 was administered initially at low doses (3 or 10 mg/kg on a QD schedule) alone and in combination with rituximab, or at higher doses (10 or 20 mg/kg on a BID schedule) alone or in combination with rituximab. After treatment, animals were monitored up to Day 132 to compare the survival between treatment groups and vehicle.
- In the first WSU-DLBCL2 study, Compound III-1 when dosed alone at either 3 mg/kg or 10 mg/kg QD did not significantly inhibit tumor growth in this model (TGI=50.9%, p>0.05, TGI=88.2%, p>0.05 respectively). Rituximab dosed alone (10 mg/kg QW) or in combination with Compound III-1 at 3 or 10 mg/kg significantly inhibited tumor growth (TGI=83.6%, p<0.05, TGI=91.8%, p<0.05, TGI=99.0%, p<0.001 respectively) in SCID mice bearing WSU-DLCL2-Luc xenografts (Table 25). In the second study, when Compound III-1 was dosed alone at either 10 mg/kg or 20 mg/kg BID, tumor growth was significantly inhibited in this model (TGI=99.7%, p<0.001, for both groups). Rituximab dosed alone at 10 mg/kg QW (TGI=88.4%, p<0.001) and in combination with Compound III-1 at 10 or 20 mg/kg BID resulted in significant tumor growth inhibition (TGI=99.6% and 99.9% respectively, p<0.001 for both), (Table 25).
-
TABLE 25 Tumor Growth Inhibition, Body Weight Change and Survival Maximum Survival Percent Body TGI Median Dose Route and Weight Change Mean p Survival p (mg/kg)b Dose Regimen (%) (%)c Valued (Days) Valued 1st WSU- DLBCL2 Study/ Treatment Groupa Vehiclef 0 po/QD × 21 days −0.3, Day 21 N/A N/A 37 N/A Compound III-1 3 po/QD × 21 days −3.1, Day 21 50.9, Day 21 >0.05 46.5 0.040 Compound III-1 3 po/QD × 21 days −2.4, Day 21 91.8, Day 21 <0.05 73 0.003 Rituximab 10 IV/QW × 3 doses Compound III-1 10 po/QD × 21 days −4.5, Day 21 88.2, Day 21 >0.05 44 0.017 Compound III-1 10 po/QD × 21 days −2.8, Day 21 99.0, Day 21 <0.001 52.5 <0.001 Rituximab 10 IV/QW × 3 doses Rituximab 10 IV/QW × 3 doses +1.7, Day 21 83.6, Day 21 <0.05 61 <0.001 2nd WSU- DLBCL2 study Vehicle 0 po/BID × 21 days +2.5, Day 22 N/A N/A 45 N/A Compound III-1 10 po/BID × 21 days −3.9, Day 19 99.7, Day 22 <0.001 70 <0.001 Compound III-1g 20 po/QD × 21 days −8.9, Day 9 99.7, Day 22 <0.001 111.5 <0.001 Compound III-1 10 po/BID × 21 days −1.7, Day 19 99.6, Day 22 <0.001 121 <0.001 Rituximab 10 IV/QW × 3 doses Compound III-1g 20 po/BID × 21 days −12.2, Day 9 99.9, Day 22 <0.001 >128 <0.001 Rituximab 10 IV/QW × 3 doses Rituximab 10 IV/QW × 3 doses +6.3, Day 22 88.4, Day 22 <0.001 59 >0.05 aThere were 10 mice in each treatment group. bFor each dose, mice received 100 μL of Compound III-1 and/or rituximab dosing solution prepared at 0.75, 2.5, 5.0 and 7.5 mg/mL (3, 10, 20, 30 mg/kg Compound III-1) or 2.0 mg/mL (10 mg/kg rituximab). These dosing solutions were prepared routinely based on historical mouse body weights of 25 or 20 grams respectively. All doses were approximate. cMean tumor volumes, and TGI values were calculated on Day 21 (1st study) and Day 22 (2nd study) of treatment. dTGI = TGI calculation B − tumor growth inhibition (TGI = [(Δ control average volume − Δ treated average volume) × 100/Δ control average volume]. p values were calculated with an ANOVA, p < 0.05 considered statistically significant eLog-rank analysis was used to compare the survival rate of each treatment group to the vehicle group, p < 0.05 considered statistically significant, fThe vehicle used in TG1 and the treatment groups was 10% HP-β-CD plus 1% NaHCO. The vehicle used in the rituximab treatment groups was 0.9% saline. gAnimals dosed with Compound III-1 at 20 mg/kg BID, and animals in the combination group dosed with 20 mg/kg Compound III-1 and rituximab at 10 mg/kg QW received a dose holiday for 5 days, from Day 9 to Day 13. - After treatment, animals were monitored for survival up to Day 125 (1st study) or Day 130 (2nd study). The median survival in days for each group is presented in Table 25 and the mean survival rate of the treatment groups were compared to the vehicle group. In the 1st study, all vehicle animals were euthanized at the humane endpoint (paralysis) by Day 44 and all treatment groups showed significantly longer survival relative to the vehicle group (p<0.04-0.001, Table 25). By the end of the study (Day 125), 1 out of 10 mice remained in the single agent rituximab group and in the 10 mg/kg Compound III-1 combination treatment group. In the 2nd study, all vehicle animals were euthanized at the humane endpoint by Day 68. With the exception of rituximab treatment alone (p>0.05), all treatment groups showed significantly longer survival relative to the vehicle group (p<0.001, Table 25). The number of mice remaining at the end of the study (Day 130) was 1 out of 10 in the 10 mg/kg single agent Compound III-1 and rituximab groups, 5 out of 10 in the 20 mg/kg Compound III-1 single agent group and the 10 mg/kg Compound III-1 combination group, and 8 out of 10 mice in the 20 mg/kg Compound III-1 combination group.
- The tumor volumes were smaller in each of the treatment groups in the first study compared to vehicle (Table 26a). Both combinations groups were additive relative to their respective individual treatments when comparing AUC values (Table 26b).
-
TABLE 26a Area Under the Curve Efficacy and Synergy Analysis (Days 0 Through 21) for first study. Average percent change in the area under the log10 photon flux vs day curves (AUC) relative to the mean AUC of the vehicle group. Pct Decrease in AUC Relative to Mean Treatment Vehicle AUC Vehicle — Compound III-1 (3 mg/kg, PO, QD) 21.1 Compound III-1 (10 mg/kg, PO, QD) 42.0 Rituximab (10 mg/kg, IV, QW) 44.4 Compound III-1 (3 mg/kg) + 48.6 Rituximab (10 mg/kg) Compound III-1 (10 mg/kg) + 75.0 Rituximab (10 mg/kg) -
TABLE 26b Area Under the Curve Efficacy and Synergy Analysis (Days 0 Through 21) for first study. Synergistic: score <0, Additive: score = 0, Sub-additive: score >0. Assessment based on whether the synergy score was significantly different from 0. 95% Synergy Confidence P Combination Score Interval Value Assessment Compound III-1 (3 mg/kg 16.9 (−10.8, 44.6) 0.22 Additive QD) + Rituximab Compound III-1 (10 mg/kg 11.3 (−12.5, 35.1) 0.33 Additive QD) + Rituximab - The tumor volumes were smaller in each of the treatment groups in the second study compared to vehicle (Table 27a). Both combinations groups were sub-additive relative to their respective individual treatments when comparing AUC values (Table 27b).
-
TABLE 27a Area Under the Curve Efficacy and Synergy Analysis (Days 0 Through 21) for second study. Average percent change in the area under the log10 photon flux vs day curves (AUC) relative to the mean AUC of the vehicle group. Pct Decrease in AUC Relative to Mean Treatment Vehicle AUC Vehicle — Compound III-1 (10 mg/kg, PO, BID) 94.0 Compound III-1 (20 mg/kg, PO, BID) 96.6 Rituximab (10 mg/kg, IV, QW) 41.3 Compound III-1 (10 mg/kg) + 98.5 Rituximab (10 mg/kg) Compound III-1 (20 mg/kg) + 100.2 Rituximab (10 mg/kg) -
TABLE 27b Area Under the Curve Efficacy and Synergy Analysis (Days 0 Through 21) for second study. Synergistic: score <0, Additive: score = 0, Sub-additive: score >0. Assessment based on whether the synergy score was significantly different from 0. 95% Synergy Confidence P Combination Score Interval Value Assessment Compound III-1 (10 mg/kg 36.8 (12.4, 61.2) 0.005 Sub-Additive QD) + Rituximab Compound III-1 (20 mg/kg 37.7 (15.5, 59.9) 0.003 Sub-Additive QD) + Rituximab - At the end of dosing on Day 21 of the 1st study, body weight loss was less than 5% for all groups (Table 25). In the second study, however, treatment with Compound III-1 at 20 mg/kg on a BID schedule and the combination treatment of Compound III-1 at 20 mg/kg BID with rituximab at 10 mg/kg QW resulted in mean maximum body weight losses of 8.9% (Day 9) and 12.2% (Day 9) respectively. This effect was managed by giving all animals in these groups a 5 day dose holiday (Day 9 through Day 13); animals then regained body weight. No other treatment group exhibited a maximum body weight loss greater than 3.9% (Table 25).
- While the foregoing invention has been described in some detail for purposes of clarity and understanding, these particular embodiments are to be considered as illustrative and not restrictive. It will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention, which is to be defined by the appended claims rather than by the specific embodiments.
- The patent and scientific literature referred to herein establishes knowledge that is available to those with skill in the art. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The issued patents, applications, and references that are cited herein are hereby incorporated by reference to the same extent as if each was specifically and individually indicated to be incorporated by reference. In the case of inconsistencies, the present disclosure, including definitions, will control.
Claims (5)
1. A method of treating a patient suffering from a hematological malignancy, comprising administering to the subject a therapeutically effective amount of an Aurora kinase inhibitor simultaneously with or consecutively with an anti-CD20 antibody, wherein the hematological malignancy is Diffuse Large B-cell lymphoma, the anti-CD20 antibody is rituximab, and the Aurora kinase inhibitor is 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid, or a pharmaceutically acceptable salt thereof.
2-4. (canceled)
5. The method of claim 1 , wherein the patient was treated previously with an anti-CD20 antibody.
6.-9. (canceled)
10. The method of claim 1 , wherein the Aurora kinase inhibitor is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/052,966 US20160271249A1 (en) | 2008-12-22 | 2016-02-25 | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
US15/387,740 US10391100B2 (en) | 2008-12-22 | 2016-12-22 | Combination of aurora kinase inhibitors and anti-CD20 antibodies |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20350908P | 2008-12-22 | 2008-12-22 | |
US12/638,018 US20100183601A1 (en) | 2008-12-22 | 2009-12-15 | Combination of Aurora Kinase Inhibitors and Anti-CD20 Antibodies |
US15/052,966 US20160271249A1 (en) | 2008-12-22 | 2016-02-25 | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/638,018 Division US20100183601A1 (en) | 2008-12-22 | 2009-12-15 | Combination of Aurora Kinase Inhibitors and Anti-CD20 Antibodies |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/387,740 Division US10391100B2 (en) | 2008-12-22 | 2016-12-22 | Combination of aurora kinase inhibitors and anti-CD20 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160271249A1 true US20160271249A1 (en) | 2016-09-22 |
Family
ID=41664630
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/638,018 Abandoned US20100183601A1 (en) | 2008-12-22 | 2009-12-15 | Combination of Aurora Kinase Inhibitors and Anti-CD20 Antibodies |
US15/052,966 Abandoned US20160271249A1 (en) | 2008-12-22 | 2016-02-25 | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
US15/387,740 Active US10391100B2 (en) | 2008-12-22 | 2016-12-22 | Combination of aurora kinase inhibitors and anti-CD20 antibodies |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/638,018 Abandoned US20100183601A1 (en) | 2008-12-22 | 2009-12-15 | Combination of Aurora Kinase Inhibitors and Anti-CD20 Antibodies |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/387,740 Active US10391100B2 (en) | 2008-12-22 | 2016-12-22 | Combination of aurora kinase inhibitors and anti-CD20 antibodies |
Country Status (13)
Country | Link |
---|---|
US (3) | US20100183601A1 (en) |
EP (1) | EP2376082B1 (en) |
JP (1) | JP5738196B2 (en) |
KR (1) | KR101741168B1 (en) |
CN (1) | CN102264368B (en) |
AU (1) | AU2009330727B2 (en) |
BR (1) | BRPI0923579A2 (en) |
CA (1) | CA2747326C (en) |
ES (1) | ES2468391T3 (en) |
HK (1) | HK1160766A1 (en) |
MX (1) | MX2011006725A (en) |
RU (1) | RU2535032C2 (en) |
WO (1) | WO2010074724A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
US10391100B2 (en) | 2008-12-22 | 2019-08-27 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-CD20 antibodies |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
WO2020106750A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
EP4252629A2 (en) | 2016-12-07 | 2023-10-04 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3434B1 (en) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders |
RU2012140021A (en) | 2010-02-19 | 2014-03-27 | Миллениум Фармасьютикалз, Инк. | CRYSTAL FORMS 4 - {[9-CHLOR-7- (2-FLUOR-6-METHOXYPHENYL) -5H-PYRIMIDO [5,4-d] [2] BENZAZEPIN-2-IL] AMINO} -2-SODIUM METHOZIBENZOATE |
EP2976086B1 (en) * | 2013-03-22 | 2020-10-14 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
JP6525474B2 (en) * | 2013-12-06 | 2019-06-05 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Combination of Aurora kinase inhibitor and anti-CD30 antibody |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
CA1138863A (en) | 1979-02-07 | 1983-01-04 | Norman W. Gilman | Benzazepine-derivatives |
US4481142A (en) | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
US4469633A (en) | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0273697A3 (en) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-benzazepines with 5- and 6- membered heterocyclic rings |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
US5210082A (en) | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5747487A (en) * | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
EP0888350A1 (en) | 1996-03-08 | 1999-01-07 | Zeneca Limited | Azolobenzazepine derivatives as neurologically active agents |
EP0946523A1 (en) | 1996-12-23 | 1999-10-06 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
PL339544A1 (en) | 1997-09-29 | 2000-12-18 | Meiji Seika Kaisha | Tricyclic derivatives of thiazolobenzazepin, method of obtaining them antillergic agents |
US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
AU4841700A (en) | 1999-05-12 | 2000-11-21 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
JP2003513012A (en) * | 1999-08-11 | 2003-04-08 | アイデック ファーマスーティカルズ コーポレイション | Treatment of patients with non-Hodgkin's lymphoma with bone marrow lesions by anti-CD20 antibodies |
RU2305561C2 (en) * | 1999-11-08 | 2007-09-10 | Байоджен Айдек Инк. | Treatment of b-cellular malignant tumors using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or by chemotherapy and radiotherapy |
WO2001052353A2 (en) * | 2000-01-12 | 2001-07-19 | Emag Technologies L.L.C. | Low cost compact omni-directional printed antenna |
JP2003531178A (en) * | 2000-04-25 | 2003-10-21 | アイデック ファーマスーティカルズ コーポレイション | Intrathecal administration of rituximab for the treatment of central nervous system lymphoma |
EP1345922B1 (en) | 2000-12-21 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
BR0211729A (en) | 2001-08-09 | 2004-08-24 | Actelion Pharmaceuticals Ltd | Compounds, pharmaceutical compositions, process for manufacturing compounds, use of one or more compounds, and process for manufacturing pharmaceutical compositions |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
ATE438644T1 (en) | 2002-12-24 | 2009-08-15 | Astrazeneca Ab | CHINAZOLINE DERIVATIVES |
MXPA05008688A (en) | 2003-02-17 | 2005-10-05 | Pharmacia Italia Spa | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them. |
GB0315657D0 (en) | 2003-07-03 | 2003-08-13 | Astex Technology Ltd | Pharmaceutical compounds |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US20050025605A1 (en) * | 2003-07-30 | 2005-02-03 | Vrana John J. | Locator stud and method of assembly |
DE602004032446D1 (en) | 2003-08-07 | 2011-06-09 | Rigel Pharmaceuticals Inc | 2,4-PYRIMIDINDIAMIN COMPOUNDS AND USES AS ANTIPROLIFERATIVE AGENTS |
CN1897950A (en) | 2003-10-14 | 2007-01-17 | 惠氏公司 | Fused-aryl and heteroaryl derivatives and methods of their use |
BRPI0511139B8 (en) * | 2004-05-14 | 2021-05-25 | Millennium Pharm Inc | compounds that inhibit aurora kinase and pharmaceutical composition containing the same |
WO2005118544A2 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
WO2006003440A1 (en) | 2004-07-05 | 2006-01-12 | Astex Therapeutics Limited | 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors |
SG156650A1 (en) | 2004-07-16 | 2009-11-26 | Sunesis Pharmaceuticals Inc | Thienopyrimidines useful as aurora kinase inhibitors |
GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
CA2580151C (en) | 2004-11-15 | 2014-02-04 | Rigel Pharmaceuticals, Inc. | Stereoisomerically enriched .beta.-lactams using candida antarctica |
JP2008520713A (en) | 2004-11-17 | 2008-06-19 | ミイカナ セラピューティクス インコーポレイテッド | Kinase inhibitor |
AU2005321091B2 (en) | 2004-12-30 | 2012-04-12 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and Aurora kinases |
WO2006070202A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives having kinase modulating activity |
WO2006070198A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
WO2006070192A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Thiazole and isothiazole derivatives that modulate the acivity of cdk, gsk and aurora kynases |
US7485661B2 (en) | 2005-01-18 | 2009-02-03 | Pfizer Italia S.R.L. | Heterobicyclic pyrazole derivatives as kinase inhibitors |
US20070104785A1 (en) * | 2005-07-29 | 2007-05-10 | Navale Suryakant V | Tablets of linezolid form iii and processes for their preparation |
ES2535854T3 (en) | 2005-09-30 | 2015-05-18 | Miikana Therapeutics, Inc. | Substituted Pyrazole Compounds |
RU2427578C2 (en) | 2005-11-03 | 2011-08-27 | Вертекс Фармасьютикалз Инкорпорейтед | Aminopyrimidines as kinase inhibitors |
PT1962830E (en) * | 2005-12-23 | 2013-05-29 | Glaxosmithkline Llc | Azaindole inhibitors of aurora kinases |
CN100346830C (en) * | 2005-12-28 | 2007-11-07 | 上海交通大学医学院附属瑞金医院 | Pharmaceutical composition for treating B cell lymphoma |
EP1987028A2 (en) * | 2006-02-10 | 2008-11-05 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
TW200808311A (en) | 2006-03-30 | 2008-02-16 | Nerviano Medical Sciences Srl | Use of a kinase inhibitor for the treatment of particular resistant tumors |
WO2007132220A1 (en) | 2006-05-12 | 2007-11-22 | Cyclacel Limited | Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder |
WO2007132221A1 (en) | 2006-05-12 | 2007-11-22 | Cyclacel Limited | Combined anticancer pyrimidine-thiazole aurora kinase inhibitors |
GB0609530D0 (en) | 2006-05-12 | 2006-06-21 | Cyclacel Ltd | Combination |
US20080004286A1 (en) * | 2006-06-30 | 2008-01-03 | Schering Corporation | Method of Using Substituted Piperidines that Increase P53 Activity |
WO2008021038A2 (en) | 2006-08-09 | 2008-02-21 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
CL2007003244A1 (en) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER. |
US20090023743A1 (en) * | 2007-05-09 | 2009-01-22 | Abbott Laboratories | Inhibitors of protein kinases |
US20090203671A1 (en) | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
US20110033461A1 (en) * | 2008-03-12 | 2011-02-10 | Vladimir Ratushny | Combination Therapy for the Treatment of Cancer |
WO2010074724A1 (en) | 2008-12-22 | 2010-07-01 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
JO3635B1 (en) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | Solid pharmaceutical compositions and processes for their production |
JO3434B1 (en) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders |
EP2496604B1 (en) * | 2009-11-06 | 2017-08-23 | IDEXX Laboratories, Inc. | Canine anti-cd20 antibodies |
RU2012140021A (en) * | 2010-02-19 | 2014-03-27 | Миллениум Фармасьютикалз, Инк. | CRYSTAL FORMS 4 - {[9-CHLOR-7- (2-FLUOR-6-METHOXYPHENYL) -5H-PYRIMIDO [5,4-d] [2] BENZAZEPIN-2-IL] AMINO} -2-SODIUM METHOZIBENZOATE |
-
2009
- 2009-12-15 WO PCT/US2009/006560 patent/WO2010074724A1/en active Application Filing
- 2009-12-15 BR BRPI0923579A patent/BRPI0923579A2/en not_active Application Discontinuation
- 2009-12-15 ES ES09795585.0T patent/ES2468391T3/en active Active
- 2009-12-15 RU RU2011130566/15A patent/RU2535032C2/en active
- 2009-12-15 CN CN200980152195.9A patent/CN102264368B/en not_active Expired - Fee Related
- 2009-12-15 CA CA2747326A patent/CA2747326C/en not_active Expired - Fee Related
- 2009-12-15 EP EP09795585.0A patent/EP2376082B1/en active Active
- 2009-12-15 KR KR1020117016859A patent/KR101741168B1/en active IP Right Grant
- 2009-12-15 MX MX2011006725A patent/MX2011006725A/en active IP Right Grant
- 2009-12-15 AU AU2009330727A patent/AU2009330727B2/en not_active Ceased
- 2009-12-15 US US12/638,018 patent/US20100183601A1/en not_active Abandoned
- 2009-12-15 JP JP2011542127A patent/JP5738196B2/en active Active
-
2012
- 2012-02-07 HK HK12101147.6A patent/HK1160766A1/en not_active IP Right Cessation
-
2016
- 2016-02-25 US US15/052,966 patent/US20160271249A1/en not_active Abandoned
- 2016-12-22 US US15/387,740 patent/US10391100B2/en active Active
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10391100B2 (en) | 2008-12-22 | 2019-08-27 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-CD20 antibodies |
EP4252629A2 (en) | 2016-12-07 | 2023-10-04 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
EP4108183A1 (en) | 2017-03-30 | 2022-12-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
WO2020106750A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
WO2020106754A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
WO2020106704A2 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Also Published As
Publication number | Publication date |
---|---|
RU2011130566A (en) | 2013-01-27 |
EP2376082A1 (en) | 2011-10-19 |
KR20110114586A (en) | 2011-10-19 |
AU2009330727A1 (en) | 2011-07-07 |
KR101741168B1 (en) | 2017-05-29 |
BRPI0923579A2 (en) | 2020-01-14 |
JP5738196B2 (en) | 2015-06-17 |
US20100183601A1 (en) | 2010-07-22 |
AU2009330727B2 (en) | 2016-07-28 |
WO2010074724A1 (en) | 2010-07-01 |
ES2468391T3 (en) | 2014-06-16 |
US20170296551A1 (en) | 2017-10-19 |
CA2747326A1 (en) | 2010-07-01 |
HK1160766A1 (en) | 2012-08-17 |
CN102264368B (en) | 2014-09-10 |
MX2011006725A (en) | 2011-09-15 |
EP2376082B1 (en) | 2014-03-05 |
JP2012513390A (en) | 2012-06-14 |
US10391100B2 (en) | 2019-08-27 |
CA2747326C (en) | 2017-05-16 |
CN102264368A (en) | 2011-11-30 |
RU2535032C2 (en) | 2014-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10391100B2 (en) | Combination of aurora kinase inhibitors and anti-CD20 antibodies | |
US9629850B2 (en) | Combination of MEK inhibitors and selective inhibitors of Aurora A kinase | |
US10980889B1 (en) | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | |
AU2022202686B2 (en) | Methods of treating and preventing graft versus host disease | |
US20180117060A1 (en) | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase | |
CN111918651A (en) | GCN2 inhibitors and uses thereof | |
AU2022203810A1 (en) | Methods of treating and preventing alloantibody driven chronic graft versus host disease | |
KR20200138294A (en) | Anticancer pharmaceutical composition for combination therapy | |
EP4277706A1 (en) | Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MILLENNIUM PHARMACEUTICALS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MANFREDI, MARK;REEL/FRAME:039004/0904 Effective date: 20160621 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |